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 Peptides are a powerful class of therapeutics with high potency, high specificity, 
low immunogenicity, and effective methods of discovery.  However, peptides often 
possess limitations including degradation by proteases, rapid clearance by renal filtration, 
and difficulty passing through membranes. 
The Kay lab at the University of Utah has applied the benefits of peptide design to 
tackling the problem of HIV-1 transmission.  In this dissertation I describe the discovery 
of our lead peptide candidate, PIE12, including its optimization by mirror-image phage 
display, its potency enhancement by defined geometric linkages and lipid conjugation, its 
engineered ability to prevent HIV-1 resistance, and finally the optimization of its 
pharmacokinetic properties.  These efforts have overcome the common limitations of 
peptide therapeutics and produced an ideal preclinical candidate for the treatment and 
prevention of HIV/AIDS. 
The first chapter examines the scope of the HIV pandemic, describes HIV-1’s 
susceptible target for which we developed PIE12, and includes a brief examination of the 
current state of the peptide therapeutic field.  The second chapter reviews methods of 
peptide discovery that enable protease resistance, including a discussion of well-validated 
techniques like mirror-image phage display followed by a review of several emerging 
technologies.  The third chapter reveals how the aforementioned techniques were utilized 
in the discovery of PIE12, including early efforts to link PIE12 peptides together in order 
to improve potency.  The fourth chapter completes this story, illuminating our efforts to 
optimize the linkages between PIE12 peptides in order to increase potency, and includes 
information on potency-enhancing membrane-tethering moieties.  The fifth chapter 
describes our efforts to make potent PIE12-conjugates suitable for subcutaneous delivery, 
including new conjugate designs and detailed evaluation of their half-life-improving 
properties.  The final chapter discusses future directions and new opportunities revealed 
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Scope of the HIV Pandemic 
 
Since the AIDS pandemic was first identified in 1981 an estimated 59 million 
people have contracted its causal agent “human immunodeficiency virus” (HIV).  To 
date, approximately 26 million people have died from HIV/AIDS, leaving 33 million 
people (including 1.2 million in the US) living with the infection (UNAIDS, 2011 UN 
Millennium Development Goals Report).  Although five classes of antiretroviral 
therapies (NRTI, NNRTI, protease, integrase and entry inhibitors) are available, HIV 
remains a formidable pathogen.  It continues to spread, affects vulnerable populations, 
and can develop resistance to current therapeutics.  New pharmacological agents and 
therapeutic targets are needed in order to stay ahead of drug resistance and keep the virus 
under control. 
Unfortunately, even new classes of inhibitors, such as the recently approved 
integrase inhibitor raltegravir, can succumb to the rapid emergence of HIV resistance 
within a few months of use1.  As such, there is a growing need not only to develop new 
promising therapies against HIV, but also to anticipate and counter the problem of HIV’s 




 The general mechanism of HIV entry into susceptible host cells is well 
understood2.  HIV expresses a homo-trimeric membrane protein Env (gp160), which 
undergoes posttranslational cleavage yielding the noncovalently associated gp120 and 
gp41 subunits.  Posttranslational cleavage allows for trapping of these proteins in a 
“spring-loaded” kinetic trap.  The trap is sprung when HIV virions recognize host cells 
through the interaction of viral gp120 with the primary receptor CD4 and one of two co-
receptors (CCR5 or CXCR4).  In general, CCR5-tropic virions are more transmissible, 
and represent the majority of early-stage HIV viral load.  In ~50% of patients, HIV 
undergoes a switch or broadening in co-receptor tropism to begin utilizing CXCR4.  This 
transition correlates with advanced disease and poorer clinical outcomes3.  It is not clear 
what is responsible for the transition, but may simply reflect a selection for tropic virions 
as CCR5-expressing host cells die from CCR5-tropic virus. 
 After gp120 interacts with CD4 and co-receptor, it undergoes a conformational 
change that releases the kinetically trapped gp41.  gp41 then adopts an extended 
conformation, plunging its N-terminal fusion peptide into the host cell membrane (Fig. 1-
1).  This extended conformation is semistable, lasting for several minutes (strain 
specific)4.  In this state, two regions become newly defined.  First, the host cell-proximal 
N-trimer is a trimeric coiled-coil with three inter-helical hydrophobic grooves.  The 
highly conserved 17 C-terminal residues of the N-trimer form three deep hydrophobic 
pockets (Fig. 1-2).  Second, the virion-proximal C-peptide region adopts an unknown 
configuration, possibly unstructured. 
 
 
Figure 1-1. Proposed Model of HIV Fusion with Host Cells.  HIV expresses several copies of the trimeric Env protein, which is 
post-translationally cleaved to produce gp120 and gp41.  gp120 interacts with its primary receptor CD4 and a co-receptor, triggering 
gp41 to adopt an extended conformation that plunges its fusion peptide (red) into the host cell membrane.  This prehairpin 
intermediate contains two regions, a host cell-proximal trimeric coiled-coil (N-trimer) and a loosely structured C-peptide region. The 
C-terminal residues of the N-trimer form three highly conserved deep hydrophobic pockets.  The prehairpin intermediate is stable for 
several minutes, after which C-peptides collapse upon the N-trimer forming the trimer-of-hairpins structure that mediates fusion.  
Soluble C-peptide analogues (e.g., C37, Fuzeon) and/or D-peptides can bind to the prehairpin intermediate, preventing trimer-of-





Figure 1-2.  Spatial Characteristics of gp41.  A) The residues assigned to each region of gp41 (HxB2 numbering).  FP = fusion 
peptide, DSL = disulfide loop, MPER = membrane-proximal external region, TM = trans-membrane, CT = cytoplasmic tail. 
B) Distances relevant to oligomerization and membrane-tethering designs.  ~25 Å PEG linkers are sufficient to span two pockets. 
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 After a brief window of time, gp41 collapses upon itself, mediating fusion of the 
virus and host cell.  The C-peptide region becomes helical and fills in the grooves of the 
N-trimer region, forming the very stable “six-helix bundle” or “trimer-of-hairpins.”  
Preventing formation of this trimer-of-hairpins is known to prevent viral infection, and is 
the basis of the FDA-approved entry inhibitor Fuzeon.  Fuzeon is a peptide derived from 
the C-peptide region and can preemptively bind the N-trimer grooves and prevent fusion 
through a dominant negative mechanism6.  Pocket-specific Inhibitor of Entry #12 
(PIE12), an optimized nondegradable D-peptide I co-discovered in the Kay lab, binds to 
the deep hydrophobic pocket of the N-trimer and also prevents trimer-of-hairpins 
formation and fusion. 
 It is worth noting that CD4 and the co-receptors are located within host cell lipid 
rafts7,8, which are regions of thicker membrane containing distinct lipid content.  The 
localization of HIV’s receptors here establishes viral entry at lipid rafts.  Thus, entry 
inhibitors that are targeted to lipid rafts will have improved local concentrations and on-
rates, leading to improved inhibition of fusion9. 
Despite this detailed understanding of viral entry, some aspects remain poorly 
understood, such as how many Env proteins are involved in fusion, and what role, if any, 
endocytosis plays in physiological virus entry10. 
 
HIV’s Vulnerable Drug Target – The Pocket 
The three deep hydrophobic pockets of gp41 are critical for HIV fusion11.  Each 
pocket is encoded by the 17-residue sequence LLQLTVWGIKQLQARIL, and binds an 
essential 8-residue sequence from the C-peptide, WMEWDREI.  Interestingly, this 
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natural ligand contains two tryptophans.  A similar motif, EWXWL, was selected in our 
early phage display efforts and became the basis of future library designs, ultimately 
leading to the D-peptide entry inhibitor PIE12: HPCDYPEWQWLCELGK.  PIE12 binds 
to the pocket with low nM affinity and potently inhibits HIV fusion5. 
The pocket is highly conserved across all major HIV-1 strains, consistent with its 
critical role in mediating fusion.  Amino acid substitutions in this site are not well-
tolerated2.  Moreover, the nucleotide sequence that encodes this region produces the Rev-
response element for Env, a critical stem-loop structure required for mRNA nuclear 
export12,13, thereby discouraging mutation even at the nucleotide level. 
 
Discovering D-Peptide Inhibitors of HIV Entry 
 
Work in the Kay lab focuses on developing novel D-peptide therapeutics and 
advancing them towards promising applications such as inhibiting HIV entry.  Peptides 
are typically defined as sequences of !40 amino acids14.  D-peptides are peptides 
composed of D-amino acids, which are the mirror image (opposite chirality) of the L-
amino acids typically utilized by living systems.  D-peptides cannot be made 
recombinantly, so they must be made by chemical synthesis.  Living systems almost 
exclusively utilize L-amino acids for peptide and protein synthesis, and metabolic 
enzymes show clear preference for their natural ligands compared to a mirror-image 
substrate (e.g., >1000-fold15,16).  This makes D-peptides essentially nondegradable by 
proteases, endowing them with the capacity to withstand harsh physiological conditions 
like human plasma, the gastrointestinal system, and vaginal mucosa.  This property is of 
obvious interest for enhancing the exposure of a peptide therapeutic. 
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However, the same property that makes D-peptides essentially nondegradable 
makes D-peptide discovery incompatible with powerful biologically-based peptide 
discovery techniques, because D-peptides cannot be expressed in living systems.  This 
problem, however, can be overcome by a clever technique called “mirror-image phage 
display.”  Briefly, a library of M13 phage can be genetically designed to display billions 
of different L-peptides fused to their g3 proteins.  There are five g3 proteins expressed on 
each M13 phage, so zero to five identical peptides can be displayed per phage.  Phage 
display involves exposing a target protein or peptide to a library of L-peptides fused to 
these phage to select for L-peptides that bind to the target.  Weak or non-binders can be 
washed away, while tighter binders can be eluted and the associate-phage amplified for 
another round of selection, thereby continually selecting for progressively better binders 
(Fig. 1-3)17. 
Mirror-image phage display involves the same process, but utilizes symmetry in 
order to discover D-peptide binders.  The phage still encode L-peptides, but the target 
they bind to is made as a mirror image (D-chirality) of the natural L-peptide or protein.  
By symmetry, the L-peptide that is selected as the strongest binder to a D-target will bind 
to the natural L-target when synthesized as a D-peptide18.  In our case, HIV’s gp41 
pocket region is the desired target, so to find a D-peptide that binds to it, an L-peptide 
phage library was screened against a synthetically produced D-gp41 pocket analog.  The 
winning sequence was synthesized as a D-peptide and was found to effectively bind and 
inhibit the natural L-gp41 pocket region.  We discovered the D-peptide HIV entry 
inhibitor PIE12 using a combination of mirror-image phage display and structure-aided 




Figure 1-3.  Phage Display. A library of phage displaying genetically encoded peptides 
is incubated with a target.  The target may be tethered to a surface (solid-phase) or in 
solution with a handle for pull-down (solution-phase) as shown here with biotin.  After 
incubation, the target is retrieved by adding magnetic beads coated with streptavidin.  
After several washes, the remaining phage contain the tightest binding peptides.  These 
are eluted and amplified in E. coli.  The amplified phage comprise a new library of 





Improving Potency Through Oligomerization 
and Membrane Tethering 
 Because gp41 is a trimeric target with three symmetric pockets, we reasoned that 
linking three PIE12 peptides together would improve potency.  Indeed, this strategy 
greatly improved potency ~200-fold over monomeric PIE12.  We also found that discrete 
PEG linkers of ~22-25 Å between the C-termini of PIE12 peptides was optimal (Fig. 1-
2), becoming the basis for a PEG scaffold enabling rapid synthesis of PIE12-trimer 
(described in Chapter 4)9. 
Through oligomerization we discovered that initial improvements in affinity (KD) 
are correlated with improvements in antiviral potency (IC50), but eventually a potency 
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plateau is reached after which further improvements in affinity no longer affect potency 
(Fig. 1-4).  The potency plateau for HxB2 is ~100-300 pM, while it is 2-3 nM for JRFL.  
JRFL is a difficult-to-inhibit primary strain known to fuse more rapidly than other strains, 
thereby reducing its exposure to fusion inhibitors, decreasing their potency4.  Of our D-
peptide oligomers, PIE12-trimer possesses the highest affinity, but the potency plateau 
prevents estimation of its KD based on IC50.  A direct measurement of KD is not possible 
because the interaction is too tight; the extraordinarily slow off-rate prevents assessment 
by biosensor analysis.  Nevertheless, PIE12-trimer affinity can be estimated by 
comparisons to the affinities and potency improvements of other D-peptide oligomers.  
Such estimates predict a sub-fM KD for PIE12-trimer. 
We reason that the cause of the potency plateau is the transient exposure of the 
prehairpin intermediate.  Because potency is typically a function of both on-rate and off-
rate, either increasing the on-rate or decreasing the off-rate will increase potency.  
However, once the off-rate exceeds the time that a target is exposed, the on-rate becomes 
the limiting factor for potency, and for peptides in solution (i.e., not tethered to the 
membrane) the on-rate is limited by three-dimensional diffusion.  This on-rate limit 
creates the potency plateau.  Although affinity can be improved by prolonging off-rates, 
the improvement will no longer be correlated with an increase in potency.  Other groups 
have noticed the same potency plateau in their HIV entry inhibitors4. 
Interestingly, the potency plateau can be overcome by increasing the on-rate via 
prepositioning inhibitors on cell surfaces using membrane-tethering moieties.  This 
tethering significantly improves potency (described in Chapter 4). 
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Resisting Resistance – the “Resistance Capacitor” 
Besides contributing potent inhibitors to the armament of antiretrovirals, our work 
aims to build into drug design a capacity to withstand viral mutations.  Drug resistance is 
the bane of HIV treatment, so instead of simply developing a drug that would inevitably 
succumb to resistance, we decided to proactively design a therapeutic that could delay it 
as long as possible.  To this end, several design strategies have been employed.  The first 
has already been discussed; choosing the gp41 pocket as our drug target reduces the 
capacity of HIV to develop drug-resistance because the pocket is highly conserved and 
genetically limited in its capacity to acquire mutations.  
The second strategy involves a deliberate over-engineering of our inhibitor.  As 
mentioned, a potency plateau is observed when increases in binding affinity are no longer 
correlated with increases in antiviral potency.  At first we questioned whether to continue 
efforts to increase binding affinity given that no further potency improvements could be 
obtained.  However, we found that increasing the affinity beyond the potency plateau 
endows the inhibitor with an excess of binding energy that can absorb the impact of 
affinity-disrupting resistance mutations by HIV.  The greater the binding affinity is with 
respect to the potency plateau, the more highly charged the “capacitor” is against resistant 
mutations.  We call this excess binding energy the “resistance capacitor.”  Practically, if 
HIV develops a mutation that damages binding affinity, the mutated virus will still be 
inhibited with equal potency (Fig. 1-4).  The mutated virus has no growth advantage over 
wildtype, preventing its selection and giving little opportunity for the mutant to acquire 




Figure 1-4.  The Potency Plateau and Resistance Capacitor.  An inhibitor that 
maintains the same potency (IC50) over a range of affinities (KD) has reached a potency 
plateau.  Increasing affinity despite no improvements in potency creates a charged 
“resistance capacitor” where excess binding energy is stored that can resist HIV 
mutations.  If HIV manages to acquire a mutation in the pocket, affinity (KD) of the 
inhibitor for the pocket will be weakened.  A 100-fold loss of affinity represents a 
particularly severe affinity-reducing mutation (red arrows).  With a charged resistance 




Resistance studies conducted in collaboration with Mike Root at Thomas 
Jefferson University reveal how difficult it is for HIV to develop mutations to escape our 
pocket-binding inhibitors.  PIE12-dimer and PIE12-trimer were incubated with virus at 
sub-therapeutic levels to encourage the development of virus resistance.  Using this 
protocol, resistance to Fuzeon developed after only 3 weeks, while resistance to PIE12-
dimer and PIE12-trimer required 40 and 65 weeks respectively5, demonstrating the 
inability of HIV to readily mutate its pocket and the effectiveness of the resistance 
capacitor design. 
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Peptide Therapeutics – Powerful Yet Fragile 
 
Peptide therapeutics have key advantages and disadvantages compared to small 
molecules and proteins.  Compared to small molecules, peptides generally have improved 
selectivity and affinity.  Furthermore, peptides can disrupt protein-protein interactions, 
which has proven a difficult challenge for small molecules.  And unlike proteins, peptides 
can be chemically synthesized, can penetrate deeper into tissues, and are generally less 
immunogenic because of their small size19,20.  However, peptides generally suffer from 
short half-lives and limited delivery options.  Unless specially designed (like our D-
peptides), peptides are susceptible to proteases and are rapidly degraded, often with half-
lives on the order of minutes19.  Furthermore, their small size leads to rapid clearance 
(e.g., by renal filtration).  Moreover, peptides do not easily cross cell membranes, which 
not only limits access to potential cytoplasmic targets, but also prevents absorption from 
the GI tract.  As a result, peptides are generally delivered parenterally. 
Fuzeon is an FDA-approved HIV entry inhibitor that exemplifies many of the 
challenges associated with peptide therapeutics.  For instance, Fuzeon is rapidly degraded 
by proteases.  Therefore, very large doses must be given to make up for its rapid 
clearance (90 mg subcutaneously injections twice each day).  Such large doses drive up 
the cost of the therapy (~$30,000/year) and require formulations that are irritating to the 
skin leading to severe injection site reactions.  Moreover, Fuzeon binds the mutation-
prone groove region of the gp41 N-Trimer, leading to rapid development of resistance.  
Although approved, these challenges limit Fuzeon to salvage therapy in patients with 
treatment-resistant HIV. 
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By overcoming the common limitations of peptides, our work aims to simplify 
patient dosing by enabling once-weekly or once-monthly subcutaneous injection.  Having 
already overcome protease susceptibility by developing D-peptides, avoiding additional 





Because we recognized the general limitations of peptide therapeutics at an early 
stage, we developed our anti-HIV candidates to be protease stable from the very 
beginning by utilizing nondegradable D-peptides.  However, rapid clearance is still a 
major concern; even nondegradable peptides can be quickly cleared by renal filtration or 
other metabolic process. 
 Numerous promising PK-enhancing strategies for peptides have emerged over the 
years, with several yielding FDA-approved products.  And because insulin, glucagon-like 
peptide 1 (GLP-1), interferon (IFN-alpha2a), and HIV C-peptide-based entry inhibitors 
all have proven efficacy, it seems that every PK-enhancing strategy has been applied to at 
least one of them.  PEGylation has yielded 11 approved products and is arguably the most 
successful strategy to date.  Lipidation is a growing field with two approved products.  
Direct albumin conjugation is perhaps the next-most developed approach, demonstrating 
impressive gains in half-life.  Chapter 5 focuses on utilizing the most promising of these 






Conjugating peptides and proteins to polyethylene glycol (PEG), also known as 
polyethylene oxide (PEO), has an impressive track record of enhancing PK in approved-
products (Table 1-1).  PEGylation primarily enhances PK by reducing renal filtration, and 
because PEG is extensively hydrated by water, less PEG is required to reduce filtration 
than might be anticipated from molecular weight alone.  While the molecular weight 
cutoff for globular proteins to avoid renal clearance is ~70 kDa, peptide and protein PEG 
conjugates need only acquire a combined molecular weight of 40-60 kDa.  This can 
usually be accomplished by the addition of 20-40 kDa of PEG. 
The PK-enhancing benefits of PEG are sigmoidal, so exceeding 40 kDa of PEG 
provides little additional PK benefit and appears to increase uptake into the 
reticuloendothelial system21.  Moreover, adding less than 5 kDa of PEG appears to 
provide little PK benefit.  Notably, PEGylation also diminishes clearance of susceptible 
therapeutics by reducing proteolysis (e.g., Omontys [peginesitide]) and immunogenicity 
(e.g., Krystexxa [PEG-uricase]). 
 Important challenges are associated with PEGylation.  PEGylation usually 
reduces activity of the protein/peptide conjugate, and the polydispersity of PEG 
complicates quantitation, essentially necessitating ELISA-based quantitation.  Viscosity 
must also be considered.  We attached a 40 kDa Y-branched PEG to PIE12 and found 
that viscosity limits its solubility to about 10 mM in 50 mM HEPES, pH 7.4.  
Hydroxyethylene starch conjugation (HESylation) is an alternative strategy based on the 
same principles of PEGylation, but HES is less viscous than PEG22. 
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 Lipid conjugation is another validated approach for improving half-life.  
Endogenous free fatty acids (FFAs) bind strongly (mid to low nM KD23-25) to human 
serum albumin (HSA), which circulates with an impressive 19 day half-life26.  Thus, 
conjugating a fatty acid (acylation) to a peptide reduces clearance by promoting HSA 
association.  The approved products Victoza (liraglutide) and Levemir (insulin detemir) 
utilize this strategy, employing palmitate and myristate respectively. 
 Cholesterol conjugation is an alternative lipidation strategy.  Cholesterol is 
reported to have a 25-435 µM affinity for albumin27,28 and a strong but reversible affinity 
for cell membranes9.  Cholesterol conjugation has been show to significantly improve PK 
properties, as well as localize antiviral peptides to lipid rafts, greatly enhancing their 
antiviral potency29.  However, PK studies of cholesterol conjugates have not been done in 
humans who possess a unique circulating lipid profile, so there may be a significant 
difference in the way cholesterol conjugates are shuttled and interact with circulating 
lipid carriers in humans compared to rodents. 
 
Albumin Binding Peptides and Molecules 
 Since acylation has demonstrated reliable PK-enhancement through albumin 
interaction, albumin-binding peptides and molecules have emerged as alternative PK-
enhancing techniques.  Genentech’s SA21 is the best studied of this group.  SA21 is an 
18 amino acid disulfide-constrained peptide (Ac-RLIEDICLPRWGCLWEDD-NH2) 
with 467 nM affinity for HSA and exhibits a 2.3 hour terminal half-life after IV injection 
in rabbits30.  A similar disulfide-bonded peptide with micromolar affinity has been 




identified by Dyax after screening a CX10C phage library31, while an extremely high 
affinity (50 fM) albumin-binding protein has been engineered by optimizing (also by 
phage display) a bacterially-derived nanomolar affinity 46-residue three-helix bundle32.  
Finally, “Albu tag” is a unique small molecule that displays a high affinity for albumin 
(330 nM at 37 °C) and a maleimide moiety for thiol-mediated peptide conjugation33. 
 
Direct Albumin Conjugation 
 As mentioned, albumin circulates with an impressive 19-day half-life in humans. 
Albumin enjoys this half-life by avoiding renal filtration.  For globular proteins, the size 
limitation for avoiding glomerular filtration is ~70 kDa, and although albumin is slightly 
below this size threshold (66.5 kDa), it avoids filtration because it is highly negatively 
charged and experiences electrostatic repulsion from the highly negatively charged 
glomerular basement membrane of the kidney.  By comparison, IgG (150 kDa), one of 
the largest circulating proteins, circulates with a half-life of 21-27 days (subclasses 1, 2 
and 4; subclass 3 has a half-life of only 7 hours)34. 
Rationally, if albumin-binding moieties increase half-life, direct conjugation to 
albumin should increase half-life even further.  To this end, three strategies have been 
described.  Two strategies involve thiol-mediated conjugation to the uniquely exposed 
Cys-34 in the Ia subdomain of albumin.  The difference between them is whether 
conjugation is completed in vitro to purified HSA or a thiol-reactive prodrug is delivered 
for conjugation in vivo to circulating HSA.  The accessibility of albumin’s Cys-34 thiol 
both in vitro and in vivo is discussed by Katz et al., who note that physiologically free 
thiols are fairly rare such that side-reactions are expected to be uncommon35.  The third 




reported strategy involves genetically linking a peptide to HSA such that a fusion protein 
can be expressed36, though such a strategy depends on recombinant expression and would 
not be suitable for D-peptides. 
 
Other PK-Enhancers 
A variety of other PK-enhancing moieties can be found in the literature.  Fc 
conjugation is a validated strategy with several approved products (e.g., Orencia, Enbrel).  
The Fc domain derived from human IgG1 increases half-life by utilizing cellular Fc 
receptors.  These receptors mediate endocytosis of Fc domains followed by a return to 
circulation37.  Moreover, Fc receptors in the lung are thought to provide an opportunity 
for trans-pulmonary delivery of peptides into circulation38. Fc domains require 
mammalian cell-line expression in order to achieve appropriate folding and 
glycosylation, although recent work has focused on mutated Fc variants to simplify 
production.39  PK-enhancing transferrin and GCSF conjugations are also reported in the 
literature but have not yet been extensively utilized.  Like Fc domains, these conjugations 
are thought to improve half-life by utilizing receptors that mediate endocytosis and 
recycling37. 
 Fuzeon has been found to contain a critical 8 amino-acid hydrophobic foot, 
WASLWNWF, which is necessary for its potency (through membrane localization) and 
half-life40.  The sequence is derived from the gp41 MPER region (Fig. 1-2).  This moiety 
is attractive as a potential PK-booster because of its short length, and because its 
generally hydrophobic sequence may enable it to function equally well in D, making it 
nondegradable. 




 Our lab has also considered multimerization as a strategy for PK-enhancement.  
As mentioned previously, globular proteins are efficiently filtered by the kidney until 
they exceed ~70 kDa in size.  Each PIE12 peptide is ~2 kDa, and each PIE12-trimer is ~7 
kDa.  To approach 70 kDa of molecular weight, strings of monomers or trimers could be 
linked together through any number of possible geometries.  PEG linkers with multiple 
reactive groups are readily available, although their polydispersity may complicate 
studies that utilize them.  Alternatively, multimerization could be achieved using 
controlled linkages, such as poly-Lys or poly(Lys-Gly-Gly) peptide scaffolds. 
 
Depots and Drug Formulation 
Depots are an attractive and validated PK-enhancing strategy that slowly releases 
compounds over a prolonged period of time, reducing clearance, increasing drug 
exposure, and prolonging the time between doses.  For example, in the GLP-1 analog 
field, Byetta (exenatide) exhibits a 2.4 hour terminal half-life (SC) and must be 
administered twice per day, while Victoza (liraglutide) is a PK-enhanced acylated 
homologue with an improved terminal half-life of 13 hours (SC) that allows for once-
daily subcutaneous administration41,42.  However, even without the aid of PK-enhancing 
conjugations, Alkermes has co-developed Bydureon (extended release exenatide) 
utilizing their biodegradable depot formulation (50:50 poly(D,L-lactide-co-glycolide) 
polymer and sucrose), enabling an impressive once-weekly subcutaneous administration.  
It is likely that PK-enhancing conjugations (e.g., acylation or cholesterol conjugation) 
would be readily compatible with extended release depot formulations resulting in 
additive PK improvements. 




Furthermore, drug formulation technology provides another means for improving 
half-life and bioavailability.  Cyclosporine is a classic example of peptide drug 
formulation where excipients enabled ~30% oral bioavailability43,44, although its success 
has not proven general for most peptides.  Instead, a relatively new field has emerged that 
utilizes gut permeabilizers and protease inhibitors to improve the oral bioavailability of 
peptides.  Gut permeability enhancers transiently reduce tight-junctions in the GI tract, 
allowing peptides to be absorbed paracellularly45,46.  A primary concern with these agents 
is the potential for bacterial transmission into the bloodstream.  For this reason, 
Unigene’s technology is perhaps the most promising; using a gentle and naturally 
occurring gut permeabilizer common in goat milk (acylated carnitine), peptides can 
become absorbed in the duodenum immediately following stomach evacuation, a 




Analytical Assay Development 
 
As we prepared for investigational new drug (IND)-enabling studies involving 
pharmacokinetics and toxicity, it was apparent that we would need a robust quantitative 
assay for plasma and tissue samples.  Pilot PK and toxicity studies are required to rank 
and select PIE12-trimer conjugates for advancement to expensive IND-enabling 
preclinical studies.  Our original approach was to develop an assay that could 
accommodate a variety of PIE12 candidates, independent of what we had conjugated to 
them (i.e., an assay based on function/binding events).  Further, we had hoped to develop 
a “homogenous” assay that required little or no sample preparation.  We wanted an assay 




where the addition of a few reagents to a sample could produce a detectable readout.  We 
initially explored fluorescence-based assays like FRET and ELISA that have 
extraordinary sensitivity, with lower-limits of detection often below 10 nM.   
Unfortunately, we encountered a variety of unanticipated barriers, some of which 
were insurmountable.  The key problem was that unknown plasma component(s) 
interfered with our fluorescent assays and could not be removed.  The interference also 
varied from animal to animal, preventing our ability to predict or account for it.  Details 
and ideas for future troubleshooting are discussed in the Appendix.  Given these 
problems, we developed an LC/MS/MS bioanalytical assay.  Method development for 
each of our conjugates has been straightforward, allowing us to achieve lower-limits-of-
detection below 10 nM.  The PK studies conducted in Chapter 5 utilize this assay. 
It is helpful to discuss briefly some basic principles behind a triple-quad mass 
spectrometer and the general MRM (Multiple Reaction Monitoring) method (Fig. 1-5). 
The triple-quad is comprised of three quadrupoles dubbed Q1, Q2, and Q3.  Each 
quadrupole functions independently such that each can be set to allow only a chosen set 
of molecular weight/charge ratios to pass.  Preceding Q1 is the source, which ionizes 
molecules that pass through it.  Peptides usually pick up multiple charges in the source 
(e.g., each PIE12 prefers a +2 charge state, though +3 is also produced).  Q1 then filters 
the influx to allow only selected parent ions to pass.  The molecular weight range that is 
selected for Q1 is based on mass (m) per charge (z) ratios.  The Q1-selected m/z parent(s) 
then enter Q2.  Q2 is filled with a collision gas that breaks the parent ion into fragments, 
termed daughter ions, while Q3 is set to capture selected daughter ions.  The MRM 
method  utilizes  all  three  quadrupoles;  Q1 to select for a parent mass,  Q2  to  break the  





Figure 1-5.  General Function of an LC/MS/MS Triple-Quad Mass Spectrometer.  A 
source sends ionized particles into the first quadrupole Q1.  One or more specified m/z 
ions are selected in Q1 and passed into Q2 where these parent ions collide with gas to 
produce daughter ion fragments.  Q3 passes selected daughter ions to the detector.  An 





parent into fragments, and Q3 to select for a daughter mass.  Notably, the process of 
breaking a parent ion and selecting a daughter ion reduces sensitivity by ~10-fold, but the 
signal-to-noise ratio improves dramatically, making the MRM method ideal for removing 
potentially confounding signals (e.g., from plasma samples).  In general, triple-quads are 
considered “unit” resolution instruments (i.e., 1 m/z resolution). 
 
 
FDA Approval Considerations 
 
Precedent is an obvious benefit when pursuing FDA approval.  As such, it is 
worth mentioning two IND’s that have been filed for full-D peptide therapeutics.  
Genzyme’s orally-administered Delmitide (NH2-D-Arg-D-Nle-D-Nle-D-Nle-D-Arg-D-
Nle-D-Nle-D-Nle-D-Gly-D-Tyr-CONH2)49,50, currently under investigation for ulcerative 
colitis, and Allelix’s IV-administered CXCR4 inhibitor ALX40-4C (N-acetyl-nona-D-
arginine amide)51 have both been tested and found to be well tolerated in human trials.  
These precedents reduce concerns over a possible generalized innate toxicity from D-
peptides. 





Chapter 2 reviews the peptide therapeutics field with special emphasis on utilizing 
protease-resistant design for the discovery of HIV inhibitors.  Chapter 3 describes how 
mirror-image phage display and structure-assisted design were utilized in the discovery 
of PIE12.  Early oligomerization efforts are also described.  Chapter 4 recounts the 
development of our powerful scaffold-based design for rapid synthesis of PIE12-trimer 
with membrane-tethering cargoes.  PK-enhancing designs and related PK studies are 
portrayed in Chapter 5.  Studies underway and immediately pending are discussed in the 
future directions in Chapter 6.  Finally, efforts and lessons involving development of a 
FRET and ELISA bioanalytical assay are illustrated in the Appendix. 
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INTRODUCTION
I
n drug discovery and development, peptide therapeutics
have many advantages. Their polymeric nature makes
synthesis straightforward, especially when compared
with the synthetic schemes typically utilized for small
molecules. Peptides are generally easier and less expensive
to produce than recombinant proteins. Peptide therapeutics
can also be more specific (and less toxic) than small mole-
cules and excel at the challenging problem of disrupting large
protein–protein interaction interfaces (i.e., ‘‘undruggable’’
targets). Due to advancements in genomics and proteomics,
a plethora of natural peptide ligand sequences for important
drug targets are available and provide a sensible starting
point for the rational development of therapeutic com-
pounds. In addition, a host of mature and emerging library-
based screening techniques provides a means to rapidly dis-
cover novel peptide sequences with specific binding proper-
ties.
Despite these enticing advantages, a major problem limit-
ing development of peptide therapeutics is their proteolytic
sensitivity and associated delivery challenges. Synthetic thera-
peutic peptides are typically relatively unstructured and are
therefore rapidly degraded in vivo, often with half-lives on
the order of minutes.1 Proteolysis commonly occurs in the
GI lumen, intestinal brush border, enterocytes, hepatocytes,
antigen-presenting cells, and plasma. Because of this in vivo
fragility, oral delivery is generally not possible, necessitating
frequent dosing by injection. Even when delivered parenter-
ally, degradation in the blood combined with rapid renal fil-
tration often results in drugs that are expensive, inconven-
ient, and unpleasant to administer.
Protease-resistant peptides would address many of these
limitations. One of the most promising approaches is to
modify the chemical structure of the peptide backbone (pep-
tidomimetics).2 Modifications that have been shown to sub-
stantially decrease proteolysis include N-methylation, ester
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utility. We focus on the use of mirror-image (D-peptide)
and ß-peptides as two leading approaches with distinct
design principles and challenges. Application to the
important and difficult problem of inhibiting HIVentry
illustrates the current state-of-the-art in peptidomimetic
technologies. We also summarize future directions for this
field and highlight remaining obstacles to widespread use
of protease-resistant peptides.# 2012Wiley Periodicals,
Inc. Biopolymers (Pept Sci) 98: 431–442, 2012.
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linkages (a-hydroxy acids), insertion of additional methylene
groups into the backbone (b-amino acids, c-amino acids
etc.), and the use of D-amino acids. More significant changes
to the peptide backbone include peptoids, azapeptides,
oligoureas, arylamides, and oligohydrazides.2–4
In this review, we describe how modified peptide back-
bones can be used to design protease-resistant inhibitors
with a special focus on the high-priority problem of design-
ing protease-resistant HIV entry inhibitors. Although these
modified backbones effectively address protease sensitivity,
each is associated with a set of design challenges using
rational design or library screening techniques. This review
will not cover traditional strategies to reduce protease sensi-
tivity, e.g., peptide capping, sequence alteration at susceptible
sites, cyclization, or stapling, which have been extensively
reviewed elsewhere.5
INHIBITING HIV ENTRY
An estimated 34 million people worldwide are infected with
HIV, the causative agent of AIDS, resulting in nearly 2 mil-
lion deaths per year and over 25 million cumulative deaths
(UNAIDS). Dramatic progress has been made in reducing
mortality since the inception of antiretroviral therapy against
HIV enzymes reverse transcriptase, protease, and recently
integrase. However, the relentless development of drug resist-
ance necessitates ongoing development of therapeutics that
target other stages in the viral lifecycle. In particular, there
have been extensive efforts to develop potent, broadly active,
and economical entry inhibitors for the prevention and treat-
ment of HIV/AIDS.6
The current HIVentry pathway model is shown in Figure 1.
Viral entry into host cells is mediated by the trimeric HIV en-
velope (Env) glycoprotein. Env contains the noncovalently
associated surface gp120 and transmembrane gp41 subunits.
gp120’s primary function is to interact with cell receptors that
mark HIV’s preferred target cells (e.g., T-cells and macro-
phages), while gp41 induces membrane fusion. Host cell inter-
actions are mediated by gp120 through association with the
primary cell receptor (CD4) and chemokine coreceptor (either
CXCR4 or CCR5, depending on viral tropism). Upon gp120
engagement with cell receptors, a complex series of structural
rearrangements in gp120 propagate to gp41, activating it for
membrane fusion (reviewed by Ref. 7). At this stage, gp41
forms an extended prehairpin intermediate containing an
N-terminal trimeric coiled coil (N-trimer) and C-terminal
region (C-peptides) of unknown structure. Fusion is driven by
collapse of this intermediate as three helical C-peptides pack
anti-parallel to the N-trimer (trimer-of-hairpins formation),
drawing the viral and host cell membranes into close proximity.
A similar fusion mechanism is utilized by many other enveloped
viruses, including influenza, Ebola, and paramyxoviruses.7
C-Peptide Inhibitors
This mechanism suggests that peptides derived from the
N- and C-peptide regions of gp41 could prevent viral mem-
brane fusion in a dominant-negative manner by preventing
trimer-of-hairpins formation. Indeed, both N-and C-pep-
tides inhibit HIV entry.8–14 The N-trimer/C-peptide interac-
tion is predominantly mediated by conserved interactions
between the hydrophobic face of helical C-peptides and a
hydrophobic groove formed between helices in the N-trimer.
C-peptide inhibitors are more promising drug candidates
because of their higher potency and better solubility com-
pared with N-peptide inhibitors.
C-peptide inhibitors were first identified through screens
of gp41-derived peptides.9,11 Fuzeon (Enfuvirtide, T-20) is a
36 amino acid L-peptide taken from the gp41 C-peptide
region. Fuzeon inhibits HIV entry with nM potency and
reduces viral loads by 2 logs,15 leading to its approval as the
first HIV entry inhibitor in 2003. Unfortunately, Fuzeon’s
clinical use has been limited by its short half-life. Fuzeon
requires injection at very high doses (90 mg, twice daily) to
overcome its proteolysis and rapid renal filtration. These
practical problems result in a drug that is expensive
(*$30,000 per year), can cause painful injection site reac-
tions, and is only approved for patients experiencing treat-
FIGURE 1 HIV entry pathway. HIV Env is composed of surface
(gp120, green) and transmembrane (gp41, blue) subunits. Fusion is
initiated by binding to CD4 and a chemokine coreceptor, which
activates gp41 and induces formation of the prehairpin intermedi-
ate. In this intermediate, the gp41 N-terminal region forms a tri-
meric coiled coil (N-trimer, gray), which is separated from the C-
peptide region (dark blue). This intermediate slowly collapses to
form a trimer-of-hairpins structure that brings the viral and cell
membranes into close apposition, leading to fusion. C-peptide and
D-peptide inhibitors bind to the N-trimer, preventing trimer-of-
hairpins formation and membrane fusion.
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ment failure due to multi-drug resistance (‘‘salvage therapy’’).
Fuzeon’s high dosing requirements and in vivo fragility also
limit options for less frequent dosing via depot formulation.
The gp41 ‘‘Pocket’’ Region
At the N-trimer’s C-terminus lie three symmetry-related
deep hydrophobic pockets. Each pocket has a volume of
*400 A˚3 that is filled primarily by three C-peptide residues
(Trp628, Trp631, and Ile635)16,17 (Figure 2). The pocket is a
promising inhibitory target because of its critical importance
in membrane fusion and very high level of conservation
across diverse HIV strains.16,18 Mutations in the pocket are
often not well tolerated due to the requirement for compen-
satory mutations in the C-peptide region to restore binding.
In addition, the pocket region is encoded by the structured
RNA region of the Rev-responsive element (RRE), which
contains a signal critical for nuclear export of viral RNA.18
Interestingly, extensive efforts by numerous groups to dis-
cover small molecule pocket-binding inhibitors have had
limited success, generally producing inhibitors with modest
potency and/or significant toxicity.19–23 Based on this body
of work, the gp41 pocket appears to be ‘‘undruggable’’ by
small molecule inhibitors, a common problem for extended
protein–protein interaction interfaces.
Fuzeon was discovered before the gp41 6-helix bundle
crystal structure and does not bind to the gp41 pocket. How-
ever, next generation C-peptide inhibitors (e.g., C34, T-1249)
do include pocket-binding residues and enjoy superior
potencies and resistance profiles.24–26 The follow-on com-
pound to Fuzeon, T-1249, performed very well in clinical tri-
als, but was not developed further due to unspecified formu-
lation problems, which we speculate includes challenges in
the economic synthesis of this 39-residue peptide and a
requirement for four 1 mL injections, once per day, as used
in a phase I/II trial.25
Fuzeon and T-1249 show that a peptide fusion inhibitor
can be very effective against HIV, but the impact of such
drugs will be limited until the problems of short half-life and
high dosing (and the resulting high cost) can be overcome.
In this review, we focus on two distinct strategies that have
yielded promising protease-resistant peptide fusion inhibi-
tors with the potential to overcome Fuzeon’s in vivo fragility.
RATIONAL DRUG DESIGN WITH MODIFIED
PEPTIDE BACKBONES
While there is much interest in the de novo development of
peptides with defined structural and functional characteris-
tics, this work is hampered by limitations in currently avail-
able modeling strategies. Thus, as illustrated below, most suc-
cessful rational designs of protease-resistant peptides start
from sequence and structural information from existing pep-
tide ligands.
In the realm of rational design of modified peptide thera-
peutics, b-peptides and mixed a/b-peptides are among the
most promising. b-peptides are composed of b-amino acids,
which contain an extra backbone methylene group (between
FIGURE 2 One pocket, two binding solutions. The gp41 pocket (from pdb code 3L35) is shown
with (A) the natural gp41 C-peptide (pdb code 1AIK) and (B) D-peptide PIE12 (pdb code 3L35).
Structures were aligned on the 17 pocket-forming residues from gp41 and rendered using Pymol.
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the amino and a-carbon, specified as a b2-amino acid, or
between the carboxylate and a-carbon, specified as a
b3-amino acid) (Figure 3). Short b-peptide sequences can
adopt robust secondary structures analogous to a-helices
formed by a-amino acids. If a natural helical peptide ligand
is known, a b-peptide mimic can be generated by the precise
placement in three dimensions of key side chains onto a
b-peptide scaffold. Two b-peptide scaffolds that have been
extensively utilized are the 12-helix and 14-helix, named after
the number of atoms between hydrogen bonding groups
(these and other b-residue-containing scaffolds are reviewed
elsewhere3,27–30). The specific structural motif adopted by a
particular b-peptide is dictated by the nature of the substitu-
ent b-amino acids.31 b-peptides composed of monosubsti-
tuted, acyclic b-amino acids or cyclic six-member ring
b-amino acids preferentially adopt the 14-helix structure,
while the 12-helix structure is favored by peptides composed
of cyclic five-member ring b-amino acids. The helical param-
eters of the 12- and 14-helices are discussed and compared
with a-helices in Refs. 27 and 31.
In a 14-helix composed of b3-amino acids, side chains at
residues i, i+3, and i+6 are presented along the same face of
the helix, and are reasonably superimposable with side chains
at residues i, i+4, and i+7 of an a-helix.32 This property can
be exploited to display epitopes that mimic an a-helical face
and has been applied to the development of low-mid lM
HIV entry inhibitors that bind to the gp41 pocket region.33,34
In an analogous approach, b-peptide inhibitors of HCMV
entry were developed using the 12-helix scaffold.35 To map
an a-helix epitope onto the 12-helix, side chains at positions
i, i+4, and i+7 on the a-helix are placed at positions i, i+3,
and i+5 on the 12-helix. Although acyclic residues diminish
12-helix propensity, they provide the easiest avenue for side
chain attachment, so a minimum number of acyclic b2 or b3
residues were introduced into the structure at specific points
to mimic side chain presentation of the native a-helix. This
approach enabled the rapid discovery of inhibitors with
modest potency, but its main challenge is the lack of a route
forward, by rational design or high-throughput screening, to
optimize these initial hits.
A sequence-based approach utilizing mixed a/b-peptides
has been applied to develop an HIV entry inhibitor that
structurally and functionally mimics C-peptides (*10 turn
a-helix).36 In this approach, a subset of C-peptide residues
were strategically replaced with homologous b3-amino acids
following an aabaaab pattern, which, despite the additional
methylene units, does not significantly alter secondary struc-
ture of the helix.37 On folding, this pattern generates an a-
helix-like conformation with a b-residue stripe that runs
down the side of the helix distal to the interaction surface,
minimizing disruption of the binding interface. On replacing
11 of the 38 residues with b3-amino acids, the resulting a/b-
peptide had >10,000-fold diminished affinity for its binding
target relative to the a-peptide counterpart.
As a second step in the design, specific b3-residues were
replaced by cyclic b-residue homologues. The cyclic residues
were incorporated to reduce the entropic penalty associated
with helix formation due to the inherent torsional flexibility
of b3-residues. b3 analogues of alanine in the a/b-peptide
were replaced with a nonpolar, five-member ring constrained
b-residue (ACPC), while b3 analogues of arginine were
replaced with a polar, heterocyclic analogue of ACPC (APC).
These replacements improved affinity by*400-fold over the
peptide with acyclic residues. Although the binding affinity
never recovers to that of the original a-peptide ligand, the
resulting a/b-peptide was nearly as potent as the a-peptide,
but with the added advantage of being 280-fold more resist-
ant to proteolytic degradation by proteinase K. The apparent
discrepancy of having diminished binding affinity, yet a-pep-
tide-like potency is likely due to the potency plateau
observed for many HIV entry inhibitors (see the discussion
of the ‘‘resistance capacitor’’ below).
The original report indicated that the N-terminal Trp-
Trp-Ile motif of the a/b-peptide does not engage the C-ter-
minal hydrophobic pocket of gp41, but subsequent crystallo-
graphic analysis indicated that that the pocket-binding motif
FIGURE 3 Peptidomimetic structures.
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on the a/b-peptide is indeed able to engage the pocket. The
authors suggest that the lack of engagement in the original
structure was an artifact caused by crystal packing, and that
the newer structure more faithfully portrays the binding of




An alternative to rational design is screening of random pep-
tide libraries. These high-throughput methods identify novel
peptides with a desired function (typically binding to an im-
mobilized target). Commonly used screening techniques
include phage, ribosome, and mRNA display, but these
methods all rely on cellular translation machinery and are
therefore not yet fully compatible with peptidomimetics in
their standard forms. Though there have been many advan-
ces and refinements in the field of synthetic peptidomimetic
library generation (e.g., split and pool synthesis, physically
addressable synthesis by photolithography), these synthetic
libraries are typically limited to <106 members39 compared
with the billion to trillion member libraries that can be gen-
erated with genetically encoded libraries.
D-Peptides
D-peptides are entirely composed of D-amino acids, which
are mirror-image stereoisomers of the L-amino acids found
in naturally occurring L-peptides. D-Peptides are a promising
therapeutic platform because they are highly resistant to nat-
ural proteases.40 In elegant work by the Kent group,41 D-HIV
protease was shown to cleave only D-peptide substrates,
showing that proteases exhibit highly stereospecific substrate
discrimination.
The symmetry relationship between L- and D-peptides can
be exploited in mirror-image display techniques42 in which a
mirror-image version of the target molecule is generated by
solid-phase synthesis using D-amino acids. Randomized ge-
netically encoded L-peptide libraries are then screened against
this D-target. The winning L-peptides are identified by DNA
sequencing and then the corresponding D-peptides are syn-
thesized. By symmetry, the D-peptide will have the same ac-
tivity toward the natural L-target as the L-peptide had against
the mirror-image D-target (Figure 4).
A major limitation of mirror-image display is the require-
ment for chemical synthesis of the D-target. Synthesis of D-
peptides is currently done using traditional solid phase pep-
tide synthesis (SPPS).43 Routine use of SPPS chemistries for
the production of peptides is limited to *50 residues,
though this limit varies widely depending on the required
purity and sequence/structure properties of the peptide in
question (e.g., extended beta-strand peptides can aggregate
during SPPS). Despite these challenges, syntheses of very
long peptides have been reported (e.g., the synthesis of the
140-residue IL-3 protein44).
Larger D-peptide targets can be obtained using peptide li-
gation techniques to link multiple synthesized peptide frag-
ments. A variety of ligation chemistries have been developed
(see Ref. 45 for a very thorough review), but the most com-
mon technique is cysteine-mediated native chemical ligation
(NCL). NCL requires the presence of an N-terminal cysteine
on one peptide fragment and a C-terminal thioester on the
other (see Ref. 46 for a summary of popular recombinant
and synthetic methods for the generation of peptides bearing
a C-terminal thioester) and results in the ligation of the two
segments via a native peptide bond. SPPS of thioester-con-
taining peptides has traditionally been carried out via Boc
chemistry, but recent advances have enabled the robust syn-
thesis of thioesters using the easier and more popular Fmoc
chemistry47 and commercially available Dawson Dbz resin
(Novabiochem). Other means of accessing peptide thioesters
via Fmoc chemistry have been recently reviewed.48
By strategically utilizing masked N-terminal cysteines
(e.g., thioproline), multiple peptide fragments can be joined
together sequentially or in a single-pot reaction.49–53 This
strategy has been used in the D-peptide synthesis of the 81-
residue snow flea antifreeze protein.54 NCL leaves a Cys resi-
due at each ligation site, but this ‘‘scar’’ can be removed by
desulphurization of the cysteine residue to alanine.55,56 Fur-
thermore, several creative adaptions of NCL allow residues
other than an N-terminal cysteine to be present at the liga-
FIGURE 4 Mirror-image phage display. Phage bearing L-peptides
are panned against a mirror-image protein (D-target). By symmetry,
D-versions of binding peptides will bind to the natural L-targets.
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tion junction, such as N-terminal, thiol-containing auxiliary
groups that can be removed via reduction,57 UV irradia-
tion,58,59 or treatment with acid60,61 after they have facilitated
peptide bond formation. In another approach, modified ver-
sions of phenylalanine,62 valine,63 or lysine64 bearing a thiol
substituent were incorporated at the N-terminus of a peptide
fragment and yielded the respective native amino acid at the
ligation site following NCL/desulfurization.
Once a D-target has been synthesized, it can be used in
conjunction with mirror-image display to screen peptide
libraries for novel sequences of interest (see our work on
HIV below and Ref. 65). The unifying feature that underlies
all of the library-based display techniques discussed here is
the physical linkage of a peptide to its corresponding geno-
type (RNA or DNA). This linkage allows the library to be
subjected to multiple rounds of interrogation/library amplifi-
cation leading to enrichment of sequences that bind to a tar-
get of interest. In these techniques, library diversity is gener-
ated in the nucleotide coding sequence, and cellular machin-
ery efficiently translates this information into a peptide
library. The display techniques most suitable for screening
high-diversity libraries can be broken down into two broad
categories: viral display and cell-free display systems
(briefly described here, but for a more extensive review see
Refs. 66–70).
Viral Display
Phage display continues to be the workhorse of the viral dis-
play techniques because of its ease of use, versatility, and low
cost. Since phage display requires a bacterial transformation
step, library size is typically limited to *109–1010. The most
commonly utilized phage display system is the nonlytic M13-
family filamentous phage, in which the peptide library is
expressed as an N-terminal fusion with the pIII minor coat
protein. Up to five copies of pIII are present on the phage
surface, making both polyvalent and monovalent display
techniques possible. Polyvalent display provides a strong
avidity effect, which is highly advantageous for screening na-
ı¨ve peptide libraries containing only rare low affinity binders.
In contrast, monovalent display reduces avidity and allows
for more stringent selection of peptides with high affinity. In
an early round of phage display, library diversity is high, but
each sequence is represented by only a few phage. As with
any library display method, the application of selection pres-
sure must be sufficient to drive selection for tighter binders,
but not so severe as to eliminate rare tight binding sequences
due to stochastic factors. In later rounds, as phage library di-
versity drops and each remaining sequence is represented by
numerous phage, selection pressure can be steadily increased.
Insufficient selection pressure can select for ‘‘cheater’’ phage
that do not bear authentic tight binding peptides (e.g., phage
with growth advantages).
Besides filamentous phage display, techniques employing
various eukaryotic viruses, including retroviruses, baculovi-
rus, Adeno-associated virus, and Adenovirus have been or
are currently being developed for displaying peptide libra-
ries.67 Other display techniques (e.g., bacterial, yeast, or
mammalian cell display) have several advantages over phage
display (e.g., more sophisticated folding machinery, post-
translational modifications, ability to use FACS sorting), but
are more complex and typically limited to less diverse libra-
ries (reviewed by Refs. 66, 67, 71, 72).
Cell-Free Display
One of the major advantages of cell-free techniques (reviewed
by Ref. 73) is that they are carried out in vitro. Because a
transformation step is not required, library diversities >1012
can be generated.69 Due to the proposed correlation between
library diversity and the affinity of selected ligands, this large
increase in library diversity over typical viral or cell surface
display systems provides a distinct advantage.
Ribosome display74,75 capitalizes on the fact that it is pos-
sible to stall the in vitro translation of a polypeptide so that
the ribosome remains assembled and attached to the mRNA
transcript and the nascent translated polypeptide. This
mRNA-ribosome-polypeptide ternary complex serves to link
genotype to phenotype and can be panned against a target to
isolate sequences of interest. The ternary complex can then
be eluted and dissociated with EDTA, allowing for the isola-
tion of the original mRNA transcript.
Alternatively, RNA display76 links phenotype to genotype
by connecting an mRNA sequence directly to the peptide it
encodes. This linkage is accomplished by chemically attach-
ing the antibiotic puromycin to the 3’ end of the RNA via a
DNA linker. As the mRNA is being translated, the ribosome
will stall once it reaches the DNA linker, allowing puromycin
to enter the ribosomal A site, where the ribosome catalyzes
covalent attachment to the recently translated polypeptide.
This peptide–RNA complex can then be subjected to panning
against a specific target.
While in vitro display techniques that link the peptide
phenotype to an RNA genotype overcome many of the limi-
tations of phage display, the instability of RNA molecules
along with other technical challenges fundamental to these
techniques has limited their application to a relatively small
number of expert laboratories. To address these challenges,
techniques that link the library peptides directly to their
encoding DNA have recently been developed.
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CIS display (Isogenica) exploits the unique activity of
RepA, a bacterial plasmid DNA-replication initiation pro-
tein.77 RepA is a cis-acting protein that tightly binds to the
origin of replication (ori) on the plasmid from which it was
expressed. A stretch of DNA between the sequence that enco-
des RepA and the ori known as the CIS element contains a
rho-dependent transcriptional terminator that is thought to
stall the RNA polymerase during transcription of RepA. The
current model holds that this delay allows the newly synthe-
sized RepA protein emerging from the ribosome to interact
with the CIS element, which subsequently directs RepA to
the ori DNA. Peptide libraries can be fused to the N-terminus
of RepA, thereby creating a link between phenotype and the
DNA genotype. Like other in vitro techniques, CIS display
has the capability to accommodate peptide libraries much
larger than those possible for phage display. In one exam-
ple,77 a library of >1012 randomized 18-mer peptides was
constructed and was used to isolate sequences that bound to
disparate targets. In a similar approach, DNA sequences
encoding randomized peptide libraries are fused to the bacte-
riophage P2A gene. P2A is an endonuclease involved in the
rolling circle replication of bacteriophage P2 DNA. P2A
becomes covalently attached to the same DNA molecule
from which it was expressed, linking phenotype to genotype.
This technique has been used in a pilot study to select single-
chain antibodies from a 107-member library and may be suit-
able for screening much larger libraries.78
D-PEPTIDE INHIBITORS OF HIV ENTRY
Here we describe the history of our potent D-peptide inhibi-
tors of HIVentry, developed in the Kim and Kay laboratories.
Initially, mirror-image polyvalent phage display was used to
screen naı¨ve peptide libraries of various lengths and geome-
tries for binding to an HIV N-trimer pocket mimic
(IQN17).18 Pocket-specific binding was only observed in di-
sulfide-constrained 10-mer sequences (CX10C) containing an
EWXWL consensus sequence. An initial group of *10 win-
ning sequences were validated by measuring their binding to
the desired target and several negative control targets
(mutated or missing pockets) to demonstrate pocket-specific
binding.
Validated D-peptides inhibited HIV entry (lab strain
HXB2) with IC50 values ranging from 11 to 270 lM.
18 A co-
crystal structure of one of the higher affinity D-peptides
(D10-p1) in complex with IQN17 shows that D10-p1 con-
tains two short left handed a-helical segments flanking a turn
imposed by the disulfide constraint. The binding interface
between the hydrophobic pocket of IQN17 and D10-p1 is
mediated by residues in the C-terminal a-helix, with residues
in the EWXWL consensus motif making the largest contribu-
tions. Comparison of the D10-p1/IQN17 crystal structure to
the native post-fusion gp41 structure17 reveals that critical
residues for binding in D10-p1 are very similar in chemical
character to those of the natural C-peptide ligand (primarily
W628, W631, and I635), but adopt distinct conformations
due to their opposite chirality.
Due to library diversity limitations, the first-generation
library only surveyed about one in a million possible sequen-
ces.18 The identification of a strong EWXWL consensus
sequence allowed us to fix these four residues to produce a
‘‘constrained’’ library with only six randomized residues
(*109 possible sequences). Panning this library produced
*4-fold more potent inhibitors.79
Surprisingly, an 8-mer (CX8C) was also among the win-
ning sequences. Since 8-mers were not part of the library
design and likely arose from rare replication errors, their rel-
ative success suggested that the 8-mer geometry might pro-
vide a better pocket-binding solution. Our crystal structure
of the first identified 8-mer, PIE1 (pocket-specific inhibitor
of entry), bound to IQN17 reveals that the key pocket-bind-
ing residues (WXWL) adopt nearly identical positions within
the pocket as seen with D10-p1, leading to very similar bind-
ing interfaces despite PIE1’s reduced length.79 The key differ-
ence between PIE1 and D10-p1 is a more compact D-peptide
structure with a tighter hydrophobic core devoid of water.
PIE1 has a D-Pro at position 8 that likely aids making the
tighter turn necessary for circularization forced by the
shorter disulfide-constrained loop.79
To completely explore 8-mer sequence space, a new library
was generated with the core consensus sequence WXWL
fixed (CX4WXWLC). While screening this library using tra-
ditional solid-phase phage display, we observed that polyva-
lency made it difficult to distinguish modest (lM) and tight
(nM) binders. Solid-phase target presentation is advanta-
geous for selection of weak initial binders from a naı¨ve
library, but problematic for identifying strong binders in a
sea of modest binders since all binders are strongly retained
on the high-density target surface. Moving the binding reac-
tion into solution (solution-phase phage display) reduces
inter-target avidity and allows additional selection pressure
by reducing target concentration through rounds of pan-
ning.80 Despite reduced inter-molecular avidity, solution-
phase phage were still found to have dramatically higher
binding affinities in the context of the panning than expected
based on KD values of the derived D-peptides, likely due to
intra-molecular avidity on the trimeric target. To overcome
this barrier, an L-peptide version of PIE279 (identified during
earlier rounds of solution-phase phage display) was
employed as a soluble competitor for subsequent rounds of
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panning. Increased selection pressure was applied by escalat-
ing PIE2 concentrations, leading to the discovery of PIE7,
which is *15-fold more potent than D10-p1 (IC50 ¼ 620
nM, HXB2 strain).
Our co-crystal structure of PIE7 in complex with IQN17
suggested that further gains in binding affinity could be
made through optimization of the residues outside the disul-
fide bond, which make significant gp41 contacts.79 Initially,
these four ‘‘flanking’’ residues outside the disulfide bond
(Gly–Ala on the N-terminus and Ala–Ala on the C-termi-
nus) were not varied due to library cloning restrictions. We
redesigned the phage display vector to relocate the cloning
sites and allow randomization of the flank residues. After
four rounds, PIE12 (HP-[PIE7 core]-EL) was identified with
*20-fold improved potency over PIE7. The PIE12/IQN17
crystal structure (Figure 2) reveals that PIE12’s improved
binding is likely due to ring-stacking interactions of D-His1
and D-Pro2 with the pocket residue Trp571 and burial of an
additional 50 A˚2 hydrophobic of surface area by D-Leu15.81
Beyond the changes in the flanking regions, the central core
structure is unchanged from PIE7.
Crosslinking and the Resistance Capacitor
After battling the confounding effects of avidity throughout
our phage display screens, we hoped to re-introduce avidity
to boost the potency of our D-peptides. Our D-peptide/N-
trimer crystal structures reveal the precise relationship
between neighboring D-peptides binding to the three symme-
try-related pockets. Using this information, we used discrete
polyethylene glycol (PEG) crosslinkers to generate dimeric
and trimeric D-peptides,79 which showed dramatically
improved antiviral potency (up to 2000-fold) over mono-
meric D-peptides.79,81 PIE12-trimer, our lead inhibitor, is
*30-fold more potent than Fuzeon and inhibits a diverse
panel of the most common circulating HIV strain subtypes
worldwide in the high pM—low nM range.81
Interestingly, we encountered a limit to the potency gains
that could be achieved by monomer affinity optimization
and crosslinking. We hypothesized that this potency plateau
was imposed by the limited time window available for inhibi-
tor binding (target is only available in the transient pre-hair-
pin intermediate) and the inhibitor association rate (limited
by diffusion), as previously observed for the pre-hairpin in-
termediate inhibitor 5-helix.82 Although this potency limit
would prevent us from designing more potent inhibitors, we
hypothesized that ‘‘over-engineering’’ our inhibitors (i.e.,
continuing to improve inhibitor binding despite a lack of
corresponding improvement in potency) would endow them
with a reserve of binding energy that would stall the develop-
ment of resistance mutations. We predict that this ‘‘resistance
capacitor’’ would also greatly delay the emergence of resist-
ance by eliminating the selective advantage conferred by
these mutations (i.e., severing the link between affinity and
potency). Only a profoundly disruptive mutation would
escape the resistance capacitor. In support of this hypothesis,
we were only able to identify high-level PIE12-trimer resist-
ance after 65 weeks of viral passaging in the presence of in-
hibitor, compared with*3 weeks for Fuzeon.81 As predicted,
PIE12-trimer was also able to absorb the impact of earlier-
generation D-peptide resistance mutations.
PROTEASE-RESISTANT PEPTIDES FACE
OTHER PHARMACOKINETIC CHALLENGES
Reduction of peptide susceptibility to proteases increases pep-
tide longevity, but another major threat to serum half-life is
rapid clearance via renal filtration. For globular proteins, the
glomerular filtration size limit is*70 kDa. Although albumin
is slightly smaller, it avoids filtration because of electrostatic
repulsion from the highly negatively charged glomerular base-
ment membrane. Albumin is the smallest major unfiltered
protein, efficiently circulating in the bloodstream with a half-
life of approximately 19 days in humans.83 The small size of
peptide therapeutics means that an additional level of design
is required to reduce renal filtration and realize the full bene-
fits of protease resistance. Several common PK optimization
strategies suitable for peptides are briefly described below.
PEG is a hydrophilic polymer commonly used for protein
conjugation. Adding PEG to a protein has been one of the
most clinically successful strategies for improving pharmaco-
kinetics.84 Early studies on the effects of PEG size on biodis-
tribution revealed that good serum retention is achieved
between 40 and 60 kDa, while exceeding this range resulted
in increased uptake and accumulation within the reticuloen-
dothelial system.85 Thus, the PEGylation field has largely
adopted the strategy of adding *40 kDa of PEG weight to
peptide and small protein therapeutics. PEG is extensively
hydrated such that its hydrodynamic radius is much larger
than expected from its molecular weight. Furthermore, dis-
tributing the weight of the PEG polymer in a branched ge-
ometry improves half-life and reduces steric interference.86
PEG conjugation can also be reversible (e.g., an ester link-
age), creating a circulating depot from which the therapeutic
is cleaved over time (e.g., in case drug activity is adversely
affected by PEG conjugation).87,88 Limitations of PEGylation
include steric interference with binding, long-lived accumu-
lation in renal tubule cells, viscosity, and polydispersity. An
alternative approach uses a hydroxyethyl starch polymer
(HESylation) to reduce renal filtration.89
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Albumin binding (covalent or noncovalent) is another
recently validated approach for prolonging serum half-life
(reviewed by Ref. 90). Promising albumin-binding strategies
include covalent albumin-peptide conjugation, as well as re-
versible binding to circulating albumin via albumin-binding
peptides, small molecules, or fatty acids.90–92 As an example,
albumin conjugation of an HIV C-peptide inhibitor (either
in vitro or in vivo) dramatically improves serum half-life,93 as
does cholesterol conjugation to a lesser extent, presumably
via weak reversible interactions with albumin and/or cell
membranes.94
FUTURE DIRECTIONS
Recombinant Production of Peptidomimetics
Although robust recombinant production of peptidomimet-
ics is not yet possible, significant recent advances in synthetic
biology may enable routine production of diverse peptidomi-
metic libraries in the near future. One promising approach is
in vitro codon reprogramming for the synthesis of unnatural
polymers. This approach relies on cell-free translation sys-
tems to reconstitute ribosomal peptide synthesis using a
minimal set of purified protein components.95–100 By chemi-
cally or enzymatically charging tRNA molecules with novel
amino acid analogues, the genetic code can be effectively
reprogrammed in vitro. When these cell-free systems with
genetic code modifications are used in conjunction with a
display technology, peptides with novel amino acids can be
screened for a desired property. For example, ribosome dis-
play was used in conjunction with in vitro codon reprogram-
ming to isolate peptide sequences from an mRNA library
that encoded an unnatural, selectable amino acid.101–103
Along these lines, it has been demonstrated that tRNAs
can be charged with a variety of amino acid analogues that
will modify the peptide backbone, including a-hydroxy acids,
N-methyl amino acids, a,a-disubstituted amino acids,
b-amino acids, and D-amino acids.104 However, the efficiency
of ribosomal incorporation of Ala/Phe analogues varies
greatly from fairly robust (a-hydroxy acid and N-methyl) to
weak (a,a-disubstituted amino acids) to undetectable (b- and
D-amino acids).104 Subsequent work has described the ability
of the translation machinery to accommodate amino acid
analogues with novel side chains and backbones.105
In one example, seven codons were each reassigned to
encode a unique a-hydroxy acid, and polymers as long as 12
consecutive a-hydroxy acids could be synthesized.106 In
another report, the incorporation efficiencies of 23 N-methyl
amino acids, 19 of which bore naturally occurring side
chains, were determined. Eight of these 19 N-methyl amino
acids were incorporated at specific points in a polypeptide
with >30% efficiency as compared with wild type. A peptide
up to 10 residues long could be synthesized from three
unique N-methyl amino acids.107
While less success has been reported with ribosomal
incorporation of D-amino acids, modifications to the ribo-
somal peptidyltransferase center and helix 89 of the 23S
rRNA can relax the ribosome’s natural substrate specificity,
thereby enhancing the incorporation of D-amino acid resi-
dues into a growing polypeptide chain.108,109 Although these
techniques have not yet been employed as such, in principle
cell-free translation systems coupled with in vitro display
techniques could be used to screen libraries of polymers with
novel backbones. As an advance in this direction, genetic
code reprogramming has already been used in conjunction
with mRNA display technology to generate mRNA-peptide
fusions containing N-methyl amino acids.110
Another approach to recombinantly produce peptidomi-
metics relies on the ability to expand the genetic code in vivo
via the generation of evolved tRNA/aminoacyl-tRNA synthe-
tase pairs. In these systems, the foreign tRNA functions as an
amber suppressor, effectively allowing the amber nonsense
codon to be reprogrammed to encode a non-natural amino
acid.111,112 It has been demonstrated that genetic code expan-
sion can be used in conjunction with phage display to incor-
porate a non-natural amino acid into a pIII fusion pep-
tide.113 In the future, multiple codons could be reassigned,
permitting the incorporation of multiple unnatural residues
in vivo. Several advances have been made toward this end. In
a recent publication describing a technique for rapid, ge-
nome-wide engineering, the authors show progress toward
replacing all 314 TAG stop codons in E. coli with the TAA
stop codon.114 This type of genome manipulation could be
used for the removal of redundancy from the genetic code,
freeing up codons for potential reprogramming. In another
approach involving evolved tRNA/aminoacyl-tRNA synthe-
tase pairs, an evolved orthogonal ribosome able to read both
3- and 4-base codons was able to efficiently incorporate two
different non-natural amino acids into a single polypeptide
chain in vivo.115,116 These approaches present tantalizing pos-
sibilities for the production of peptide libraries with unnatu-
ral side chains and backbones, but the technology is not yet
sufficiently robust to allow for widespread application. Addi-
tional engineering of tRNA molecules, elongation factors,
and the ribosome itself will likely be required for use with
certain diverse peptidomimetics.109,117,118
D-Peptides present a unique opportunity for designing an
artificial recombinant production system. Because of their
symmetry relationship with natural peptides, an in vitro
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translation system composed of all opposite-chirality compo-
nents (D-proteins and nucleotides containing L-ribose) would
function equivalently to natural translation, when provided
with mirror-image DNA substrates. Synthesis of all ribo-
somal components presents an enormous synthetic chal-
lenge, but recent advances in SPPS and peptide ligation may
now make this approach feasible. A mirror-image in vitro
translation system would provide a useful tool for D-peptide
drug discovery and production, but may not be ideal for
large-scale production, especially of complex D-proteins (e.g.,
those requiring chaperones or post-translational modifica-
tions). The ultimate goal is to produce D-peptides using a
synthetic mirror-image organism, a strategy we dub the ‘‘D.
coli’’ project. The key to this project is synthesizing the mini-
mal set of RNAs and proteins necessary to allow enzymatic
production of other larger components and ultimately all
components needed for a self-replicating organism. It is also
not yet clear how to ‘‘start up’’ such an organism.119,120
Cost and Toxicity of Peptidomimetics
In addition to achieving their biological objectives, peptido-
mimetics will need to overcome concerns about cost and tox-
icity to succeed as therapeutics. Currently there are no FDA-
approved fully peptidomimetic peptides, so information on
their in vivo toxicity is extremely limited. Initial data from
two D-peptides that have advanced to clinical trials (Gen-
zyme’s Delmitide121 and Allelix’s ALX40-4C122) showed that
both D-peptides (one orally administered, one systemically
delivered) were well tolerated in humans. Further comfort is
provided by over a dozen approved D-amino acid-containing
peptides, as well as two approved ß-amino acid-containing
peptides.123 These data suggest that these amino acids are
not intrinsically toxic, but more rigorous animal toxicology
studies on different classes of fully protease-resistant peptides
will be required for a definitive determination. Such studies
will also determine whether these peptidomimetics induce
significant immunogenicity upon chronic administration.
Finally, the cost of D-, b-, and other uncommon amino acids
is currently significantly higher than the corresponding com-
mon L-amino acids, largely because of their current status as
specialty reagents. However, we anticipate the cost of these
amino acids will drop dramatically as they are adopted in
high-volume production of therapeutic peptides, as has al-
ready occurred with several D-amino acids in large-scale pep-
tide production.
The authors thank Debra Eckert for critical review of the article and
figures preparation. M.S.K. is a Scientific Director and consultant of
the D-peptide Research Division of Navigen, which is commercializ-
ing D-peptide inhibitors of viral entry.
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The HIV gp41 N-trimer pocket region is an ideal viral target because it is extracellular, highly conserved, and
essential for viral entry. Here, we report on the design of a pocket-specific D-peptide, PIE12-trimer, that is
extraordinarily elusive to resistance and characterize its inhibitory and structural properties. D-Peptides
(peptides composed of D-amino acids) are promising therapeutic agents due to their insensitivity to protease
degradation. PIE12-trimer was designed using structure-guided mirror-image phage display and linker opti-
mization and is the first D-peptide HIV entry inhibitor with the breadth and potency required for clinical use.
PIE12-trimer has an ultrahigh affinity for the gp41 pocket, providing it with a reserve of binding energy
(resistance capacitor) that yields a dramatically improved resistance profile compared to those of other fusion
inhibitors. These results demonstrate that the gp41 pocket is an ideal drug target and establish PIE12-trimer
as a leading anti-HIV antiviral candidate.
The HIV envelope protein (Env) mediates viral entry into
cells (11). Env is cleaved into surface (gp120) and transmem-
brane (gp41) subunits that remain noncovalently associated to
form trimeric spikes on the virion surface (16). gp120 recog-
nizes target cells by interacting with cellular receptors, while
gp41 mediates membrane fusion. Peptides derived from hep-
tad repeats near the N and C termini of the gp41 ectodomain
(N and C peptides) interact in solution to form a six-helix
bundle, representing the postfusion structure (3, 55, 56). In this
structure, N peptides form a central trimeric coiled coil (N
trimer), creating grooves into which C peptides bind. This
structure, in conjunction with the dominant-negative inhibitory
properties of exogenous N and C peptides, suggests a mecha-
nism for Env-mediated entry (10, 22, 58–60).
During entry, gp41 forms an extended prehairpin interme-
diate that leaves the exposed N-trimer region vulnerable to
inhibition for several minutes (18, 35). This intermediate ulti-
mately collapses as the C-peptide regions bind to the N-trimer
grooves to form a trimer of hairpins (six-helix bundle), juxta-
posing viral and cellular membranes and inducing fusion. En-
fuvirtide (Fuzeon), the only clinically approved HIV fusion
inhibitor, is a C peptide that binds to part of the N-trimer
groove and prevents six-helix bundle formation in a dominant-
negative manner (61). Enfuvirtide is active in patients with
multidrug resistance to other classes of inhibitors and is a
life-prolonging option for these patients (30, 31). However,
enfuvirtide use is restricted to salvage therapy due to several
limitations, including (i) high dosing requirements (90 mg,
twice-daily injections), (ii) high cost (!$30,000/year/patient in
the United States), and (iii) the rapid emergence of resistant
strains (21, 47).
A deep hydrophobic pocket at the base of the N-trimer
groove is an especially attractive inhibitory target because of its
high degree of conservation (3, 12, 48), poor tolerance to
substitution (4, 34), and critical role in membrane fusion (2).
Indeed, this region is conserved at both the amino acid level
(for gp41 function in membrane fusion) and the nucleotide
level (for the structured RNA region of the Rev-responsive
element). Enfuvirtide binds to the N-trimer groove just N
terminal to the pocket and is significantly more susceptible to
resistance mutations than 2nd-generation C-peptide inhibitors,
such as T-1249, that also bind to the pocket (8, 13, 29, 44, 46,
47, 58).
Peptide design, molecular modeling, and small-molecule
screening have produced a diverse set of compounds that in-
teract with the gp41 pocket and inhibit HIV-1 entry with mod-
est potency, but often with significant cytotoxicity (7, 14, 15, 17,
23, 24, 26, 34, 51, 54). The first direct evidence that pocket-
specific binders are sufficient to inhibit HIV entry came with
the discovery of protease-resistant D-peptides identified using
mirror-image phage display (12). In this technique, a phage
library is screened against a mirror-image version of the target
protein (synthesized using D-amino acids) (50). By symmetry,
mirror images (D-peptides) of the discovered sequences will
bind to the natural L-peptide target. As the mirror images of
naturally occurring L-peptides, D-peptides cannot be digested
by natural proteases. Protease resistance provides D-peptides
theoretical treatment advantages of extended survival in the
body and possible oral bioavailability (41, 42, 49).
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These 1st-generation D-peptide entry inhibitors possess po-
tency against a laboratory-adapted isolate (HXB2) at low to
mid-!M concentrations (12). We previously reported an affin-
ity-matured 2nd-generation D-peptide called PIE7, pocket-spe-
cific inhibitor of entry 7 (57). A trimeric version of PIE7 is the
first high-affinity pocket-specific HIV-1 inhibitor and has po-
tency against X4-tropic (HXB2) and R5-tropic (BaL) strains at
sub-nM concentrations. However, significant further optimiza-
tion is required to create a robust clinical candidate for two
reasons. First, this D-peptide is much less potent (requiring
high nM concentrations) against JRFL, a primary R5-tropic
strain. Therefore, improved PIE potency is necessary to com-
bat diverse primary strains. Second, by improving the affinity of
our inhibitors for the pocket target, we hope to provide a
reserve of binding energy that will delay the emergence of drug
resistance, as described below.
We and others have reported a potency plateau for some
gp41-based fusion inhibitors that is likely imposed by the tran-
sient exposure of the prehairpin intermediate (9, 27, 53, 57).
For very high-affinity inhibitors, association kinetics (rather
than affinity) limits potency so that two inhibitors with signif-
icantly different affinities for the prehairpin intermediate can
have similar antiviral potencies. We proposed that overengi-
neering our D-peptides with substantial affinity beyond this
potency plateau would provide a reserve of binding energy that
would combat affinity-disrupting resistance mutations (57).
Such a resistance capacitor should also prevent the stepwise
accumulation of subtle resistance mutations in Env by elimi-
nating the selective advantage that such mutants would other-
wise confer.
Here, we report on the design and characterization of a
3rd-generation pocket-specific D-peptide, PIE12-trimer, with
"100,000-fold improved target binding compared to that of
the best previous D-peptide, significantly broadened inhibitory
potency, and an enhanced resistance capacitor that provides a
strong barrier to viral resistance. We achieved this increased
potency via structure-guided phage display and crosslinker op-
timization. PIE12-trimer has a dramatically improved resis-
tance profile compared to the profiles of earlier D-peptides, as
well as those of enfuvirtide and T-1249. These results validate
the resistance capacitor hypothesis and establish PIE12-trimer
as a leading anti-HIV therapeutic candidate.
MATERIALS AND METHODS
Peptide synthesis. All peptides were synthesized as described previously (57).
All dimers and trimers except PIE12-trimer were made essentially as described
using bis-dPEG5 NHS ester (where PEG is polyethylene glycol and NHS is
N-hydroxysuccinimide; catalog no. 10224; Quanta BioDesign); PIE12-trimer was
synthesized using the following higher-yield protocol. PIE12-GK (2 mM) was
reacted with bis-dPEG5 NHS ester crosslinker (1 M stock in dimethylacetamide)
at a 1:20 (peptide/PEG) molar ratio in 100 mM HEPES (pH 7.8 to 8) for 90 s at
room temperature (RT). The reaction was stopped by addition of acetic acid to
5% and 3 M guanidine HCl (GuHCl) and purified by reverse-phase high-pres-
sure liquid chromatography (RP-HPLC; C18 column; Vydac). This product ("3
to 5 mM) was reacted at a 2:1 molar excess with PIE12-GKK in dimethylacet-
amide buffered by triethylamine (pH 7.5) for 75 min and purified by RP-HPLC
(C18 column; Vydac).
Phage display vector design. Use of a commercially available phage library
cloning system (NEB) allowed us to relocate cloning sites away from the flanking
regions (38). We redesigned the regions immediately outside the flanking resi-
dues in our cloning vector in order to structurally isolate them and minimize any
bias caused by flanking sequence randomization. Our library peptides are dis-
played as fusions to the phage p3 protein, which contains an N-terminal leader
sequence that is cleaved by Escherichia coli secretion signal peptidases. In the
original vector, the N-terminal flanking residues of the library peptides are
immediately adjacent to the secretion signal. Due to proximity to the secretion
signal cleavage site, it is likely that randomization of these residues would
differentially affect library-p3 protein secretion and peptide presentation on the
phage surface. This bias would confound the selection of N-terminal flanking
sequences solely on the basis of their affinity for the N trimer. To avoid this bias,
we introduced a five-amino-acid spacer to structurally isolate the cleavage site
from the randomized N-terminal flanking residues. We choose the N-terminal
residues (KIEEG) from maltose binding protein (MBP) as the spacer sequence,
since MBP is very efficiently cleaved during secretion from E. coli.
We have observed that mutations in the C-terminal sequence that links the
peptide to the phage p3 protein can also create undesirable selection bias (pre-
sumably by allowing the C terminus of the D-peptides to form a continuous helix
with the N terminus of p3, thus enhancing peptide presentation to the target)
(57). Therefore, a flexible GGGS spacer was inserted after the C-terminal flank-
ing residues to structurally isolate them from the N terminus of p3.
To validate this new phage display vector, we used it to clone an earlier PIE
(PIE2) along with a mutant (PIE2-AAA) which had previously been observed to
enhance phage affinity for the pocket target via mutation of the linker between
the library peptide and p3, although this mutation did not enhance inhibitor
potency when incorporated into a D-peptide (57). We assayed the target binding
affinity of the resultant phage (#) and compared it to that of phage produced
with the previous phage vector. In the previous phage vector, PIE2-AAA-#
“cheated” in order to bind to the target with an "70-fold more affinity than
PIE2-#, but this difference was abolished in the modified vector (data not
shown). Furthermore, sequencing revealed that N-terminal flanking residues
from the amplified phage library prior to selection were random, indicating a lack
of bias due to signal peptidase cleavage efficiency.
Phage display. An 8-mer flanking library phage display was performed essen-
tially as described previously (57). Four rounds of mirror-image solution-phase
phage display were performed by incubating (for 2 h at RT) 1010 phage (ampli-
fied from the previous round) with 10 nM biotinylated D-IZN17 (a mimic of the
D-peptide gp41 pocket target) in the presence of escalating soluble competitor
(L-2K-PIE2) (10, 30, 90, and 360 !M for rounds 1 to 4, respectively) (57).
Phage-bound D-IZN17 was rapidly captured from solution using Dynal T1
streptavidin-coated magnetic beads (Invitrogen) and briefly washed 3 times with
500 !l of 0.1% Tween 20 in Tris-buffered saline (wash buffer contained 100 !M
D-biotin for the 1st wash). Phage was eluted in 50 !l of glycine (pH 2.2) elution
buffer (10 min at RT) and neutralized with 7.5 !l of 1 M Tris, pH 9.1. The
amplified phage library was sequenced prior to the first round of selection to
confirm randomization, and preamplified eluted phage was sequenced following
each round. All phage binding experiments were performed using the same
protocol described above using 270 !M L-PIE2 soluble competitor. A 7-mer
phage display was performed using a similar protocol.
Crystal growth and data collection. The original form of PIE12 (see Table 1)
contains a C-terminal GK extension and did not yield highly diffracting crystals
in complex with IQN17, a gp41 pocket mimic. Variants of PIE12 instead con-
taining an N-terminal K or KG extension (K-PIE12, KHPCDYPEWQWLCEL;
KG-PIE12, KGHPCDYPEWQWLCEL) crystallized in complex with IQN17
under a variety of conditions. In each case, the reservoir (850 !l) comprised a
solution from a commercially available crystallization screen, and the crystalli-
zation drop was prepared by mixing 0.3 or 0.5 !l of the IQN17-PIE12 or
IQN17-PIE71 protein solution (1:1.1 molar ratio, 10 mg/ml total in water) with
0.3 !l of the reservoir solution. Crystals typically grew in 1 to 10 days. All crystals
were grown by sitting-drop vapor diffusion. IQN17-PIE12 form I crystals (KG-
PIE12) were grown at 21°C in Hampton Scientific condition Screen II 48 (10%
PEG 20,000, 0.1 M bicine, pH 9.0, 2% dioxane). IQN17-PIE12 form II crystals
(KG-PIE12) were grown at 21°C in Emerald Biosystems condition Cryo-II 37
(50% ethylene glycol, 0.1 M imidazole, pH 8.0). IQN17-PIE12 form III crystals
(K-PIE12) were grown at 4°C in Emerald Biosystems condition Cryo-II 25 (40%
2-methyl-2,4-pentanediol (MPD), 0.1 M N-cyclohexyl-3-aminopropanesulfonic
acid (CAPS) [pH 10.5]). IQN17-PIE71 crystals were grown at 21°C in Qiagen
PACT crystallization condition G4 (20% PEG 3350, 0.2 M potassium thiocya-
nate, 0.1 M bis-Tris propane, pH 7.5).
Crystals were mounted in a nylon loop and either directly cryocooled by
plunging them into liquid nitrogen or cryocooled following brief (20 s) immer-
sion in 20 !l crystallization buffer with 30% (IQN17-PIE12) or 15% (IQN17-
PIE71) added glycerol. Crystals were maintained at 100 K during data collection.
Data were collected either in the laboratory using a rotating copper anode X-ray
generator or at a synchrotron beam line. Data were processed using the DENZO
and SCALEPACK programs (40). All structures were determined by molecular
replacement using the PHASER program (33) with IQN17-PIE7 as the search









model. The models were rebuilt using the O program (25) and refined against a
maximum-likelihood target function using the REFMAC program (36). Struc-
tures were checked using the MolProbity program (6) (see Table 2 for data and
refinement statistics).
Explanation of Lys placement. We were concerned that direct C-terminal
addition of Lys would not be well tolerated because the D-peptide C-terminal
region forms an ! helix critically involved in the pocket-binding interface, with
the C terminus itself being amidated for helix stability. Therefore, we inserted a
Gly between the original C terminus of PIE7 and the C-terminal Lys, both to cap
the helix and to separate the Lys from the binding interface. Unexpectedly,
PIE7-GK-monomer is slightly more potent than PIE7 (see Table 1). A version of
PIE7 containing an N- and C-terminal Lys (K-PIE7-GK) has the same potency
as PIE7-GK (data not shown), indicating a beneficial effect imposed by the
C-terminal Gly-Lys, as opposed to a deleterious effect created by a single Lys at
the N terminus. This benefit is likely the reason that the linkage consisting of an
"22-Å cross-linker at the C terminus whose spacer arm consists of 5 PEGs (C5C)
results in a potency slightly superior to that of the N5C linkage (see Table 1).
Viral infectivity assays. Pseudovirion infectivity assays were performed as
described previously (57). Purified lyophilized inhibitors were dissolved in water
(monomers) or 50 mM HEPES, pH 7.5 (dimers and trimers), to make high-
concentration stocks. For HEPES-containing samples, all media were adjusted
so that the HEPES content matched that in the sample with the highest HEPES
concentration (typically, "1 mM). HEPES at higher concentrations (e.g., 3 mM)
enhanced infectivity up to "15% but had minimal effect at !0.5 mM. The
Monogram Biosciences PhenoSense Entry and peripheral blood mononuclear
cell (PBMC) assays were performed as described previously (43, 52).
CD studies. Samples were prepared with 2 #M IZN17, a 1.1$ molar ratio of
inhibitor to target binding sites, phosphate-buffered saline (PBS; 50 mM sodium
phosphate, 150 mM NaCl, pH 7.4), and 2 M GuHCl in a total volume of 2.5 ml.
Thermal melts were performed by melting the sample in a square 1-cm cuvette
from 25°C to 90°C (or 93°C for PIE12-trimer) in 2°C increments with 2 min of
equilibration. To show reversibility, reverse melts were performed on each sam-
ple from 90°C to 30°C in 10°C increments with 5 min of equilibration. Data were
averaged from a 30-s collection on an Aviv model 410 circular dichroism (CD)
spectrapolarimeter.
For each sample, the CD data followed a smooth sigmoid transition as the
sample was heated or cooled. The data were smoothed in the Kaleidagraph
program (Synergy Software) using 2 points from both sides. The derivative value
of the smoothed data was used to determine the point with the steepest rate of
change on the melt curve, which is the melting temperature (Tm).
Passaging studies. Laboratory-adapted HIV-1 strain NL4-3 was generated by
transient transfection of proviral DNA (pNL4-3) into 293T cells using Lipo-
fectamine (Invitrogen). Cell-free supernatants containing virus were collected
48 h posttransfection and used to infect 5 $ 105 CEM-1 cells in RPMI 1640
medium (0.5 ml). Virus was serially propagated once a week by 1:5 dilution of
cell-free viral supernatants into fresh CEM-1 cells (5 $ 105 cells, 0.5 ml) in the
absence or presence of inhibitor (PIE7-dimer, PIE12-dimer, or PIE12-trimer).
Viral titers were monitored biweekly by p24 antigen enzyme-linked immunosor-
bent assay (PerkinElmer). The inhibitor concentration started at approximately
the 50% inhibitory concentrations (IC50s; 20 nM for PIE7-dimer; 1 nM for
PIE12-dimer, and PIE12-trimer) and was raised 1.5- to 2-fold when p24 antigen
levels in inhibitor-containing cultures approached that in inhibitor-free cultures
(usually 2 to 3 weeks for PIE7-dimer). PIE12-dimer and PIE12-trimer required
a slower escalation strategy with prolonged incubation at a fixed inhibitor con-
centration for 5 to 15 weeks before escalation.
To identify PIE7-dimer escape mutations, viral RNA was isolated from cell-
free supernatants of at least two cultures independently propagated in either the
presence (resistant virus) or absence (control virus) of inhibitor (Qiagen RNA
purification kit). Env cDNA was generated by reverse transcription (Eppendorf
cMaster RTplus system and cMaster reverse transcription kit), amplified by
PCR, and sequenced in five stretches (Thomas Jefferson University Nucleic Acid
Facility). To confirm selected mutations in the gp41 N-peptide region, the cDNA
segment encoding the gp41 ectodomain was reamplified by PCR and subcloned
into the pAED4 vector, and the plasmid DNA from three or more individual
clones was sequenced. The substitutions E560K and V570I were observed in all
sequences from PIE7-dimer-resistant virus but were not observed in any se-
quence from control virus. An expression plasmid for HXB2 Env (pEBB_HXB2
Env) incorporating these substitutions was generated using site-directed muta-
genesis (QuikChange; Stratagene) and was utilized in the pseudoviral infectivity
assay described above.
Protein Data Bank accession numbers. The Protein Data Bank (PDB) acces-
sion numbers for the PIE12-IQN17 complex are 3L35, 3L36, and 3L37 for crystal
forms I, II, and III, respectively, and 3MGN for the PIE71-IQN17 complex.
RESULTS
Structure-guided phage display to optimize flanking resi-
dues. PIE inhibitors consist of a short core sequence sur-
rounded by a disulfide bond that imparts structural rigidity
required for binding (Table 1) (12). The large jump in affinity
between our 1st-generation (12) and 2nd-generation (57) in-
hibitors was accomplished by optimizing this core sequence.
There were also four fixed flanking residues outside the disul-
fide that arose from phage library cloning restrictions, Gly-Ala
on the N terminus and Ala-Ala on the C terminus. Interest-
ingly, our cocrystal structures of D-peptides in complex with a
mimic of its gp41 pocket target (IQN17) reveal significant
contacts between these presumed inert flanking residues and
the pocket (12, 57). Thus, we reasoned that their optimization
would likely lead to improved D-peptide affinity for the pocket.
To optimize these flanking residues, we used a commercially
available phage library cloning system (NEB) that allowed us
to relocate cloning sites away from the flanking regions (38).
We redesigned the regions immediately outside the flanking
residues in our cloning vector in order to structurally isolate
them and minimize any bias caused by flanking sequence ran-
domization. Using this vector, we constructed a phage library
that varied only these four residues in the context of our
previously optimized PIE7 core sequence (XXCDYPEWQW
LCXX). After four rounds of panning, our phage library
showed "100-fold improved binding to a gp41 pocket mimic
(D-IZN17) compared to that of clonal PIE7 phage with the
original GA/AA flanking sequence. We extensively sequenced
this phage pool to identify a consensus sequence, H(A/P)-
[PIE7 core]-(R/K/E)L, as well as five dominant individual se-
quences. Using a phage clone binding assay, we found that
these sequences bound the gp41 pocket 70- to 900-fold more
tightly than PIE7, with PIE12 (HP-[PIE7 core]-EL) having the
highest affinity (data not shown).




PIE7 KGA%PIE7&AA 620b 24,000b
PIE7-GK GA%PIE7&AAGK 390 16,000
PIE7-GKK GA%PIE7&AAGKK 380 19,000
PIE12 HP%PIE7&ELGK 37 580
PIE13c HP%PIE7&KL 41 1,500
PIE14 HP%PIE7&RLGK 33 1,100
PIE15 HA%PIE7&ELGK 67 1,400
N9N(PIE7)2 (KGA%PIE7&AA)2 1.9b 2,300b
N5C(PIE7)2 GA%PIE7&AAGKKGA%PIE7&AA 0.6 300
C5C(PIE7)2 (GA%PIE7&AAGK)2 0.5 200
C5C(PIE12)2 (HP%PIE7&ELGK)2 0.4 14
N9N(PIE7)3 (KGA%PIE7&AA)3d 0.3b 220b
C5C(PIE7)3 (GA%PIE7&AAGK)3d 0.1 6.7
C5C(PIE12)3 (HP%PIE7&ELGK)3d 0.5 2.8
C37 1.4b 13b
Enfuvirtide 3.7b 5.0b
a The IC50 standard error of the mean is '25% for duplicate assays for all
values.
b Values are from reference 57.
c PIE13 does not include a C-terminal GK extension because its C-terminal
flanking sequence contains a Lys residue.
d The central peptide of each trimer has two tandem Lys residues (not shown).
e PIE7, CDYPEWQWLC, or PIE7 core motif.









Enhanced potency of 3rd-generation D-peptides. We synthe-
sized D-peptides corresponding to the top three phage se-
quences in the binding assay (PIE12, PIE13, and PIE14) and
tested their antiviral potencies in a pseudovirion entry assay
(Table 1 and Fig. 1). Pairwise comparisons of both phage
binding and inhibitor potency indicate that Pro is preferred
over Ala at position 2 and Glu is preferred over Arg or Lys at
position 13. As predicted from the phage binding assay, PIE12
has the best potency and is !40-fold more potent than PIE7
(our best previously reported monomer) against strain JRFL.
Crystal structure of PIE12. To better understand the
sources of PIE12’s improved binding and potency, we crystal-
lized PIE12 in complex with the N-trimer pocket mimic
IQN17. Data were collected from three crystal forms (Table 2)
at between 1.45- and 1.55-Å resolution. Each IQN17 trimer
from the three crystal forms reported here and from the PIE7
structure (PDB accession number 2R5D) agreed well with one
another (root mean square deviation [RMSD], 0.6 to 1.2 Å) on
the basis of the least-squares overlap on all C" atoms (residues
1 to 45 of all three chains). The structures suggest two sources
of the improved affinity of PIE12 for IQN17 compared to that
of PIE7. First, the new N-terminal flank residues (His1 and
Pro2) form favorable ring stacking interactions with the pocket
(IQN17-Trp571) (Fig. 2). Second, the substitution of Leu for
Ala in the C-terminal flank sequence buries an additional
!50-Å2 hydrophobic surface area in the pocket. Neither of
these new interactions with the flanking sequence perturbs the
original pocket-binding structure of the core PIE7 residues.
Importantly, the structures reveal that PIE12’s improved affin-
ity does not result from new interactions with less conserved
FIG. 1. Optimization of flanking residues enhances PIE potency.
Each point represents the average of quadruplicate measurements from a
representative pseudovirion entry inhibition assay (JRFL strain) normal-
ized to the measurement for an uninhibited control. Error bars represent
the standard errors of the means. PIE12 is !2-fold more potent than
PIE13 or PIE14 and is !25-fold more potent than PIE7-GK.
TABLE 2. PIE12 and PIE71 crystallographic data and refinement statistics
Data
Result for PIE12 crystal:
Result for PIE71 crystal
Form I Form II Form III
Space group P21 R3 P321 P21
Resolution (Å) 30.0–1.55 (1.61–1.55)a 30.0–1.45 (1.50–1.45) 30.0–1.45 (1.50–1.45) 30.0–1.40 (1.45–1.40)
No. of reflections measured 113,335 98,687 186,351 468,599
No. of unique reflections 25,088 10,475 14,802 82,774
Redundancy 4.5 9.4 12.6 5.7
Completeness (%) 86.5 (66.8) 97.1 (80.1) 99.7 (96.6) 98.2 (97.6)
#I/$I%b 18 (2.4) 19 (3.1) 17 (2.7) 15 (2.0)
Mosaicity (degree) 0.44 0.37 0.45 0.29
Rsymc 0.051 (0.250) 0.058 (0.102) 0.107 (0.235) 0.052 (0.316)
Refinement
Resolution (Å) 30.0–1.55 (1.59–1.55) 30.0–1.45 (1.49–1.45) 30.0–1.45 (1.49–1.45) 30.0–1.40 (1.44–1.40)
No. of reflections used for refinement 23,765 9,448 13,629 80,532
No. of reflections in Rfreed set 1,273 1,026 1,136 1,654
Rcryste 0.232 (0.465) 0.234 (0.301) 0.243 (0.299) 0.261 (0.306)
Rfree 0.288 (0.624) 0.264 (0.392) 0.278 (0.350) 0.288 (0.335)
RMSD bonds (Å)/angles (degrees) 0.012/1.440 0.013/1.693 0.010/1.530 0.009/1.094
#B%g
All atoms (Å2)/no. of atoms 23.7/1,172 31.9/384 29.2/384 Molf 1, 24.3/1,555; mol 2,
36.0/1,491
PIE12 molecules only (Å2)/no. of atoms 21.3/420 30.8/144 25.9/144 Mol 1, 18.3/368; mol 2,
39.9/322
Water molecules (Å2)/no. of water atoms 32.0/197 38.0/36 40.6/49 39.9/389
&/'h most favored (%) 100 98.1 100 99.0
a Values in parentheses refer to data in the high-resolution shell.
b #I/$I%, average intensity of a group of reflections divided by the average standard deviation (sigma) of the same group of reflections.
c Rsym ( )!I * #I%!/)I, where I is the intensity of an individual measurement and #I% is the corresponding mean value.
d Rfree is the same as Rcryst calculated with a randomly selected test set of reflections that were never used in refinement calculations.
e Rcryst ( )!!Fo! * !Fc!!/)!Fo!, where !Fo! is the observed and !Fc! is the calculated structure factor amplitude.
f Mol, molecule.
g #B%, temperature factor.
h &/+, dihedral angles.









regions outside the pocket that might render PIE12 more vul-
nerable to resistance mutations.
Discovery and structure of a 7-mer D-peptide. The core
sequence of PIE7 and PIE12 comprises 8 residues flanked by
cysteines (8-mer). Modeling based on our 8-mer D-peptide/
IQN17 crystal structures suggests that a 7-mer core is compat-
ible with pocket binding of the WXWL consensus and forma-
tion of a disulfide bond (57). Previously, we saw that decreasing
the size of the PIE core (from 10 to 8 residues) led to dramat-
ically increased pocket binding (57), so we reasoned that fur-
ther decreasing the size of the core might lead to additional
potency gains. To explore this alternative geometry, we used a
mirror-image discovery process similar to that employed with
8-mers to identify a 7-mer, PIE71 (FVCPPEWRWLCDL).
PIE71 contains the same WXWL motif found in 8-mer and
10-mer pocket binders and inhibits strain HXB2 entry with an
IC50 of 410 nM (data not shown), which is !1.5 fold better
than that of PIE7 but an order of magnitude worse than that of
PIE12.
To gain a better understanding of the 7-mer binding solu-
tion, we determined a cocrystal structure of PIE71 in complex
with IQN17 (Table 2). The key residues involved in the binding
interface (WXWL) adopt nearly superposable conformations
to those observed in PIE7 and PIE12, as do the C-terminal
flank residues. However, the two structures deviate signifi-
cantly at the N terminus (Fig. 2 and 3). Specifically, the 7-mer’s
disulfide bond is shifted much closer to the pocket, which
directs the N-terminal flank residues away from the pocket
region. As a result, the N-terminal flanking residues (Phe-Val)
only graze the pocket, whereas PIE12’s N-terminal flanking
residues have an intimate interaction. So although the 7-mer is
compatible with pocket binding, the smaller core is too con-
strained to allow optimal binding of the flank residues to the
pocket. Due to this decreased binding interface and therefore
decreased potency, we decided not to pursue the 7-mer geom-
etry further.
Optimization of crosslinker length and geometry. We pre-
viously took advantage of the trimeric nature of the gp41
pocket target to geometrically increase the PIE7 binding affin-
ity by cross-linking it into dimers and trimers (57). PIE7 has an
N-terminal lysine, which furnishes a unique primary amino
group (the N terminus is acetylated) and which was added for
solubility. This lysine was used to produce dimers via reaction
with a bis-PEG NHS ester crosslinker (NHS esters selectively
react with primary amino groups). Trimers were produced by
cross-linking two PIE7s to a central peptide with two lysines at
the N terminus (2K-PIE7).
We hypothesized that the strength of the avidity effect is
related to the length of the crosslinker and that shorter
crosslinkers that still allow simultaneous binding to multiple
pockets could strengthen potency. For the original N- to N-
terminal linkage, we used a crosslinker with an !35-Å spacer
arm consisting of 9 PEG units (N9N linkage). However, our
crystal structures of D-peptides in complex with IQN17 reveal
that C- to C-terminal or N- to C-terminal linkages could be
significantly shorter and could be spanned by an !22-Å
crosslinker whose spacer arm consists of 5 PEGs (C5C and
N5C linkages). Therefore, we relocated Lys to the C terminus
of PIE7 (PIE7-GK) in order to make the N5C heterodimers
and C5C homodimers (see Materials and Methods for addi-
tional details).
The resulting N5C- and C5C-PIE7-dimers have similar po-
tencies that are significantly enhanced compared to the po-
tency of our previous N9N-PIE7-dimer (Table 1 and Fig. 4A).
On the basis of these data, we chose C5C connections as our
standard linker, since they are simpler to produce than the
hetero-N5C linkage. Here, all dimers and trimers use the C5C
linkage unless otherwise specified. Combining our new opti-
mized flanking residues and linkages, we produced PIE12-
dimer and PIE12-trimer. Both are extremely potent against the
difficult-to-inhibit primary strain JRFL (low-nanomolar IC50s;
Fig. 4B; Table 1), being up to 2 orders of magnitude more
potent than our best previously described D-peptide (N9N
PIE7-trimer) (57).
Breadth against a diverse multiclade panel. HIV-1 has
jumped from chimpanzees to humans at least three separate
times, giving rise to groups M, N, and O (19). The main group
(group M) accounts for "99% of all HIV-1 infections world-
FIG. 2. Crystal structure of PIE12 binding to IQN17. Trp571 of the
gp41 pocket (gray) and the N-terminal flank residues (dH1 and dP2) of
PIE12 (green) appear to stabilize binding via ring-stacking interac-
tions. The disulfide bond (yellow) is shown in the background.
FIG. 3. Crystal structure of PIE71 binding to IQN17. The N-ter-
minal flank residues (dF1 and dV2) of PIE71 (orange) are directed
away from the pocket compared to the structure in PIE12 (Fig. 2). The
disulfide bond (yellow) is shown in the background.









wide (32). HIV’s high mutation rate has led to the emergence
of diverse subtypes within group M that are categorized as
clades A to D, F to H, J, and K and various circulating recom-
binant forms (CRFs; e.g., AE and BF). In 2000, clades A to D
were estimated to represent !90% of HIV infections (39);
however, in recent years CRFs have become more prevalent
(1). Different subtypes contain up to 35% sequence diversity in
Env, often causing antibodies raised against a particular strain
to be ineffective against others (20).
To ensure that our pocket-specific D-peptides are potent and
broadly neutralizing against the most common subtypes of
HIV, we measured the potency of PIE7-trimer, PIE12-trimer,
and PIE12 (with enfuvirtide as a control inhibitor) using the
PhenoSense Entry pseudovirion assay (Monogram Bio-
sciences) (Table 3) (43). The inhibitors were tested against a
panel of 23 viruses pseudotyped with clonal and polyclonal
envelopes representing clades A to D, several CRFs, and en-
fuvirtide-resistant strains. Both PIE7 and PIE12-trimers po-
tently inhibited all strains tested, though PIE12-trimer was
generally a superior inhibitor (and in all cases more potent
than enfuvirtide). While PIE12-monomer is much less potent
than PIE12-trimer, it is also broadly active. Interestingly,
PIE12-trimer is "10-fold more potent than PIE7-trimer
against polyclonal virus from clades B and C (samples ampli-
fied from patient plasma), which is consistent with a resistance
capacitor mechanism for maintaining potency in the presence
of various Env sequences. All of the D-peptide inhibitors are
unaffected by enfuvirtide resistance mutations. Additionally,
lack of inhibition against a murine leukemia virus (MLV) con-
trol indicates that these inhibitors are specific and nontoxic in
this assay.
Breadth against replication-competent primary viral iso-
lates on PBMCs. To more closely mimic in vivo infection and
further establish inhibitory breadth, we also tested the ability
of PIE7-trimer, PIE12-trimer, and PIE12 to inhibit PBMC
infection by replicating primary strains, again with enfuvirtide
as a control (Table 4). These data confirm the potent and
broad inhibitory activities of PIE7 and PIE12-trimer against all
group M strains tested, including several CRFs. Toxicity was
not observed on these cells at inhibitor concentrations up to 1
#M (the highest concentration tested), demonstrating a high
therapeutic index for the trimers. Interestingly, the inhibitors
are more potent in this assay than in the PhenoSense Entry
assay, which may be due to differential receptor expression
levels between the two cell types (45).
Notably, two group O strains were also tested in this assay
and are much less sensitive to inhibition than group M strains.
Group O contains several mutations (compared to the se-
quence of group M) in the pocket, including Q567R, T569S,
K574R, Q577R, and V580L. The crystal structures of PIE7 and
FIG. 4. Optimization of linkage geometry. Each point represents the average of quadruplicate measurements from a representative
pseudovirion entry inhibition assay (JRFL strain) normalized to the measurement for the uninhibited control. Error bars represent the standard
errors of the means. (A) Comparison of N9N to C5C linkages; (B) PIE7 versus PIE12-dimers and trimers (all C5C linkages).




PIE7-trimer PIE12-trimer PIE12-monomer Enfuvirtide
Aa A 5.5 4.1 2,300 18
92RW008 A 2.0 1.0 1,400 7.2
92UG031 A 18 4.2 2,600 20
94KE105 AC 16 0.7 1,900 13
CMU02 AE 32 12 1,500 16
Ba B 140 13 3,300 30
1168 B 54 31 4,700 140.0
BaL B 2.0 2.5 1,700 10
ENFr1a B 2.0 0.8 790 760
ENFr2a B 0.7 1.0 300 5,400
HXB2 B 0.1 0.3 50 2.6
JRCSF B 13 3.4 1,100 14
JRFL B 21 5.7 1,900 7.9
NL4.3 B 0.3 0.4 150 62
SF162 B 3.4 4.5 940 34
98CN009 BC 0.4 0.4 320 7.9
93BR029 BF 1.5 0.9 750 12
Ca C 220.0 26 5,100 71
97ZA012 C 2.0 0.7 1,500 10
98IN022 C 1.1 1.1 820 6.9
21068 C 6.6 5.0 1,800 47
Da D 3.1 3.2 820 17
92UG005 D 3.9 2.5 2,000 10
aMLV !10,000 !10,000 !500,000 !15,000
a Polyclonal viral envelopes amplified from patient plasma.









PIE12 in complex with IQN17 reveal that, of these residues,
the D-peptide directly interacts only with K574 (via a hydro-
phobic interaction) and Q577 (via hydrogen bonds). Group O
gp41 has several other mutations in the groove just outside the
pocket (i.e., H564E) that could also affect PIE potency (e.g., by
slowing the association rate). It will be interesting to analyze
the effects of these mutations in a group M (e.g., strain HXB2
or JRFL) background to see if they are responsible for the loss
of potency.
Evidence for a charged resistance capacitor.With the design
of PIE12-trimer, we now observe strong evidence for a highly
charged resistance capacitor in which the PIE12-trimer pocket-
binding affinity vastly exceeds the inhibitory potency. Compar-
ing PIE7 and PIE12-trimers, we observe similar potencies
against pseudovirion entry (Fig. 4B; Table 1), although we
expect their target affinities to be extremely different.
Due to extraordinarily slow off rates, direct measurements of
the pocket affinities for PIE7 and PIE12-trimers via surface
plasmon resonance, used for earlier D-peptides (57), were not
possible. Since the binding affinity of inhibitors correlates with
the stability of inhibitor-target complexes, we used thermal
denaturation monitored by CD to measure the relative stabil-
ities of each IZN17-inhibitor complex and infer the relative
affinities of our ultra-high-affinity binders. The melts were per-
formed in 2 M GuHCl to destabilize the complexes and shift
their melting points into an observable range (below 100°C).
The normalized thermal melts for each IZN17-inhibitor
complex are plotted in Fig. 5, with Tm values being shown in
the key. As expected, PIE12-trimer forms the most stable com-
plex and has a Tm 8°C higher than that of the next most stable
inhibitor complex (PIE7-trimer). PIE12 also forms a more
stable complex than PIE7, as expected. Our previous experi-
ence showed that improvements in monomer affinity translated
to approximately squared and cubed improvements in the cor-
responding dimers and trimers (57). On the basis of PIE12-
trimer’s optimized C5C linkage (35-fold improved antiviral po-
tency over that of the trimer with an N9N linkage; strain JRFL
data) and the !25-fold difference in monomer potency be-
tween PIE7 and PIE12 (JRFL data), we estimate that PIE12-
trimer binds to gp41 "105-fold (35 # 253) more tightly than
N9N PIE7-trimer. This predicted binding at subfemtomolar
concentrations translates to a resistance capacitor charged to
!6 kcal/mol against strain JRFL. Interestingly, the potency
plateau lies at a slightly better potency for trimers than for
dimers, likely due to their faster association rates (i.e., three
versus two opportunities for initial collision with the target).
Selection of resistant strains. To measure the resistance
profile of our D-peptide inhibitors and test our resistance
capacitor hypothesis, we conducted viral passaging studies
with escalating inhibitor concentrations to select for resis-
tant strains. These studies initially used PIE7-dimer, which
was available from our previous study (57) and inhibits the
parental strain, NL4-3, with an IC50 of !20 nM. By doubling
the PIE7-dimer concentration every 2 to 3 weeks, we ob-
tained stable viral cultures in 2,000 nM inhibitor within 20
weeks of propagation. In comparison, we were able to ob-
tain high-level enfuvirtide resistance ("1,000-fold) in only
!3 weeks using a similar protocol (H. K. Steger et al.,
submitted for publication).
Sequencing the N-peptide region of PIE7-dimer-resistant
viruses revealed two selected mutations: E560K and V570I.
These substitutions in the context of HXB2 pseudovirions con-
ferred !400-fold resistance to PIE7-dimer. These mutations
also dramatically weaken the binding of D-peptides to the gp41
pocket but not the C-peptide inhibitor C37 (M. J. Root et al.,
unpublished data). It is not obvious from the PIE7 structure
how these mutations weaken PIE7 binding. Despite this loss of
affinity, the escape mutations had a minimal effect on the
FIG. 5. Stability of D-peptide complexes. Normalized melting
curves of IZN17 alone and with D-peptide inhibitors were monitored
by CD in PBS–2 M GuHCl. Tm values are indicated in the key.




PIE7-trimer PIE12-trimer PIE12-monomer Enfuvirtide
92UG029 A 1.6 0.7 290 190
92UG037 A 0.1 0.2 36 41
93TH073 AE 0.6 0.8 270 200
CMU02 AE 0.2 0.4 300 44
CMU06 AE 0.3 0.4 210 5.7
IIIB B 0.3 0.8 140 28
BaL B 0.2 0.3 72 20
JRCSF B 0.1 0.1 120 7.0
JRFL B 0.5 0.3 110 1.7
93BR019 BF 1.7 4.7 170 "1,000
92BR025 C 15 5.2 "1,000 310
93IN101 C 0.4 0.4 160 22
92UG001 D 0.8 4.5 230 180
92UG046 D 0.1 1.2 170 130
93BR020 F 0.2 0.4 190 59
93BR029 F 0.2 0.8 86 19
G3 G 0.3 1.2 310 23
RU570 G 0.3 0.4 480 37
BCF01 Group O "1,000 "1,000 "1,000 330
BCF02 Group O "1,000 440 "1,000 0.4









potencies of PIE12-dimer and PIE12-trimer, as well as the C37
control inhibitor (Fig. 6). This result is predicted by the resis-
tance capacitor hypothesis: affinity-disrupting escape muta-
tions selected in the presence of weaker-binding inhibitors
should be less disruptive to the potencies of tighter-binding
inhibitors.
The rapid inhibitor escalation strategy utilized to generate
PIE7-dimer resistance was not effective in generating HIV-1
resistant to PIE12-dimer or PIE12-trimer. Rather, the HIV-1
titer fell precipitously when inhibitor concentrations exceeded
20 nM (5 to 20 times the IC50). Instead, we switched to a much
slower escalation strategy with prolonged periods at stable
inhibitor concentrations (5 to 15 weeks). Resistant virus
emerged after 40 weeks of propagation in PIE12-dimer and
after 65 weeks of propagation in PIE12-trimer. These obser-
vations suggest that a strong resistance capacitor profoundly
delays selection of resistance mutations for these optimized
fusion inhibitors.
Sequencing of the pocket region of PIE12-trimer-resistant
viruses reveals only one mutation, Q577R. Interestingly, this
substitution is present in nearly all group O isolates (including
BCF01 and BCF02; Table 4) but is rare among group M
isolates. Pseudovirions bearing Q577R confirm that this muta-
tion confers substantial resistance to PIE12-trimer (data not
shown). Examination of the PIE12 crystal structure shows that
Q577 makes hydrogen bonds with Glu7 and Trp10 in PIE12,
which may explain the disruptive effects of this mutation.
Q577R’s codon is predicted to disrupt the RRE stem-loop V
structure, since it base pairs with the invariant W571 codon
(Trp is encoded by only one codon).
DISCUSSION
PIE12-trimer is a D-peptide entry inhibitor with !80-fold
enhanced potency and an estimated "100,000-fold improved
binding affinity compared to those of the best previously re-
ported D-peptide. This dramatic improvement in affinity pro-
duces excellent breadth and a charged resistance capacitor to
combat the emergence of resistance mutations. Indeed, PIE12-
trimer was able to withstand the impact of resistance mutations
to earlier D-peptides and required a much longer selection (65
weeks) to generate resistant strains. Ongoing work is exploring
the mechanism of PIE7-dimer, PIE12-dimer, and PIE12-tri-
mer resistance and its relationship to group O’s insensitivity. A
key question is whether HIV can develop resistance to these
inhibitors independent of changes in affinity (e.g., kinetics) that
are capable of maintaining viral fitness.
Viral escape affects even the newest class of FDA-approved
HIV-1 drugs, integrase inhibitors. Resistance to raltegravir and
corresponding treatment failure were observed in a significant
subset of patients in both the phase II and III clinical studies
(5), and corresponding resistance mutations can be seen within
4 weeks when resistant virus is selected in viral passaging stud-
ies (28). Our studies indicate that PIE12-trimer is a promising
entry inhibitor that could overcome the limitations associated
with the two currently approved entry inhibitors, enfuvirtide
(high dosing, susceptibility to resistance) and maraviroc (Sel-
zentry; effective only against R5 viruses) and may also prove to
have a better resistance profile than even the newest class of
HIV-1 inhibitors.
In addition to being a possible therapeutic agent, PIE12-
trimer is an ideal candidate for a topical microbicide, as its
protease resistance would allow it to withstand the protease-
rich environment of the vaginal mucosa. In the absence of a
safe and effective HIV vaccine, a topical microbicide to pre-
vent the sexual transmission of HIV is an urgent unmet global
health need. The ultimate utility of PIE12-trimer as a micro-
bicide or therapeutic agent will be determined by advanced
preclinical and clinical studies, including characterization of
pharmacokinetics, in vivo toxicity, effectiveness in animal mod-
els of HIV infection (alone or in combination with other HIV
inhibitors), and optimization of formulations for microbicide
gels or vaginal rings.
More generally, the present work unequivocally shows that
D-peptide inhibitors can be designed with high potency and
specificity against natural L-protein targets. The D-peptide de-
sign methodology described here can be applied to diverse
biomedical applications, particularly for the many viruses that
share HIV’s hairpin-closing entry mechanism (e.g., influenza
virus, Ebola virus, respiratory syncytial virus, severe acute re-
spiratory syndrome coronavirus, Dengue virus, and West Nile
virus). Our resistance capacitor design strategy may also be
generally applicable for treating other rapidly evolving dis-
eases, especially when combined with recent advances in an-
ticipating likely structural sources of drug resistance (37). Fi-
nally, the development of PIE12-trimer as a strong clinical
candidate will allow D-peptide therapeutics to be evaluated in
vivo to determine if their theoretical advantages warrant a
prominent role as a new class of therapeutic agents.
FIG. 6. Effect of PIE7-dimer resistance mutations on PIE7-dimer,
PIE12-dimer, and PIE12-trimer potency. IC50s against wild-type (wt)
and PIE7-dimer-resistant (E560K/V570I) strain HXB2 pseudovirion
entry are shown. The C-peptide inhibitor C37 is included as a control.
Data represent the means from at least two independent experiments.
Error bars represent the standard errors of the means.
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Design of a Modular Tetrameric Scaﬀold for the Synthesis of
Membrane-Localized D-Peptide Inhibitors of HIV-1 Entry
J. Nicholas Francis, Joseph S. Redman, Debra M. Eckert, and Michael S. Kay*
Department of Biochemistry, University of Utah School of Medicine, 15 N Medical Drive East Room 4100, Salt Lake City, Utah
84112-5650, United States
ABSTRACT: The highly conserved HIV-1 gp41 “pocket” region is a promising target for
inhibiting viral entry. PIE12-trimer is a protease-resistant trimeric D-peptide inhibitor that binds to
this pocket and potently blocks HIV entry. PIE12-trimer also possesses a reserve of binding
energy that provides it with a strong genetic barrier to resistance (“resistance capacitor”). Here, we
report the design of a modular scaﬀold employing PEGs of discrete lengths for the eﬃcient
optimization and synthesis of PIE12-trimer. This scaﬀold also allows us to conjugate PIE12-trimer
to several membrane-localizing cargoes, resulting in dramatically improved potency and retention
of PIE12-trimer’s ability to absorb the impact of resistance mutations. This scaﬀold design strategy
should be of broad utility for the rapid prototyping of multimeric peptide inhibitors attached to
potency- or pharmacokinetics-enhancing groups.
■ INTRODUCTION
HIV entry is mediated by the trimeric viral envelope
glycoprotein (Env), which is cleaved into surface (gp120)
and transmembrane (gp41) subunits.1,2 Viral entry is triggered
by binding of gp120 to a primary receptor (CD4) and
subsequently a coreceptor (typically CXCR4 or CCR5), which
induces large conformation changes in gp120 that activate gp41
for fusion.3 gp41 then adopts an extended pre-hairpin
conformation, embedding its N-terminal hydrophobic fusion
peptide into the host cell membrane, bridging the virus and the
host cell (Figure 1). In this state, the gp41 N-peptide region
forms a trimeric coiled-coil (N-trimer), while the C-peptide
region is in a structurally undeﬁned state. This pre-hairpin
intermediate then slowly collapses into a hairpin structure, with
the C-peptide folding back upon the N-trimer to pack in an
antiparallel orientation into the grooves of the N-trimer. The
formation of this trimer-of-hairpins structure brings the viral
and host membranes into close proximity and drives membrane
fusion.4,5
In the pre-hairpin intermediate, gp41 is vulnerable to
inhibitors that bind to either the N-trimer or C-peptide2,6
and prevent hairpin formation.7−9 This vulnerability has been
exploited by the C-peptide-derived therapeutic Fuzeon
(enfuvirtide). Fuzeon binds to a portion of the N-trimer
groove, preventing fusion with nanomolar potency. Though
eﬀective, Fuzeon is currently utilized only as “salvage therapy”
for patients with multidrug resistance because of its high cost
(∼$30 000/year/patient), dosing requirements (90 mg twice
daily), injection site reactions, and the rapid emergence of
resistant strains.10,11
The gp41 N-trimer contains a functionally critical and highly
conserved deep hydrophobic pocket at its C-terminus.4,12,13
The genomic region that encodes for the pocket also forms the
structured RNA region of the Rev-responsive element (RRE),
which is critical for the export of viral mRNA to the
cytoplasm,14 further constraining evolution of this region on
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Figure 1. HIV entry pathway. Upon engagement with cellular receptor
and coreceptor, gp120 and gp41 undergo a conformational change
resulting in extension of gp41 into the pre-hairpin intermediate,
exposing the hydrophobic pocket region of the N-trimer. gp41
collapses into the trimer-of-hairpins structure, juxtaposing the viral and
host membranes and causing membrane fusion. The hydrophobic
pocket targeted by PIE12 is an estimated 60 Å from the cell
membrane, which can be bridged by a relaxed PEG24 linker. In
contrast, the C-peptide C-terminus is directly adjacent to the




© 2012 American Chemical Society 1252 dx.doi.org/10.1021/bc300076f | Bioconjugate Chem. 2012, 23, 1252−1258  
 




the nucleotide level. Fuzeon binds to the N-trimer groove
region just outside the pocket, an area that is more tolerant of
resistance mutations. Second/third-generation C-peptide in-
hibitors (e.g, T1249, T2635) bind the groove and pocket and
are much less susceptible to resistance.10,15−20
We have utilized structure-guided mirror-image phage
display to generate D-peptide inhibitors that bind with high
aﬃnity to the pocket.13,21,22 D-Peptides are protease resistant
(as proteases have stereochemical speciﬁcity and generally only
cleave L-substrates),23 giving them the potential for a much
longer lifetime in the body. PIE12, our most potent monomeric
D-peptide, is a pocket-speciﬁc inhibitor of HIV-1 with high-nM
potency against the diﬃcult-to-inhibit primary HIV isolate
JRFL. Since the N-trimer contains three symmetric pockets, we
designed a trimeric version of PIE12 that uses PEG to link
three monomers and greatly improves aﬃnity and potency via
avidity. PIE12-trimer inhibits all major HIV clades with high-
pM to low-nM potency21 and is a promising preclinical
candidate for the treatment and prevention of HIV-1. Here, we
describe a novel modular PEG scaﬀold used to optimize the
production and the potency of PIE12-trimer.
While designing D-peptide inhibitors with progressively
greater potency, we encountered a potency limit that could
not be overcome by aﬃnity optimization because the target is
only available in the short-lived pre-hairpin intermediate. Due
to the ﬁnite target exposure and the limits of diﬀusion, the
potency of inhibitors with very high aﬃnities (and on-rates) is
limited by the diﬀusion-limited on-rate rather than binding
aﬃnity. For such diﬀusion-limited inhibitors, a potency plateau
is reached beyond which further improvements in aﬃnity do
not improve potency. Similar potency plateaus have been
observed for several inhibitors that target the transient pre-
hairpin intermediate.21,22,24−26 “Over-engineering” our inhib-
itors with improved aﬃnity, but no corresponding improve-
ment in potency, provides a reserve of binding energy and
slows the evolution of resistance mutations. This “resistance
capacitor” eliminates the selective advantage conferred by
aﬃnity-disrupting resistance mutations, since viruses bearing
mutations that reduce aﬃnity are still inhibited with equal
potency, depriving HIV of an eﬃcient evolutionary pathway to
resistance. A profoundly disruptive mutation could escape the
resistance capacitor, but such severe pocket mutations are
discouraged due to the high cost to viral ﬁtness. With high pM
to low nM potency but sub-fM binding aﬃnity, PIE12-trimer
has a very strong resistance capacitor.21
We hypothesize that potency could be improved beyond the
plateau by pre-positioning inhibitor on the cell surface, the site
of viral entry, thus increasing the association rate beyond the
diﬀusion limit. Using our novel modular PEG scaﬀold, we
conjugate PIE12-trimer to membrane-localizing groups (cho-
lesterol and alkyl chains) that improve potency up to ∼160-
fold. This approach greatly simpliﬁes trimer synthesis and
improves yield. Importantly, our data show that this gain in
potency does not disrupt the resistance capacitor, leaving intact
PIE12-trimer’s strong barrier to resistance mutations. Using a
discrete PEG scaﬀold with orthogonal reactive groups and
deﬁned geometry allows for rapid optimization of multimeric
inhibitors and scouting of various potency-enhancing cargoes
and should be of broad utility for the design of other
multimeric peptide inhibitors.
■ EXPERIMENTAL PROCEDURES
Peptide Synthesis. Peptides were synthesized using a PTI
PS3 peptide synthesizer or by RS Synthesis as previously
described21,22 to generate either PIE12-GK or ΔHP-PIE12-GK
(lacks two N-terminal residues, D-His and D-Pro). PIE12-
dPEG4/5-NH2 (the precursor to PIE12-trimer synthesis) was
synthesized as follows: PIE12-GK (10 mM in dimethylaceta-
mide, DMAC) was reacted with 250 mM stock solution of
Fmoc-N-amido-dPEG4/5-NHS ester (Quanta BioDesign 10994
and 10053) in dry DMAC (Acros Organics, septa sealed with
molecular sieves) at a 1:1 molar ratio buﬀered by triethylamine
(200 mM, pH 7.5) for 60 min at RT. This reaction was
quenched by addition of acetic acid to 5% and puriﬁed by
reverse-phase HPLC (water/acetonitrile gradient in 0.1% TFA)
on a Waters BEH X-Bridge 10 μm, 300 Å C18 column (RP-
HPLC). Puriﬁed product was lyophilized, then resuspended in
20% piperidine in DMAC for 20 min to remove Fmoc and
produce PIE12-PEG4/5-NH2, which was then puriﬁed by RP-
HPLC.
Trimer Synthesis. PIE12-PEG4/5-NH2 (10 mM) was
reacted with 250 mM stock solution trimethylolethane-triNHS
ester (Figure 2A, Quanta BioDesign 10674) in DMAC at a
3.3:1 (peptide/scaﬀold) ratio in DMAC buﬀered by triethyl-
amine (200 mM, pH 7.5) for 60 min at RT. Product was
puriﬁed by RP-HPLC. All masses were conﬁrmed by ESI-MS
(AB Sciex API-3000).
Cholesterol-PIE12-trimer and alkyl-PIE12-trimer were syn-
thesized as follows: PIE12-PEG4-NH2 (10 mM) was reacted
with Maleimide-PEG12-triNHS ester (Quanta BioDesign
10676, 250 mM in DMAC) or Maleimide-PEG24-triNHS
ester (Figure 2B, Quanta BioDesign 10680, 250 mM in
DMAC) at a 3.3:1 (peptide/scaﬀold) ratio in DMAC buﬀered
by triethylamine (200 mM, pH 7.5) for 45 min at RT.
Thiocholesterol (Sigma Aldrich, 136115, 250 mM in chloro-
form), 1-octanethiol (Sigma-Aldrich 471836), 1-hexadecane-
thiol (Sigma-Aldrich 52270), or 1-octadecanethiol (Sigma
Aldrich 01858) were then added to a ﬁnal concentration of
4.5 mM and reacted for an additional 60 min. For PEG16,
PIE12-PEG4-NH2 was ﬁrst reacted with Mal-PEG12-triNHS
ester, followed by reaction with D-Cysteine (5 mM) to yield
(PIE12-PEG4)3-PEG12-Cys. This product was then puriﬁed by
RP-HPLC before sequential reaction with Maleimide-PEG4-
NHS and thiocholesterol under conditions identical to those
used to generate chol-PEG24-PIE12-trimer. PEG36, PEG57, and
PEG132-trimer were produced through conjugation of PIE12-
Figure 2. Trimeric and heterotetrameric PEG scaﬀolds and cargoes. A.
Trimethoylethane-triNHS ester. B. Heterotetrameric PEG scaﬀold.
The fourth maleimide arm is available for reaction with thiol-
containing cargoes, such as 1-octadecanethiol (C18-SH) and
thiocholesterol.
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PEG4-NH2 to Maleimide-PEG24-triNHS ester, followed by
addition of D-cysteine. This intermediate was then conjugated
to Mal-PEG12-NHS ester (Quanta Biodesign, 10284), Mal-
PEG2K-NHS ester (Creative PEGWorks, PHB-950, ∼45 PEG
units), or Mal-PEG5K-NHS ester (Creative PEGWorks, PHB-
952, ∼120 PEG units) to yield Chol-PEG36-PIE12-Trimer,
Chol-PEG57-PIE12-trimer, and Chol-PEG132-PIE12-trimer, re-
spectively. The reaction was quenched by addition of acetic acid
to 5% before puriﬁcation by RP-HPLC.
Viral Infectivity Assays. Pseudovirion infectivity assays
were carried out as previously described21,22 using HXB2 and
JRFL luciferase reporter pseudovirions (NL4−3 strain) and
HOS-CD4-CXCR4 (for HXB2) or HOS-CD4-CCR5 (for
JRFL) target cells. Inhibitor curves were generated using six
concentration points measured in quadruplicate, and luciferase
counts were normalized to an uninhibited control. Inhibition
curves were ﬁt using a standard IC50 eq [1 − c/(IC50 + c)]
weighting each concentration point by its standard error in
KaleidaGraph (Synergy software). Reported IC50 values are the
average of at least 2 independent assays.
■ RESULTS
Our ﬁrst goal was to simplify the synthesis of PIE12-trimer
while also optimizing the linkages between PIE12 monomers.
In our previous work, we synthesized PIE12-trimer by attaching
bis-NHS ester PEG5 spacers to PIE12-GK. After puriﬁcation,
two of these PEGylated monomers were reacted with a central
PIE12-GKK monomer (two primary amines) to produce
PIE12-trimer.21 This method is cumbersome for large-scale
production, because it requires the synthesis of two distinct D-
peptides and a series of HPLC puriﬁcations to assemble the
trimer, resulting in low yields. In addition, our PIE12 crystal
structure suggested that shorter PEG linkers might adequately
bridge the neighboring pockets and improve avidity. To address
these goals, we redesigned the PIE12-trimer using a scaﬀold
strategy. We designed a homotrimeric scaﬀold containing three
NHS ester arms for conjugation to PIE12-GK (Figure 2a) in a
single-pot reaction. PEG linkers of various lengths can be
appended to the PIE12-GK peptide, allowing for the simple
production of PIE12-trimers with varying PEG lengths.
PIE12-trimer’s estimated sub-fM aﬃnity for the N-trimer
makes direct comparative KD measurements (e.g., by surface
plasmon resonance) very challenging. Although antiviral
potency can be used as a surrogate for aﬃnity, PIE12-trimer’s
potency plateau can mask even large changes in aﬃnity. To
overcome this problem, we designed a PIE12 variant with
weakened aﬃnity to allow comparative evaluation of diﬀerent
trimer geometries by measuring inhibitor potency. We
previously observed that PIE12’s two N-terminal residues
make important contacts with the N-trimer and reasoned that
deletion of these residues (D-His and D-Pro) would signiﬁcantly
reduce binding aﬃnity without disrupting the overall
orientation of PIE12 binding to the gp41 pocket or the local
structure at the C-terminal PEG linkage site. ΔHP-PIE12 is 84-
fold less potent than PIE12 (Table 1). In the context of the
homotrimeric scaﬀold, ΔHP-PIE12 connected via our standard
PEG5 linkers has an IC50 of 380 nM against HXB2 (a standard
lab-adapted strain) and is therefore well outside of the potency
plateau (∼500 pM for HXB2). Using ΔHP-PIE12-trimer, we
can now detect changes in potency due to linker changes that
subtly alter aﬃnity.
Our initial exploration of PEG linker lengths in PIE12-trimer
showed that PEG2 and PEG3 were slightly less potent than the
original PEG5. To determine whether PEG4 or PEG5 was the
optimal arm length, both PEG5 and PEG4 ΔHP-PIE12
conjugates were attached to the homotrimeric scaﬀold, and
we observed that a PEG4 linker was slightly more optimal
(Table 1). Therefore, PEG4 was selected as the new standard
linker for conjugating PIE12 to the scaﬀold. The scaﬀold
synthesis strategy is dramatically simpler than our previous
method for generating trimer since it requires only one peptide
and a single puriﬁcation. Additionally, the yields are
considerably higher due to the reduced number of puriﬁcation
and lyophilization steps that led to loss of active NHS esters in
the previous strategy. Finally, the high activity of the scaﬀold
and single-pot reaction allow for near-stoichiometric concen-
trations of peptide and scaﬀold, further improving yield.
Heterotetrameric Scaﬀold. With the optimal PEG linker
length in place, we next turned our attention to improving
PIE12-trimer’s potency via localization to sites of viral entry
(the cell surface). To enable the conjugation of membrane-
localizing groups to PIE12-trimer, we designed a heterotetra-
meric scaﬀold containing three short arms with NHS ester
groups (for addition of PIE12-PEG4-NH2) and a fourth PEG
arm of variable length functionalized with maleimide (an
orthogonal reactive group for the addition of thiol-containing
cargoes) (Figure 2b).
Our ﬁrst cargo for the heterotetrameric scaﬀold was
cholesterol. Several recent studies have shown that cholesterol
conjugation improves both the potency and the circulating half-
life of C-peptide inhibitors of HIV27 and paramyxoviruses.28,29
Cholesterol conjugation has also been shown to speciﬁcally
localize dyes to the membrane surface.30,31 A challenge of
applying this approach to PIE12 is that, while the N-terminus
of the C-peptide lies immediately adjacent to the membrane,
PIE12 targets a pocket that we estimate is ∼60 Å from the
membrane (Figure 1). We used ﬂexible PEG linkers of varying
lengths to span this distance. PEG12 is suﬃciently long if
Table 1. D-Peptide Inhibition Dataa
IC50 (nM)
inhibitor HXB2 JRFL
PIE12b 37 ± 2.3 580 ± 21.4
ΔHP-PIE12 3100 ± 783 nd
Chol-PEG2-PIE12 69 ± 11 nd
Chol-PEG12-PIE12 12 ± 3.6 nd
Chol-PEG24-PIE12 0.64 ± 0.25 nd
C34 1.4 ± 0.3 13.4 ± 0.1
C34-PEG2-Chol 0.044 ± 0.0004 0.05 ± 0.01
C34-PEG11-Chol 0.021 ± 0.0014 0.024 ± 0.005
C34-PEG80-Chol 0.022 ± 0.0004 0.1 ± 0.045
PEG4-ΔHP-PIE12-trimer 300 ± 7.2 nd
PEG5-ΔHP-PIE12-trimer 380 ± 13 nd
PEG4-PIE12-trimer 0.72 ± 0.04 2.1 ± 0.28
Chol-PEG12-PIE12-trimer 0.052 ± 0.02 0.06 ± 0.004
Chol-PEG16-PIE12-trimer 0.02 ± 0.002 0.017 ± 0.0002
Chol-PEG24-PIE12-trimer 0.013 ± 0.0013 0.019 ± 0.003
Chol-PEG36-PIE12-trimer 0.011 ± 0.0015 0.015 ± 0.005
Chol-PEG57-PIE12-trimer 0.007 ± 0.0013 0.013 ± 0.003
Chol-PEG132-PIE12-trimer 0.012 ± 0.0015 0.025 ± 0.002
C8-PIE12-trimer 0.42 ± 0.01 nd
C16-PIE12-trimer 0.09 ± 0.014 0.11 ± 0.012
C18-PIE12-trimer 0.054 ± 0.018 0.087 ± 0.012
aAntiviral potency against HXB2 and JRFL HIV-1 strains. bFrom ref
21.
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stretched taut, but PEG typically assumes an average length
approximately half of its fully stretched distance.32
To study the potency eﬀects of cholesterol (chol)
conjugation to PIE12 and the length of the linker between
chol and PIE12, we used monomeric PIE12, which is not in a
potency plateau and therefore should be a sensitive reporter for
optimal linker length. We began by generating chol-PIE12
conjugates using heterobifunctional PEG2, PEG12, and PEG24
NHS ester/maleimide cross-linkers to conjugate thiocholesterol
(cholesterol with a thiol replacing its hydroxyl group) to
PIE12’s C-terminal Lys (its only primary amine). We observed
that the PEG2 conjugate, much too short to bridge the
membrane to pocket distance, causes a 2-fold loss of potency
(HXB2 strain) compared to unconjugated PIE12. In contrast,
chol-PEG12-PIE12 shows 3-fold improved potency, while
PEG24 provides an even greater 58-fold increase in potency
compared to PIE12. For comparison, we also synthesized C-
peptide (C34) cholesterol conjugates of varying lengths (Table
1). We reproduce Ingalinella’s ﬁnding of ∼40-fold improved
potency27 using a short PEG2 linker, but surprisingly, a longer
linker (PEG11) provides an additional 2-fold improvement in
potency, and a much longer linker (PEG80) maintains the same
potency (HXB2 strain). A similar pattern is seen with the JRFL
strain, but with signiﬁcant attenuation at very long PEG linker
lengths (4-fold worse than the optimal PEG length).
On the basis of these dramatic potency gains, we next
conjugated cholesterol to PIE12-trimer using the heterotetra-
meric scaﬀold. Using the optimal PEG4 linker determined
earlier for the three NHS ester (PIE12) arms, we synthesized
chol-PIE12-trimers with a variety of fourth arm (maleimide)
lengths to conﬁrm the relationship between PEG length and
potency observed with the monomer. In the context of chol-
PIE12-trimer, we did not need to utilize ΔHP-PIE12, as the
cholesterol-mediated improvement in potency was discernible
using PIE12. This sensitivity was expected because membrane
localization aﬀects the association rate rather than changing
aﬃnity (masked by the resistance capacitor). We varied the
fourth arm from 12 to 132 PEG units, covering a distance range
of ∼60 to 480 Å (fully extended).
Cholesterol conjugation dramatically improves PEG4-PIE12-
trimer potency against both HXB2 and JRFL entry (up to 160-
fold, Table 1 and Figure 3). Comparison of varying fourth arm
lengths in chol-PIE12-trimer shows that inhibitor potency
varies modestly in an optimal range between PEG24 and PEG57.
A shorter PEG12 linker is suboptimal, though it performs better
than seen in the monomer series, likely due to the additional
length provided by the PEG4 arms. Only a slight decrease in
potency is observed with the longest (PEG132) linker. Despite
being slightly less potent than Chol-PEG57-PIE12-trimer, we
have chosen Chol-PEG24-PIE12-trimer as our lead candidate
due to its ease of synthesis and the availability of monodisperse
PEG24. A monodisperse PEG scaﬀold will ease future preclinical
studies of chol-PIE12-trimer purity, metabolism, pharmacoki-
netics, and stability. Importantly, cholesterol conjugates retain
high (mM) aqueous solubility.
Another established strategy for localizing inhibitors to
membranes is fatty acid conjugation.33−37 Using the same
heterotetramer scaﬀold strategy described above with choles-
terol, we synthesized PIE12-trimers conjugated to aliphatic
chains of 8, 16, and 18 carbons (C8/C16/C18-PIE12-trimer).
While C8 conjugation has little eﬀect on PIE12-trimer potency,
C16 and C18 both provide substantial gains in potency, though
to a lesser degree than seen with cholesterol (Table 1). C18-
PIE12-trimer was slightly more potent than C16-PIE12-trimer.
Eﬀect of Membrane Localization on the Resistance
Capacitor. Drug resistance is a constant threat to the
eﬀectiveness of HIV inhibitors. PIE12-trimer is an attractive
drug candidate in part because of its strong resistance capacitor,
which provides a high genetic barrier to resistance.21 The
resistance capacitor depends on the diﬀusion-limited associa-
tion rate for PIE12-trimer binding to gp41. The cholesterol and
C16/18 conjugation strategies described here break through
this kinetic barrier via inhibitor localization to viral entry sites
(i.e., increasing eﬀective inhibitor concentration and over-
coming the diﬀusion rate limitation). In theory, this improve-
ment in potency could come at the cost of weakening the
resistance capacitor. To test for this possibility, we measured
the potency of chol- and C16/C18-conjugated PIE12-trimer
against resistance mutations we have previously identiﬁed.21
Previous selection for resistance to PIE7-dimer (an earlier-
generation D-peptide inhibitor)22 generated E560K/V570I,
which minimally aﬀects the potency of PIE12-trimer, but
Figure 3. JRFL pseudovirion infectivity assay. A. Dependence of linker length on chol-PIE12-trimer potency. B. Thio-alkane-conjugated PIE12-
trimer series with diﬀering alkane lengths. Representative curves shown.
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dramatically reduces PIE7-dimer potency.21 Selection of
resistance to PIE12-trimer required more than a year of viral
passaging, but ultimately resulted in the Q577R mutation,
which decreases PIE12-trimer potency by >1000-fold.21 The
eﬀect of these resistance mutations on chol- and C16/18-
PIE12-trimer potency is shown in Table 2. The relative eﬀects
of both resistance mutations are similar for PIE12-trimer and
the cholesterol/alkane-conjugated PIE12-trimers. However,
because of the greatly improved potency of the conjugated
PIE12-trimers, these inhibitors maintain nanomolar potency
even against the severe Q577R resistance mutation. The impact
of the less severe E560K/V570I resistance mutation is absorbed
by all of the conjugated PIE12-trimers, as well as plain PIE12-
trimer. These data suggest that the improvement in potency
through C16/C18 and cholesterol conjugation retains enough
excess binding energy to maintain an eﬀective resistance
capacitor.
■ DISCUSSION
PIE12-trimer, our previously described D-peptide inhibitor, is a
promising preclinical candidate for the treatment and
prevention of HIV-1 due to its strong potency, wide breadth,
and highly charged resistance capacitor that slows the
emergence of resistance mutations. However, the transient
nature of PIE12-trimer’s target means that its potency is
restricted by its diﬀusion-limited association rate with the gp41
pocket. In an attempt to break through this potency barrier, we
designed a heterotetrameric scaﬀold to allow us to conjugate
various membrane-localizing cargoes to PIE12-trimer. This
scaﬀold also allows us to produce PIE12-trimer variants much
more eﬃciently than previously reported. As hoped, con-
jugation of PIE12-trimer to cholesterol or C16/C18 reduces
the kinetic limitation and greatly improves potency up to 160-
fold.
We hypothesize that this increased potency is due to local
concentration of inhibitor at membrane sites of viral entry.
Cholesterol is speciﬁcally enriched at sites of viral entry (lipid
rafts, where CD4 and coreceptor are localized).38,39 The
mechanism by which cholesterol improves potency is the focus
of ongoing work. Preliminary evidence suggests that the
interaction between cholesterol and the membrane is readily
reversible, which may explain why there is a broad range of
compatible linker lengths. It may also be the case that
cholesterol-conjugated inhibitors interact directly with Env, as
a cholesterol recognition/interaction amino acid consensus
sequence (CRAC) has been identiﬁed in the membrane
proximal region of gp41.40
By comparison, C16 and C18 conjugates are less potent than
the cholesterol conjugate. Saturated fatty acids C16:0
(palmitate) and C18:0 (stearate) are also enriched in lipid
rafts,41 but are abundant in the general plasma membrane as
well.42 The reduced potency of alkylated PIE12-trimer
compared to cholesterol may therefore be explained by a
relatively lower aﬃnity of alkyl chains for lipid rafts. Another
possible explanation is fatty-acid sequestration by albumin,
which is known to bind fatty acids with high aﬃnity (compared
to cholesterol),43 though it is not known how loss of the acid
group (leaving an alkane chain) aﬀects this binding.
GPI anchors in lipid rafts contain C16 and C18 alkyl chains
as well as acylated C16 and C18 fatty acids.44 Originally, we
synthesized alkyl conjugates, and noted that they improved
potency through membrane association (overcoming the
potency plateau). For completeness, we also synthesized an
acylated C16 (fatty acid) conjugate. Surprisingly, the C16 acyl
conjugate was much less potent than the C16 alkyl conjugate
(data not shown), presumably because it does not associate as
eﬀectively with plasma membranes. This ﬁnding may explain
why a recent study did not observe a potency enhancement
with C16 acylation of C34.27
Importantly, we show that membrane localization does not
impair the resistance capacitor. Both chol- and C16/C18-
conjugated PIE12-trimer are able to absorb the aﬃnity-
disrupting impact of PIE7-dimer resistance mutations
(E560K/V570I). For the more severe PIE12-trimer resistance
mutation Q577R, the relative loss of potency for both
conjugates is comparable to that seen with PIE12-trimer. The
full resistance proﬁle of these conjugates will be determined by
ongoing viral passaging studies starting from both wild-type and
PIE12-trimer resistant virus.
Although PIE12-trimer has ideal antiviral properties, its
relatively small size (∼8 kD) will likely lead to a short serum
half-life due to renal ﬁltration. In addition to their potency-
boosting eﬀects, we hypothesize that both cholesterol and alkyl
conjugation will also lead to improvements in the pharmaco-
kinetic (PK) properties of these inhibitors via interaction with
cell membranes and albumin that slow renal clearance. Albumin
serves as a carrier for both cholesterol45 and fatty acids,46
reducing the rate of renal ﬁltration. Adherence to membrane
surfaces may also slow the absorption of inhibitor from the
subcutaneous space, enabling prolonged dosing via a slow-
release depot eﬀect. This type of depot would be especially
attractive for nondegradable D-peptides.
This work demonstrates the successful application of
modular PEG scaﬀold-based design to peptide drug optimiza-
tion (both peptide geometry and localization to the site of
action via conjugated localizing cargoes). This approach allows
for alterations in the scaﬀold to accommodate a variety of
cargoes and chemistries (e.g., “click” chemistry), as well as rapid
optimization of PEG arm lengths. For viruses that undergo
membrane fusion within the endosome, such as Ebola, this
strategy could be employed to attach an endosome-targeting
moiety to localize inhibitor to the site of entry and increase
potency. Additionally, the scaﬀold allows for conjugation to a
variety of cargoes to modulate PK properties (e.g., large
branched PEGs, albumin, or albumin-binding peptides).47,48
The scaﬀold itself is inexpensive to produce and can be used
directly for cost-eﬀective large-scale production.
PK and animal toxicity studies for chol- and C16/C18-
PIE12-trimer are underway to determine how conjugation
alters serum half-life and to determine if any speciﬁc toxicity
arises as a result of conjugation. Fatty acid conjugation has been
used to prolong serum half-life of a GLP-1 peptide (liraglutide,
Table 2. Antiviral Potency against Resistant Strainsa
IC50 (nM)
inhibitor WT HXB2 E560K/V570I Q577R
PEG4-PIE12-trimer 0.72 0.89 >3 μM
Chol-PEG24-PIE12-trimer 0.013 0.01 10.1
C8-PIE12-trimer 0.42 0.86 452
C16-PIE12-trimer 0.09 0.045 39
C18-PIE12-trimer 0.054 0.035 32.5
aAntiviral potency against identiﬁed resistant strains (HXB2 back-
ground). The IC50 standard error of the mean values are <35% for all
samples.
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C16) and insulin (detemir, C14). Alkane toxicity in the context
of peptide conjugates has not been studied.
The in vivo eﬃcacy of these conjugates will be determined in
future studies of systemic treatment via subcutaneous injection
or as a vaginally/rectally applied preventative (microbicide) in
human tissue and animal models. Our D-peptide scaﬀold is
especially advantageous for application as a microbicide due to
its protease resistance, which should enable it to persist for
extended periods in the vaginal/rectal mucosa’s harsh protease-
rich environment. The addition of membrane-binding groups
may also improve microbicide tissue penetration and retention.
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Unmodified peptides generally have in vivo half-lives on the order of minutes, 
making pharmacokinetic (PK) enhancement necessary.  Herein we evaluate several 
strategies for enhancing PK in the context of our lead candidate PIE12-trimer, a protease-
resistant D-peptide HIV entry inhibitor.  Surprisingly, PIE12-trimer conjugates show a 
general reduction in half-life compared to equivalent monomeric conjugates.  PEGylation 
with a 40 kDa Y-branched PEG greatly improves PIE12’s half-life but reduces antiviral 
potency.  Moreover, fatty acid conjugation (acylation) and alkane conjugation of 
comparable lengths were found to behave significantly differently.  Fatty acids failed to 
improve potency, but reduced the volume of distribution and clearance 6-fold, while 
alkane conjugates significantly improved potency with only modest effects on half-life.  
Cholesterol conjugation dramatically improves potency while concurrently improving 
half-life.  Because of its simultaneous improvements in potency and PK, cholesterol 









Peptide therapeutics are an increasingly important class of medicines.  Peptides 
have advantages over small molecules in terms of improved target affinity and 
specificity, as well as an ability to disrupt protein-protein interactions (generally 
considered “undruggable” by small molecules)1.  Furthermore, peptides have advantages 
over proteins in that they can be chemically synthesized, can penetrate deeper into 
tissues, and are generally less immunogenic1. 
Despite these advantages, peptide therapeutics face considerable pharmacokinetic 
(PK) challenges.  Peptides can be rapidly cleared by the kidneys and degraded by 
proteases, leading to short half-lives.  They also do not readily penetrate through cell 
membranes1, limiting access to potential intracellular targets and reducing transcellular 
migration.  These same limitations prevent oral administration of peptides such that they 
must be delivered parenterally, usually by subcutaneous (SC) injection.  Although 
generally not as preferable as oral delivery, self-administered subcutaneous drugs are 
readily accepted by patients for multiple indications, such as diabetes and HCV. 
Recently we reported the development of a highly potent protease-resistant         
D-peptide inhibitor of HIV-1 entry, PIE12-trimer, that exhibits sub-pM binding affinity 
and high pM potency against every major circulating clade of HIV-12,3.  Using a 
polyethylene glycol (PEG) scaffold with three arms of discrete length for the attachment 
of PIE12 (a peptide composed solely of D-amino acids), synthesis of PIE12-trimer has 




been simplified and yields increased.  Moreover, an orthogonally reactive fourth linker 
arm makes conjugation to potency and PK enhancing moieties possible (Fig. 5-1).   
PIE12-trimer’s target, gp41, is only transiently exposed during HIV fusion.  
Because PIE12-trimer’s off-rate greatly exceeds that time, PIE12-trimer potency is only 
limited by on-rate, which can be increased by membrane-tethering moieties on the fourth-
arm.  Prolonging the off-rate improves affinity for gp41, but not its potency.  Thus, 
PIE12-trimer binds gp41 with an excess of binding energy.  This excess affinity, dubbed 
the “resistance capacitor,” significantly delays the onset of HIV resistance because 
mutations that reduce affinity are still inhibited with equal potency, preventing the 
stepwise accumulation of resistance mutations3.  Overall, PIE12-trimer’s broad potency 
combined with its “charged” resistance capacitor provides an ideal preclinical candidate 
for the prevention and treatment of HIV/AIDS. 
 Ultimately our goal is to develop a weekly or monthly subcutaneous injectable by 
conjugating potency and PK enhancing moieties to PIE12-trimer.  For peptides in 
general, PK-enhancing moieties can improve half-life by reducing clearance (e.g., by 
avoiding renal filtration) or sheltering peptides from proteases.  As a D-peptide, PIE12-
trimer is unique because it is already protease stable.  Thus, our conjugates will provide 
the first clear view of the pure clearance-reducing potential endowed by a given PK-













Figure 5-1.  PIE12 and PIE12-trimer Scaffolds with PK-Enhancing Cargoes.  PIE12 
is represented by green circles.  A) PIE12-trimer, activated PIE12, and activated PIE12-
trimer are shown schematically (each PIE12 of PIE12-trimer is linked to the scaffold with 
a discrete PEG4 linker, not shown). B) 40 kDa Y-branched PEG, palmitic acid, aliphatic 
C16 and C18 chains, and cholesterol are conjugated to PIE12 and PIE12-trimer by 




Selection of PK-Enhancing Moieties 
 
When choosing PK-enhancing moieties, we considered both clinically validated 
strategies  (such  as  PEGylation utilized for INF!2a in PEGASYS, and acylation utilized 
for a GLP-1 analogue in Victoza) as well as strategies in preclinical development 





PEGylation is a validated strategy for enhancing PK with eleven approved 
products.  PEG conjugation improves PK primarily by increasing drug size to reduce 




renal filtration, while also decreasing proteolysis and reducing immunogenicity for 
susceptible proteins.  The primary challenge of PEGylation is to add enough PEG to 
improve pharmacokinetics without sterically inhibiting the activity of the conjugate.  
Approved PEGylated compounds to date have utilized 20-40 kDa of PEG through single 
or multiple attachments.  This amount of PEG is large enough to avoid renal filtration, 
but not too much as to completely inhibit activity or promote uptake into 
reticuloendothelial cells6. 
PEGASYS is a particularly well-studied PEGylated protein, and utilizes a single 
branched 40 kDa PEG.  Branched PEGs are reported to increase half-life and better 
preserve conjugate activity compared to mass-equivalent straight-chains7.  Branched 
PEGs also better protect against proteolysis8.  Compared to unconjugated interferon, the 
40 kDa branched PEG of PEGASYS increases IV half-life in humans from 3.8 to 65 h 
and reduces the volume of distribution 5-fold, thereby slowing clearance 100-fold9 (Table 
5-1).  This enhanced PK profile enables once-weekly subcutaneous administration. 
Unlike most PEGylated products, however, our peptide is an inhibitor, not a 
hormone or enzyme.  Therefore doses must be higher and steadier, so questions regarding 
PEG toxicity become necessary to consider.  Fortunately, PEG appears to be remarkably 
nontoxic.  For example, the PEG 400 excipient in intravenous (IV) busulfan can be given 
at 300 mmoles (110 g) per week without noticeable toxicity10.  With increasing dose, 
eventually PEG toxicity manifests as proximal renal tubule swelling.  Recently a patient 
was given an average of 650 mmoles (240 g) per week of PEG 400 excipient in IV 
lorazepam for a duration of 43 days.  Renal toxicity developed but completely resolved 
upon   discontinuation   of   therapy11.     In   another   report,   32   patients   received   IV 




Table 5-1.  Terminal Half-Lives and Volumes of Distribution for Relevant FDA-










 IV SC Vd (L) IV SC Vd (mL) IV SC 
Vd 
(mL) 
PEGylation          
Unconjugated 
INF!2a 3.8 h
9 3-8 h8; 
4-6 h9 31-73
8 2.1 h8 0.7 h12     
PEGASYS               
[40 kD PEG-
INF!2a] 
60-80 h 160 h = 6.7 d 8-12





 14 d13 6-813       
Omontys 
(peginesitide) 
[40 kDa PEG with 
21aa dimerized 
peptides] 




      
Lipidation          
       Acylation          
Unconjugated 
GLP-1 (7-37) 1-2 m








4.9 per     
70 kg17  4 h
16     
Unconjugated 
Insulin 4-6 m





23 7 per 70 kg23       
       Cholesterol          
T20 (Fuzeon) 1.83 h24 3.8 h25 6-724 2.8 h26   
   
C34 










conjugation          
Unconjugated 
Albumin 19 d
27  8.4 per     70 kg28 
1.9 
d27   1 d
27   
C34-HSA ND ND N/A    ~1 d29 ~1 d29  
Albuferon  
(INF!2b-HSA)  140 h




 9-15 d30   15-20 h30     




nitrofurantoin containing 120-225 g of PEG 300 (~650 mmoles) over 3-5 days.  Of these, 
six developed renal toxicity and two died11.  It is not clear whether the total mass of PEG 
or molar concentration contributes more to renal toxicity.  However, the high molarity 
required to observe toxicity, often in the 10’s of mM, exceeds the dose of current 




Acylation and Alkylation 
 
 PK-enhancement by acylation is based on the strong interaction of fatty acids with 
human serum albumin (HSA), which circulates for 19 days (Table 5-1).  A secondary PK 
benefit of acylation is self-association that prolongs absorption from the subcutaneous 
space17,31.  Physiologically, free fatty acids (FFAs) circulate bound to HSA, which has 
two high-affinity sites for FFAs and several secondary sites.  [Note that “free” means it is 
not esterified to glycerol, and should not be taken to mean it is unbound].  Palmitate (C16 
fatty acid) and stearate (C18 fatty acid) are the predominant forms of circulating FFAs32.  
FFA levels follow a diurnal pattern (rise during an overnight fast) that normally does not 
exceed a 2-fold molar excess over HSA33, although >6-molar excess has been reported in 
diabetic and obese patients34.  Circulating FFAs are anionic, although the charge is 
reputed to contribute little to albumin binding.35 
The affinity of HSA for FFAs is in the mid-to-low nM range35-37.  Notably, FFAs 
do not bind significantly to any other circulating particles, including low-density 
lipoproteins (LDL)35.  Furthermore, FFAs bind sites on HSA that appear to be 
independent of those used by most small molecules.  For example, although more than 




98% of circulating myristoylated (C14 fatty acid) insulin detemir is bound to albumin, 
there have been no clinically relevant interactions noted with other protein-bound 
drugs23,35. 
 Victoza (liraglutide), a GLP-1 analogue, utilizes palmitate conjugation to increase 
its half-life, enabling once-daily subcutaneous dosing.  During the development of 
liraglutide, a myriad of other potential PK-enhancing lipids were evaluated18.  Notably, 
stearate conjugates had a better half-life but reduced activity, so palmitate was chosen for 
development.  Interestingly, liraglutide is not cleared by the kidneys or liver17, consistent 
with its high association with albumin.  Apparently the majority of liraglutide is 
catabolized and absorbed by cells. 
Based on publications that identify a fatty acid’s aliphatic chain as the critical 
moiety for albumin interaction35, we also explored alkane-conjugation as a substitute for 
acylation.  Alkanes only differ from fatty acyl groups by a single terminal carbonyl, and 
thiol-alkanes made synthesis straightforward using the maleimide chemistry of our 





 Cholesterol conjugation of an HIV C-peptide inhibitor improves PK in mice4.  As 
a newer strategy for which there are no FDA-approved examples, it is as yet unclear 
exactly how cholesterol improves PK, although we suspect a combination of cell 
membrane and albumin association.  Two studies report 435 µM38 and 24.6 µM39 
cholesterol affinity for HSA.  It is also reported, and consistent with our data, that 




cholesterol provides superior membrane-binding over palmitate4, although this 





 Whereas acylation and, likely, cholesterol conjugation improve PK by 
noncovalently interacting with albumin, a direct linkage is reported to improve PK even 
further, consistent with albumin’s long half-life (Table 5-1).  Of HSA’s 35 cysteines, only 
one is available for thiol-specific conjugation, Cys-34, found in the Ia subdomain40. 
Importantly, Cys-34 is buried and unavailable for conjugation unless the neighboring 
fatty acid binding site is occupied by fatty acid40.  Physiologically, free thiols like Cys-34 
are unusual, prompting the development of in vivo HSA conjugation prodrugs40.  Among 
albumin conjugates studied to date, Albiglutide (GLP-1), Albugon (GLP-1), and 
Albuferon (INF!2b) are the most developed5,30,41.  An albumin-C34 anti-HIV entry 
inhibitor has also been reported29. 
 
Materials and Methods 
 
Synthesis of Monomeric PIE12 and Conjugates 
 
PIE12 was synthesized by RS Synthesis (Louisville, KY) using standard solid-
phase methods.  PIE12-PEG12-cholesterol was synthesized by reacting 3 mM PIE12 with 
4 mM maleimide-PEG12-NHS ester (Quanta Biodesign, 10284) in dimethylacetamide 
(DMAC) with 200 mM triethylamine (TEA) for 30 min at RT, and then purified by 
reverse-phase HPLC (water/acetonitrile gradient in 0.1% TFA) on a Waters BEH 
XBridge 10 µm, 300 Å C18 column (RP-HPLC).  Two mM of the purified product, 




PIE12-PEG12-maleimide, was reacted with 4 mM thiocholesterol (Sigma-Aldrich, 
136115) in DMAC with 200 mM TEA for 45 min at RT.  PIE12-PEG12-palmitate was 
synthesized by reacting 3 mM PIE12 with 3 mM Fmoc-N-amido-PEG12-NHS ester 
(Quanta Biodesign, 10996) in DMAC with 200 mM TEA for 30 min at RT, and then 
purified by RP-HPLC.  The lyophilized product, Fmoc-N-amido-PEG12-PIE12, was 
dissolved in 20% piperidine in DMF to deprotect the terminal amine and repurified by 
RP-HPLC.  Two mM of the purified product, PIE12-PEG12-NH2, was reacted with 4 mM 
palmitic acid NHS ester (Sigma-Aldrich, P1152) in DMAC with 500 mM TEA for 45 
min at RT.  PIE12-PEG5-40 kDa Y-branched PEG was synthesized by reacting 2 mM 
PIE12 with 20 mM bis-NHS ester PEG5 (Quanta Biodesign, 10224) in 100 mM HEPES 
pH 8.0 for 90 seconds.  The reaction was quenched in 5% acetic acid and purified by RP-
HPLC.  Two mM of the purified product, PIE12-PEG5-NHS ester, was reacted with 2.5 
mM 40 kDa Y branched PEG-amine (JenKem, A0010), and then purified by RP-HPLC. 
 
 
Synthesis of PIE12-trimer and PIE12-trimer Conjugates 
 
PIE12-trimer and PIE12-trimer-PEG24-maleimide were synthesized as previously 
described3.  PIE12-trimer C8, C16, C18 and cholesterol conjugates were synthesized by 
reacting 3 mM PIE12-trimer-PEG24-maleimide with 4.5 mM thiocholesterol (Sigma 
Aldrich, 136115), 1-octanethiol (Sigma-Aldrich, 471836), 1-hexadecanethiol (Sigma-
Aldrich, 52270), or 1-octadecanethiol (Sigma Aldrich, 01858) in DMAC with 200 mM 
TEA for 60 min at RT, and then purified by RP-HPLC.  Palmitate conjugated PIE12-
trimer was synthesized by first reacting 3 mM PIE12-trimer-PEG24-maleimide with 4.5 
mM D-Cysteine in DMAC with 200 mM TEA for 60 min at RT, and then purified by RP-




HPLC.  Two mM of the purified product was reacted with 5 mM palmitic acid NHS ester 






Pseudovirion infectivity assays were conducted as previously described2,42.  
Briefly, a six-point dilution series of inhibitor was generated in quadruplicate in HOS-
CD4-CXCR4 (for HXB2) or HOS-CD4-CCR5 (for JRFL) target cell seeded plates, after 
which HXB2 (X4) and JRFL (R5) luciferase reporter psuedovirions were added.  After 2 
days, cells were lysed using GloLysis buffer (Promega) and BrightGlo (Promega) 
luciferase reagent was added.  Luminescence was read on a PolarStar Optima (BMG) 
plate reader.  Counts were normalized to uninhibited controls.  Curves were plotted and 
fit to a standard IC50 equation for normalized data [1 – c/(IC50 + c)], weighting each point 
by its standard error using KaleidaGraph (Synergy software).  Reported IC50 values are 
the average of at least two independent assays. 
 
HSA Affinity Studies 
 
A 4 x 100 mm, 5 µm Chiral-HSA column was generously donated from Chiral 
Technologies Inc. to enable HSA affinity studies.  Samples were injected on an Agilent 
HPLC system and eluted isocratically at 0.9 mL/min with 15 mM potassium phosphate 
buffer, pH 7.4 with 7.5% ACN and 7.5% isopropanol at 37 °C.  All absorbance traces 
were measured at 214 nm except for warfarin, which was measured at 308 nm. 
 
 






Animals, Dosing, and Collection 
 
For monomers PIE12, Chol-PIE12 and PEG40-PIE12, PK studies were conducted 
by Invitek.  All other studies were conducted by Navigen.  Studies were conducted by 
dosing three Sprague Dawley rats (0.22-0.44 kg) for each compound and route (doses 
listed in Table 5-5).  ~300 !L blood samples were taken over 10 timepoints and 
anticoagulated with lithium heparin.  Samples were spun and ~150 !L plasma was 





Drug concentrations in plasma were determined using an AB Sciex API 3000 
triple-quad LC/MS/MS by MRM methods.  Standard curves were produced in pooled 
Sprague Dawley rat plasma anticoagulated with lithium heparin (Bioreclamation).  
Plasma samples were prepared for LC/MS/MS by spiking with internal standard followed 
by precipitation 2:1 with 98% acetonitrile (ACN) / 2% formic acid.  Supernatants were 
run over a C18 reverse-phase column (Waters, 4.6 x 50 mm, 5 µm, XBridge BEH300) on 
an Agilent HPLC system.  Lipid conjugates required lower source temperatures (300 °C 
vs. 500 °C) for best reproducibility.  For all studies except PEG40-PIE12 the column was 
regenerated after every group of 3 rats by running an isocratic gradient of 25% ddH2O, 
25% MeOH, 25% IPA, and 25% ACN for 30 min.  This procedure was found to be 
sufficient for removing retained phospholipids.  For PEG40-PIE12, a blank run and 
isocratic wash of 25% ddH2O, 25% MeOH, 25% IPA, and 25% ACN for 5 min were 
required after every sample to prevent carryover. 




Determining an appropriate starting ACN concentration was also necessary for 
effective elution.  For PIE12 (mass transition 1022.3/180.1), Palm-PIE12 (mass transition 
721.4/282.3), and Chol-PIE12 (mass transition 1066.6/229.1), the starting concentrations 
were 15%, 40%, and 82% ACN, respectively.  PEG40-PIE12 was fragmented in the 
source (5000 Volts) and the mass transition monitored was 133.1/89 with a starting 
concentration of 37% ACN.  For PIE12-trimer (mass transition 1431.7/180.1), Palm-
PIE12-trimer (mass transition 1466.5/554.5), C16-PIE12-trimer (mass transition 
1450.1/453.4), C18-PIE12-trimer (mass transition 1454.5/481.3), and Chol-PIE12-trimer 
(mass transition 1474.2/1694.9), the starting concentrations were 35%, 40%, 65%, 65%, 
and 75% ACN, respectively. 
 
 
Fitting the Data 
 
IV-dosed time-points were plotted and fit to a noncompartmental model to 
determine C0 and the terminal half-life (T1/2) using the equation C(t) = C0*((1/2)(t/T1/2)), 
where C0 represents the theoretical starting concentration if drug were instantly 
distributed (no alpha phase).  The terminal half-life is then converted into the decay rate 
ke (ke = ln2/T1/2).  SC-dosed time-points were plotted and fit to the model C(t) = 
K*(ka/(ka-ke))*[exp(-ke*t) - exp(-ka*t)], where K is a constant, ka is the rate of 
absorption, and ke is the decay rate determined from the IV fit (weighting to the standard 
deviation of duplicate measurements, KaleidaGraph).  Volume of distribution (Vd) is 
determined by dividing dose (in moles) by C0.  Because elimination is first order, 
clearance (CL) can be determined by the relationship CL = ((ln2)*(Vd))/(T1/2).  Areas 




under the curve (AUCs) were calculated by integrating fits from zero to infinity.  





PK plasma samples were prepared for pseudoviral assay by 2:1 precipitation with 
98%ACN/2%FA, followed by centrifugation for 10 min in a microcentrifuge at 13,000 
rpm.  Supernatants were spun to dryness on speed-vac, followed by resuspension in 50 
mM HEPES pH 7.4 to their original volumes.  Pooled plasma was prepared as a control.  
Samples were then diluted 1:10 or 1:100 in DMEM/10% FBS and assessed in a 
pesudoviral assay as described (diluting samples 2-fold further) with normalization for 
uninhibited controls in the presence of prepared control plasma (1:20 prepared plasma 
slightly reduced viral infectivity).  A standard IC50 curve was prepared alongside plasma 








Using clinically successful and promising preclinical PK-enhancing moieties, we 
designed and synthesized several PIE12 and PIE12-trimer conjugates (Table 5-2).  The 
effects of each conjugation on antiviral potency are shown in Table 5-3.  As expected, the 
large 40 kDa Y-branched PEG reduces the potency of our inhibitors, likely due to steric 
interference with target binding.  Specifically, the potency of monomeric PIE12 is 
reduced by 2.5 (HxB2)  and 10-fold  (JRFL),  and the potency of PIE12-trimer is reduced 




Table 5-2.  Conjugate Designs and Naming Scheme 
Abbreviated name Full name 
Monomers  
PIE12 PIE12GK 

















Table 5-3.  Potency Effects of PK Conjugation 







Monomers    
PIE12 41 37 ± 2.3† 580 ± 21.4† 
PEG40-PIE12 47 93 ± 32 5640 ± 950 
Palm-PIE12 67 243 ± 23 1660 ± 14 
Chol-PIE12 88 12 ± 3.6* 28 ± 2.4 
    
Trimers    
PIE12-trimer 51 0.72 ± 0.04* 2.1 ± 0.28* 
PEG40-PIE12-trimer 47 9.5 ± 1.4 71 ± 12 
C8-PIE12-trimer 55 0.42 ± 0.01* 2 ± 0.58 
Palm-PIE12-trimer 62 0.225 ± 0.008 0.540 ± 0.041 
C16-PIE12-trimer 71 0.09 ± 0.014* 0.11 ± 0.012* 
C18-PIE12-trimer 76 0.054 ± 0.018* 0.087 ± 0.012* 









by 13 (HxB2) and 34-fold (JRFL).  In comparison, the same PEG on PEGASYS reduces 
activity 14-fold9.  
In contrast, the smaller hydrophobic conjugations mostly increased the potency of 
our inhibitor, but to varying extents, from little or no increase with C8 conjugation to a 2 
log improvement with cholesterol conjugation.  The C8 alkane only modestly improves 
potency, while C16 and C18 alkanes improve potency significantly.  A C16 fatty acid 
(palmitate) also improves potency, but to a much lesser extent than C16 alkane, 
suggesting that acyl groups interact with membranes differently than alkanes.  
Cholesterol interacts with membranes even more strongly4, improving potency over other 
lipid conjugates.  Notably, cholesterol conjugates remain very soluble3. 
 PIE12-trimer conjugations to albumin are still preliminary, but have been 
informative.  Using incompletely purified material (approximately 4:1 HSA to HSA-
PIE12-trimer), there appears to be only a modest five-fold loss in potency compared to 
PIE12-trimer in pseudoviral infectivity assays.  However, challenges remain regarding 
complete purification of HSA-PIE12-trimer, and reliable quantitation of HSA-PIE12-
trimer in plasma samples.  Gel filtration is successful at removing unreacted PIE12-
trimer, but does not remove unreacted HSA.  Unreacted HSA and HSA-PIE12-trimer 
conjugates can be separated by reverse-phase HPLC, but this process completely 
denatures albumin.  It has been reported, however, that not only can HSA be completely 
recovered off a reverse-phase column43, it can also be efficiently refolded following 
HPLC denaturation and lyophilization44,45.  Soluble microaggregates, if present, can be 
detected by light scattering44. 
 
 




HSA Affinity Studies 
 
Acyl and alkane conjugates were synthesized with the intention to improve PK 
through HSA binding.  To assess the relative HSA affinities of PIE12 and PIE12-trimer 
conjugates we utilized an immobilized HSA affinity column.  Longer retention times on 
this column correlate with higher HSA affinity46 (Table 5-4, Fig. 5-2).  Small molecules 
with known affinities for HSA have been included for reference; L-Tryptophan (90.9 µM 
KD) and (R)- and (S)-warfarin (4.8 and 3.8 µM KD respectively)46. 
Notably, Chol-PIE12-trimer shows reduced affinity for HSA compared to Palm-
PIE12-trimer, but comparable affinity to C18-PIE12-trimer.  PEG40-PIE12 shows the 
least affinity for HSA.  Interestingly, C8-PIE12-trimer, with its long fourth-arm PEG 
linker, shows slightly reduced affinity for HSA compared to the three-armed PIE12-
trimer, while C16-PIE12-trimer is not so limited. 
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Figure 5-2.  HSA Affinity Column Retention Times.  Compounds are listed in order of 






In order to understand the PK effects of the different PK-enhancing moieties, we 
studied conjugates of both PIE12 monomer as well as PIE12-trimer (our lead anti-HIV 
drug candidate).  PK studies of C8 conjugates were not pursued due to poor potency 
improvements and low affinity for HSA.  Similarly, significant losses in potency for 
PEG40-PIE12-trimer reduced our interest in it as a lead preclinical candidate.  Although 
we did not pursue PK studies for PEG40-PIE12-trimer, we did study PEG40-PIE12 to 
assess the general PK-enhancing properties of PEGylation.  Representative PK data are 
shown in Figures 5-3 and 5-4, and a summary of PK parameters is given in Tables 5-5 
(IV data) and 5-6 (SC data). 
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Figure 5-3.  Pharmacokinetics of four intravenously administered monomers in rats.  
Data are from single representative animals.  Terminal half-life fits are shown, with 
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Figure 5-4.  Pharmacokinetic data of five trimers in rats.  A) Intravenously-administered 
trimer data from single representative animals.  Terminal half-life fits are shown, with 
linearity establishing first-order clearance.  B) Subcutaneously-administered trimer data 
from single representative animals. Standard two-phase absorption-elimination fits are 
shown.  Error bars are the standard deviation of duplicate measurements. 




Table 5-5.  IV Pharmacokinetic Parameters of PIE12 and PIE12-trimer Conjugates 
in Rats. 








Monomers       
PIE12 2043.3 1.4 mg/kg 1.9 h 2,891 116 42 
PEG40-PIE12 42345.8 0.9 mg/kg* 26.8 h 223,658 20 0.5 
Palm-PIE12 2881.6 1.2 mg/kg 1.8 h 15,534 17.5 6.7 
Chol-PIE12 3196.9 2.2 mg/kg 5.1 h 26,451 22 3 
Trimers       
PIE12-trimer 7153.2 1 mg/kg 0.54 h 153 211 271 
C16-PIE12-trimer 8692.2 1 mg/kg 0.65 h 876 37 39 
C18-PIE12-trimer 8720.2 1 mg/kg 0.84 h 814 50 41 
Palm-PIE12-trimer 8793.3 1.2 mg/kg 1.5 h 1675 42 20 
Chol-PIE12-trimer 8835.4 1 mg/kg 1.6 h 2049 38 16 




Table 5-6.  SC Pharmacokinetic Parameters of PIE12-trimer Conjugates in Rats. 




SC AUC0!"  
(nM*hr)† 




Trimers        
PIE12-trimer 1 mg/kg 1 h 0.7 h 451 295 0.84 h 84 
C16-PIE12-trimer 1 mg/kg 1.3 h 0.9 h 936 107 1.1 h 183 
C18-PIE12-trimer 1 mg/kg 1.5 h 1.2 h 745 92 1.4 h 187 
Palm-PIE12-trimer 1.2 mg/kg 2.1 h 0.5 h 609 36 1.2 h 603 
Chol-PIE12-trimer 1 mg/kg 3.4 h 2.7 h 340 17 3 h 146 




The terminal half-life is the most commonly reported PK parameter, often 
referred to simply as “half-life”; it is the steady half-life that occurs after a compound is 
distributed throughout an animal.  PIE12 has a 1.9 hour IV terminal half-life vs. only 0.54 
hours for PIE12-trimer.  Similarly, Chol-PIE12 and Chol-PIE12-trimer IV terminal half-
lives differ by 3- to 4-fold, 5.1 hours and 1.6 hours, respectively.  Whereas PEG40-PIE12 
greatly enhances half-life to 26.8 hours, Palm-PIE12 did not affect the terminal half-life 
compared to PIE12 (1.8 vs. 1.9 hours, respectively).  However, the palmitate moiety did 
reduce the volume of distribution and clearance 6-fold.  Palmitate on Palm-PIE12-trimer 




did improve half-life compared to PIE12-trimer (1.5 vs. 0.54 hours, respectively), 
reduced clearance ~10-fold, and reduced volume of distribution ~6-fold. 
Notably, identical compounds have different terminal half-lives depending on the 
route of administration, because terminal half-lives are apparent half-lives (a mix of 
absorption from tissue compartments and elimination47).  All PIE12-trimer conjugates 
acquired an approximate 2-fold improvement in terminal half-life after subcutaneous 







It is interesting to note that for PIE12-trimer conjugates, elution time off a C18 
reverse-phase column correlates with potency, indicating that potency enhancement is 
directly related to hydrophobicity of the lipid moiety.  PIE12-trimer potency is limited by 
on-rate, so improvements in potency reflect improvements in membrane binding3.  This 
indicates a relationship where the more hydrophobic lipids interact more effectively with 
membranes. 
Given the potency increase with palmitate conjugation to PIE12-trimer, it is 
surprising that monomeric PIE12 is not similarly enhanced.  Although the PEG12 linker 
between PIE12 and palmitate is shorter than optimal3, the same linker between PIE12 and 
cholesterol still improves potency over PIE12.  Considering palmitate’s higher affinity 
for HSA over cholesterol, it is possible that fatty acid conjugates are being sequestered by 
albumin in the assay, and that PIE12-trimer’s branched PEG scaffold prevents 
sequestration to the same degree. 






Because of PIE12-trimer’s large volume of distribution and rapid equilibration 
(no alpha phase noted), the resultant low concentrations were near the sensitivity limit of 
our method of quantitation.  Reduced accuracy regarding AUC calculations are likely 
responsible for the apparent higher bioavailability of SC vs. IV administered PIE12-
trimer. 
The difference in half-life between alkylated and acylated conjugates, which 
differ only by a carbonyl group, is surprising (comparing data for C16 acylation and C16 
alkylation). The uncharged acyl group significantly reduces hydrophobicity compared to 
an equivalent alkane, lowering membrane affinity and antiviral potency while 
simultaneously improving albumin affinity and half-life.  Differences can also be 
observed in the absorption rate, with the more hydrophobic alkanes prolonging 
absorption from the subcutaneous space.  Like PEG, acylation reduces the volume of 
distribution, consistent with albumin binding.  Compared to Palm-PIE12, Palm-PIE12-
trimer has reduced albumin affinity and a larger volume of distribution, suggesting the 
PEG scaffold may be interfering with beneficial HSA interactions. 
Half-life comparisons between related PIE12 and PIE12-trimer conjugates are 
also surprising. While originally we assumed that increasing molecular weight from a 
monomer to a trimer could only improve half-life by reducing renal filtration, there is 
actually an across-the-board 3- to 5-fold higher clearance for each PIE12-trimer 
conjugate.  Conjugations to PIE12 monomer improve PK consistent with the literature; 
PEGylation increases half-life to 26 hours (compared to 15 hours for PEGASYS8), 
acylation reduces the volume of distribution and clearance 6-fold (despite no apparent 




change in half-life), and cholesterol conjugation increases half-life to 5.1 hours in rat 
(comparable to 3 hours for C34-Chol in mice4).  Notably, for PIE12-trimer the rank order 
of PK-enhancement is still retained for each moiety, as is the magnitude of improvements 
endowed by each conjugate.  Therefore something specific to PIE12-trimer itself must be 
reducing its half-life. 
One explanation is reduced efficacy of PK-enhancing moieties in the context of 
PIE12-trimer.  There are indications that PIE12-trimer’s PEG scaffold may be restricting 
beneficial interactions between PK-enhancing moieties and HSA and cell membranes.  
PIE12-trimer conjugates show reduced affinity for HSA and C18 on reverse-phase 
columns compared to monomer equivalents (Tables 5-3 and 5-4, Fig. 5-2).  Furthermore, 
a C8 alkane conjugated to the long PEG fourth-arm scaffold demonstrates even less 
affinity for HSA than regular PIE12-trimer.  Volumes of distribution are also greater for 
PIE12-trimer conjugates compared to monomers, consistent with reduced albumin 
binding.  Finally, palmitate conjugation improves PIE12-trimer potency while reducing 
PIE12 potency, a finding that might be explained by significant HSA sequestration for 
Palm-PIE12, but less HSA interaction for Palm-PIE12-trimer. 
Of the affinity-boosting conjugates, cholesterol produces the best terminal half-
life.  Cholesterol interacts more weakly with HSA than palmitate, so the enhanced 
retention is likely due to superior cell membrane binding.  This explanation is also 
consistent with the prolonged absorption rate of Chol-PIE12-trimer from the 
subcutaneous space (2.7 hours half-life).  Cholesterol also reduces the volume of 
distribution like acylation.  However, the cholesterol moiety may be causing 
sequestration of Chol-PIE12-trimer.  The bioavailability of SC-administered Chol-PIE12-




timer is only ~20%, suggesting that long durations of exposure to cell surfaces may lead 
to cell surface sequestration, endocytosis, or local metabolism.  The cholesterol moiety 
might also direct clearance to the liver through LDL binding.  It is known that siRNA-
cholesterol conjugates, even pre-bound to HDL or albumin, are redistributed and taken up 
into LDL particles in mice48, and humans circulate significantly more LDL than 
rodents49.  This disparity may change the pharmacokinetics of cholesterol conjugates in 
humans.  Animal models with more human-like lipid profiles (e.g., Guinea pig, Golden 
Syrian hamsters, and the LDLR-/- mouse)49-51 could provide some insight on in vivo 
kinetics in the context of increased circulating LDL concentrations, and may more 
accurately predict PK in humans. 
In the end, the best clinical candidate must balance potency with 
pharmacokinetics.  Although PEGylation improves half-life the most, potency suffers.  
Palmitate conjugation improves half-life and potency modestly, but to a lesser extent than 
cholesterol.  Alkane conjugation improves potency but does little to improve half-life.  Of 
unknown significance is the decreased volume of distribution created by each 
conjugation because it is not clear which tissue compartments must be accessed for 
successful inhibition of HIV transmission.  However, it is clear that Fuzeon is highly 
HSA-bound25, has a reduced volume of distribution in humans (Table 5-1), and 
successfully inhibits HIV.  Taken as a whole, Chol-PIE12-trimer has become our lead 













We envision four possibilities to explain the enhanced clearance of PIE12-trimer 
conjugates.  Reduced affinity for membranes and albumin is the simplest explanation.  
However, enzyme modifications, breakdown, and sequestration are also possible. 
To rule out enzyme modification we developed a method to determine the 
concentration of active compound in plasma samples using our pseudovirus infectivity 
assay.  We reasoned that although molecular weight-shifted metabolites may be missed 
by LC/MS/MS analysis, it is unlikely that such metabolites would lose antiviral potency, 
especially given PIE12-trimer’s charged resistance capacitor.  We analyzed C18-PIE12-
trimer because it was the first to reveal a surprisingly low terminal half-life by 
LC/MS/MS.  C18-PIE12-trimer concentrations calculated from the antiviral activity of 
plasma samples agree with the LC/MS/MS values, indicating that there were no 
detectable active metabolites in the plasma being missed by LC/MS/MS.  Therefore if 
drug clearance is due to a metabolic process, the metabolites must have greatly reduced 
antiviral activity.  Notably, PIE12-trimer is stable in rat plasma, even after weeks of 
incubation at 37 °C.  Chol-PIE12-trimer is also quite stable in rat plasma, although ~20% 
becomes oxidized (+16 Daltons) after 24 hours. 
We are also pursuing additional methods to discover metabolites.  For instance, 
all PIE12-containing analytes produce an acetylated histidine ion fragment (180.1 Da, +1 
charge) with 5% efficiency.  By utilizing the “Precursor Ion” mode on the LC/MS, any 
parent molecule that produces the 180.1 Da daughter ion can be identified with a ~1 !M 
sensitivity limit (following acetonitrile precipitation of plasma samples), enabling the 
detection of mass-shifted PIE12-containing metabolites.  The sensitivity of this method 




might be improved with better cleanup of the sample, so we also plan to utilize affinity 
purification with IZN17.  IZN17 binds PIE12 and PIE12-trimer with 20 nM and sub-pM 
affinity, respectively.  By adding it to plasma samples, all PIE12-containing molecules 
could be selectively purified.  These cleaner samples should enable sensitive 




Future studies will include a pilot efficacy study in SHIV-infected macaques in 
order to demonstrate the pharmacokinetics and viral response to unmodified and 
cholesterol-conjugated PIE12-trimer.  Suppression of viral load would indicate successful 
exposure and efficacy of our D-peptide antivirals in vivo.  To rule out nonspecific 
mechanisms of viral clearance, treatment will be halted after one month to demonstrate 
viral rebound. 
Dose-escalation studies in rats are also planned.  We would like to assess how PK 
is affected by changes in stock concentrations (e.g., by creating local depots of self-
associated peptide) and total mass delivered.  Moreover, these high-dose studies should 
enable investigation into the clearance mechanism(s) of PIE12-trimer and conjugates.  
Urine, feces, and bile will be collected to determine the roles of renal filtration and biliary 
excretion. 
Next, we plan to track fluorescently labeled PIE12-trimer conjugates in vivo (in 
rodents) to better understand clearance, volumes of distribution, and possible sites of 
sequestration.  A companion PK study will be done to control for possible PK changes 
created by the fluorescent moiety.  This in vivo study will help reveal routes of 




elimination and assess access to different tissue compartments (e.g., lymphatic tissue, 
brain, etc.).   
 Further, the protease-resistant design of PIE12-trimer enables novel applications.  
For instance, PIE12-trimer is a promising microbicide candidate (antiviral prophylactic) 
because it can withstand the protease-rich environment of the vaginal mucosa.  Moreover, 
our several lipid conjugations may enhance PIE12-trimer exposure by augmenting cell 
surface binding.  Oral bioavailability may also be possible.  By surviving gut proteases, 
PIE12-trimer might be formulated with a gut permeabilizing agent to achieve significant 
circulating concentrations.  Promising gut permeabilizers have been extensively 
reviewed52,53. 
 Finally, sustained delivery technologies may also be readily compatible with 
PIE12-trimer and its conjugates.  Microsphere delivery like that utilized by the recently 
approved Bydureon (once-weekly extended release exenatide) may enable a similarly 
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Utilizing Other PK-Enhancing Strategies 
 
Numerous PK-enhancing strategies are discussed in the Introduction, but only 40 
kDa Y-branched PEGylation and lipidation (i.e., acylation, alkane conjugation, and 
cholesterol conjugation) have been carefully assessed in our lab to date.  Other 
techniques, especially direct HSA conjugation and Fuzeon’s hydrophobic tail, should also 
be evaluated for their PK-enhancing potential. 
Synthesis of the HSA-PIE12-trimer has been straightforward, but purification has 
been more challenging.  Gel filtration can remove unreacted peptide, but does not 
effectively remove unreacted HSA.  Fortunately, it has been reported that HSA might be 
readily purified and appropriately refolded after reverse-phase HPLC and 
lyophilization1,2.  These results are encouraging, because HSA and HSA-PIE12-trimer do 
separate on a C18 reverse phase column.  Using gel-filtered material (about 1:4 HSA-
PIE12-trimer to unreacted HSA), I have shown that the IC50 of HSA-PIE12-trimer is 
about 5-fold worse than PIE12-trimer itself.  With improved purification (e.g., RP-
HPLC), more accurate IC50’s could be determined. 
Significant analytical method development will also be required for HSA-PIE12-
trimer before PK experiments can be conducted.  Although HSA-PIE12-trimer may




acquire enough charges to become detectable by LC/MS, this has not yet been 
established.  It is also unlikely that HSA-peptide conjugates would survive an acetonitrile 
precipitation of plasma samples, and it is not yet clear how much crosstalk exists between 
HSA-PIE12-trimer and endogenous albumin on LC/MS.  Affinity purification of plasma 
samples or a non-LC/MS quantitative assay are likely the best strategies for quantifying 
peptide-HSA conjugates. 
The 8 amino acid tail, or hydrophobic foot, of Fuzeon is also worth future 
investigation.  Fuzeon-tail conjugates would be trivial to produce and easy to evaluate in 
both pseudoviral assay and PK studies.  It would also be interesting to discover whether 
this sequence functions equally well in L and D.  If so, this moiety could also become a 
nondegradable component of PIE12-trimer. 
Conjugations to albumin-binding peptides might also be of interest, but would 
require a substantial amount of development.  The peptides discussed in the introduction 
are quite large (making scale-up difficult and costly) and contain disulfide bonds that 
complicate conjugation to our existing PIE12-trimer scaffold’s thiol-reactive maleimide.  
It is also unclear whether these constructs would offer any benefit over simple lipidation. 
Fc domains are unlikely to be of practical use to us, primarily because they 
require mammalian cell expression for appropriate folding and glycosylation, making 
them too complicated to produce synthetically (though simpler production methods are 
being investigated3).  Further, D-peptides cannot be genetically fused to an Fc domain.  
However, it might be possible to express Fc domains in mammalian cells and then post-
translationally link them to D-peptides, but this strategy is unlikely to produce conjugates 
amenable to scale-up for large therapeutic production. 




Two future directions are envisioned for PEGylation.  First is assessing the effects 
of smaller PEG conjugations.  While PEGylation with a single 40 kDa Y-branched PEG 
has proven beneficial for improving PIE12’s half-life, it reduced the potency of PIE12 
(2.5- to 10-fold) and PIE12-trimer (13- to 34-fold).  It is possible that smaller PEGs (e.g., 
5 kDa or 20 kDa) may provide significant PK enhancement while retaining potency. 
The second future direction involves improving the way PEGylated compounds 
are quantified.  Because of the polydispersity of large PEGs and their propensity to 
acquire multiple charges in LC/MS, determining a reliable Q1 parent mass for LC/MS 
quantitation is difficult.  Although much of the PEG can be fragmented off PIE12 in the 
source, the resulting peptide-containing fragments still contain a polydisperse amount of 
PEG, making detection of a discrete peptide fragment unreliable.  Instead, for quantifying 
PEGylated PIE12 I was forced to follow ionizable PEG fragments as a surrogate for 
intact parent mass. 
Quantifying PEGylated PIE12-trimer by this method is risky.  If PIE12-trimer is 
susceptible to metabolism, we would be unaware if we only followed PEG fragments as a 
surrogate for the parent.  A possible solution for robust quantitation of polydisperse 
PEGylated PIE12-trimer is to develop a non-LC/MS quantitative assay.  We have had 
trouble with this task before, and my recommendations are given in the Appendix. 
 
 
Combining PK-Enhancing Moieties 
 
Of the PK-enhancing strategies we assessed so far, PEGylation provided the 
longest half-life.  However, the large 40 kDa Y-branched PEG reduces potency.  
Cholesterol conjugation, on the other hand, greatly improves potency while modestly 




improving half-life.  As the two most promising strategies, it is tempting to consider 
whether PEGylation and cholesterol conjugation can be combined. 
Cholesterol’s ability to increase potency is based on its ability to tether PIE12-
trimer close to cell surfaces so that it is prepositioned to bind HIV’s gp41 pocket 
approximately 60 Å away.  Although the fourth arm linker is not taut and can 
accommodate excess linker length, it is not clear exactly how much it can tolerate.  In 
Chapter 4 we showed that for cholesterol conjugates, 60 PEG units appeared ideal for 
increasing potency, while lengths of up to 140 PEG units were well tolerated and 
demonstrated comparable potencies.  Further studies are required to determine how long 
the linker can become before potency drops off significantly. 
PK enhancement from PEGylation exhibits a sigmoidal relationship between size 
and reduction in clearance.  PEGs less than 5 kDa provide little PK benefit because they 
are rapidly cleared by renal filtration.  Forty kDa PEGs provide near-maximal PK benefit, 
while exceeding 40 kDa provides little additional benefit.  Replacing the fourth arm of 
our scaffold with a linear 40 kDa PEG would almost certainly reduce clearance and 
improve half-life, but would likely reduce potency because of long linker length and 
steric blocking.  However, adding less than 5 kDa of PEG is unlikely to provide much PK 
benefit.  Five kDa appears to have about one tenth the clearance-reducing benefit of a 40 
kDa PEG, while 20 kDa appears to have about half the clearance-reducing benefit of a 40 
kDa PEG4. 
To see if the PK and potency-enhancing benefits of PEGylation and cholesterol 
can be combined, cholesterol conjugates that utilize 5 kDa PEG and 20 kDa PEG fourth-
arm linkers should be developed and assessed by pseudoviral assay.  If tolerated, PEG 




length should be increased until a potency reduction is observed.  The longest PEG that 
maintains potency should then be analyzed in a PK study to assess its clearance-reducing 
benefit. 
There is one caveat; if cholesterol dominates how the conjugate is cleared (e.g., it 
directs clearance through the liver), increasing the fourth arm PEG length may provide 
little PK benefit.  PEG size improves half-life by reducing renal filtration.  Thus, if the 





A multimer of PIE12 might be made large enough to avoid renal filtration.  The 
renal filtration cutoff for globular proteins is ~70 kDa and ~40-60 kDa for PEGylated 
peptides/proteins.  Because each PIE12 is ~2 kDa and each PIE12-trimer is ~7-8 kDa, 
about 20-30 monomers or 5-10 trimers might be linked together to become large enough 
to avoid rapid filtration.  Polydisperse 4-arm and 8-arm activated PEG scaffolds are 
readily available in radial symmetry or comb designs.  For more precise control over the 
number, position and length of each bond, a poly-Lys or poly(Lys-Gly-Gly) peptide 





To date, all the PEG linkers utilized for PIE12-trimer and conjugates have been 
discrete in length.  However, for ease of large-scale synthesis, or for improvements in 
potency and PK (by using long fourth-arm linkers), polydisperse PEGs may become our 
preferred material for synthesizing PIE12-trimer.  There are analytical challenges 




associated with large polydisperse PEGs that need to be overcome.  As discussed, 
polydisperse PEGs make LC/MS/MS analysis challenging.  I was able to quantitate large 
40 kDa PEGylated PIE12 conjugates only by fragmenting PEG in the source and 
following charged PEG ions in Q1 and Q3.  It is possible that if our scaffold’s fourth-arm 
linker becomes long enough, this same strategy might be applied to all PIE12-trimer 
conjugates.  It is not yet clear how long the linker must become before this technique 
becomes sufficiently sensitive.  Studies that explore this question might be coupled to 
studies that seek to combine the PK benefits of PEG and cholesterol.  Ultimately, mass-
independent assays might be required for effective quantitation of polydisperse 
compounds. 
Developing an antibody to PIE12 would provide a powerful tool for a variety of 
applications, including immunohistochemistry and quantitation.  For example, an ELISA 
assay might utilize an anti-PIE12 antibody coupled to a fluorescent or enzymatic readout 
(e.g., horseradish peroxidase).  Efforts to develop a PIE12 antibody are currently 
underway, but because small peptides are generally nonimmunogenic, PIE12 must first 
be coupled to a carrier protein (e.g., KLH).  Adjuvants must also be included to improve 
the immune response.  Additional challenges surround PIE12’s nondegradable nature 
such that antigen presenting cells are unlikely to become involved in the process.  This 
may limit the kinds of antibodies produced to lower affinity IgM, which may nonetheless 
be sufficient for assay development.  Alternatively, an ELISA kit that utilizes antibodies 
to PEG itself is commercially available (Enzo Life Sciences)5,6.  Although expensive, this 
option would also be compatible with polydisperse PEG. 




Webster et al. suggest two other methods for quantifying polydisperse PEGylated 
proteins and peptides; Western blot and NMR.  In my own experience, Coomassie-blue 
stain of an SDS-PAGE is insufficient to detect PEGylated peptides because PEG 
excludes the dye.  However, PEGylated protein bands can be transferred to nitrocellulose 
and probed with anti-PEG antibodies. 
NMR is an intriguing possibility because of the cumulative signal of PEG protons 
(all protons on PEG are identical).  Some practical considerations are worth mentioning.  
Jack Skalicky, local NMR expert at the University of Utah, suggests that for a single 
species in buffer, 10 µM is the lower limit of detection for a single unique proton.  If 
there are 200 identical protons in a molecule, such as in a linker of 50 PEG units (2.2 
kDa), the limit of detection would drop to 50 nM.  However, methylene protons, like 
those found in PEG, might be quite abundant in plasma.  It is not clear yet what kind of 
background noise would be present in acetonitrile-precipitated plasma samples.  NMR 
has the added benefit of directly detecting changes in the parent molecule (i.e., 
metabolites), although it is unclear how sensitive detection of these changes might be nor 
how the FDA might perceive such a strategy for primary quantitation. 
 
 
Evaluating the Species-Dependence of PK 
 
So far, cholesterol conjugation has proven to be the most promising overall 
strategy for improving the potency and pharmacokinetics of PIE12-trimer conjugates.  
However, there is no precedent for approved cholesterol conjugates (or D-peptides for 
that matter!).  While the body of literature is just beginning to flourish7-13, it suggests that 




circulating lipids may directly affect the clearance of lipid conjugates, indicating that PK 
for cholesterolated peptides might differ significantly between species. 
Rodents have significantly different lipid profiles than humans, both in quantity of 
LDL and HDL particles as well is in the profile of lipid receptors that direct lipid 
circulation14.  Fortunately, several animal models have been developed that better 
simulate human lipid content, including Guinea pig, Golden Syrian hamster, the        
LDLR (-/-) knockout mouse, and several rabbit models14-16.  Assessing Chol-PIE12-
trimer in one of these animal models seems prudent and may provide the best indication 





Dose escalation studies are necessary to demonstrate a correlated increase in drug 
exposure (AUC) and to establish an accurate therapeutic index.  For example, if higher 
doses initiate alternate clearance mechanisms in rodents, one might be led to believe that 
high doses are well tolerated, and incorrectly establish a therapeutic index that can lead to 
toxic doses in humans.  Exposure (AUC) evaluations reduce this risk by establishing a 
correlation with the administered dose. 
We have recently conducted dose escalation studies for PIE12-trimer and Chol-
PIE12-trimer (3 mg/kg, 10 mg/kg, and 30 mg/kg in rat).  Early evaluation suggests that 
terminal half-lives may increase with an increase in dose.  While these doses are much 
higher than would reasonably be given to actual human patients, it provides us with an 
opportunity to understand the mechanism behind clearance. 




Two possible scenarios explain the data.  Either increased overall dosage (in 
mg/kg) leads to a saturation of the clearance-process, or simply increasing the 
concentration of the subcutaneous dose (in mg/mL) leads to a local self-association or 
precipitation of the compound with a delayed resolubilization and circulation.  
Unfortunately, our existing studies have changed both dose and stock concentrations.  
Therefore, an independent future study that deliberately evaluates the effects of just dose 
or stock concentration will be required in order to completely answer this question.  Still, 
if high stock concentrations lead to a PK-enhancing local precipitation, then there are 
important implications regarding how to formulate our compound in order to achieve the 





Paracelsus, Renaissance alchemist, physician, and father of toxicology, once said 
“All things are poison and nothing [is] without poison. Only the dose makes a thing not 
to be poison.”17  Toxicity is of particular interest to the Kay lab because, as of yet, no D-
peptides or cholesterol conjugates have been approved by the FDA.  It is not known how 
toxicity might manifest for a nondegradable D-peptide.  Will they permanently 
accumulate somewhere?  Will accumulation have physiological consequences? 
Speculation is of little benefit on this subject; toxicity must be empirically 
determined.  We can, however, surmise what organs might become affected.  Given that 
Fuzeon produced dose-limiting injection-site reactions after subcutaneous administration, 
it is prudent to evaluate whether PIE12-timer injection sites develop similar reactions.  




Moreover, because of the cholesterol moiety on Chol-PIE12-trimer, liver accumulation 
and toxicity might also be anticipated. 
A set of defined toxicity studies are required by the FDA as part of filing an IND 
(investigational new drug) and again for the NDA (new drug application) following 
clinical trials.  IND toxicity studies must be conducted in two animal species, one rodent 
and one nonrodent.  Early requirements include an acute, 7-day and 28-day toxicity 
studies.  In general, chronic toxicity studies in animals should always be longer (often 
twice as long) as intended studies in humans.  These studies are currently underway with 





Metabolism of therapeutics presents a daunting challenge because almost 
anything can happen to modify a parent compound.  In industry, generally a precise set of 
experiments is done to evaluate a defined number of most-likely metabolic changes.  
These include plasma stability studies, microsomal incubations, and tissue homogenate 
incubations. 
Microsomal incubations help to identify phase-I metabolic products from the 
intracellular Cyp-450 oxidative system, a common site of small molecule metabolism.  If 
susceptible, these enzymes will add +16 and +32 to the molecular weight of a parent 
compound (single or double oxidation).  For peptides, however, we are skeptical that the 
intracellular Cyp-450 system will play much of a metabolic role because peptides do not 
readily cross cell membranes.  However, cryopreserved hepatocytes are also 
commercially available, and may provide a superior alternative to liver microsome 




studies.  Intact hepatocyte incubation will determine whether peptides are actively 
transported intracellularly where they might become metabolized by Cyp-450 enzymes. 
 A number of other defined metabolic molecular weight changes that are common 
for small molecules can be assayed, one at a time, using defined MRM methods on 
plasma samples containing metabolized analyte18.  Unfortunately, this process is tedious, 
sample-consuming, and unable to detect catabolism, uncommon metabolic changes, or 
sequestration.  Furthermore I have recently demonstrated by pseudoviral assay that our 
LC/MS determined concentrations match the amount of functional PIE12-trimer-
cholesterol in plasma samples, indicating that no detectable active metabolites are present 
in our Chol-PIE12-trimer plasma samples.  If metabolism is occurring, metabolites would 
have to be inactive.  Because such inactivation seems unlikely, breakdown of PIE12-
trimer or sequestration seems more plausible. 
Open Q1 scans might directly reveal metabolites if they are especially abundant. 
Unfortunately, plasma is rife with confounding signals, even after acetonitrile 
precipitation, limiting detection of analytes and metabolites to those with >5 µM 
concentrations.  Open scans of urine are more promising because it contains less of a 
background signal, although urine requires careful handling to prevent analyte loss to 
tubes (no proteins in urine to prevent tube sticking), and urine too contains a surprisingly 
high number of confounding signals, complicating metabolite identification. 
Fortunately, the MS “Precursor Ion” mode is capable of scanning a range of 
masses on Q1, fragmenting them in Q2, detecting a selected daughter ion on Q3 (i.e., a 
unique daughter ion common to PIE12-trimer and its conjugates) and then reporting what 
parent mass produced that ion.  This mode has the capability of directly reporting any 




metabolite that can produce a known daughter ion.  Furthermore, I have observed that the 
N-terminal residue of PIE12, an acetylated histidine (mw 180.1), is common to all PIE12-
containing molecules.  This ion is relatively unique compared to plasma, and is produced 
at about 5% efficiency from parents in Q2.  Some troubleshooting of the precursor ion 
mode may improve sensitivity, but current assessments allow for detection of any parent 
that produces the unique 180.1 m/z daughter ion if that parent concentration is 1 µM or 
higher in plasma or urine.  This is still a fairly high concentration for a metabolite, but 
several of our highly dosed animals contain analyte concentrations that easily exceed this 
limit. 
Future studies to find metabolites might also utilize affinity purification to help 
isolate metabolites from confounding signals in urine and plasma.  IZN17 is a 
synthetically produced HIV pocket mimic for which PIE12 has a ~20 nM affinity.  
Attaching IZN17 to retrievable magnetic beads and incubating them in biological 
samples is a feasible strategy to pull out any PIE12-containing analyte, metabolite or 
fragment.  Eluting some analytes, like the high-affinity PIE12-trimer, from IZN17-coated 
beads might require very strong conditions, but should be possible.  The eluted samples 
should have vastly improved signal to noise on LC/MS, allowing for higher sensitivity 
detection modes such as the open Q1 scan (low nM sensitivity) to search for metabolites. 
 
 
In Vivo Imaging 
 
 Because of the higher-than-expected clearance of PIE12-trimer and its conjugates, 
and the benefits of actually visualizing distribution, excretion, and possible accumulation 
of these compounds, we envision actively utilizing in vivo imaging to monitor the fate of 




labeled drug (e.g., via MRI, CT, PET and fluorescence tomography).  Unfortunately, 
synthesizing labeled peptides with identical physical properties (i.e., radiolabeling) is a 
significant technical challenge.  Instead, we intend to utilize fluorescently labeled PIE12-
trimer and/or its conjugates as a substitute.  A fluorescent molecule might redistribute 
PIE12-trimer in a manner unrepresentative of its unlabeled correlate, but parallel PK 
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PROGRESS TOWARDS A FLUORESCENT BIOANALYTICAL 
 
ASSAY FOR PIE12-TRIMER IN PLASMA SAMPLES;  
 






While preparing for our initial PK studies with Invitek, we prepared stocks of 
PIE12 and its conjugates to reach starting concentrations of 5 µM in plasma (>1000-fold 
over PIE12-Trimer IC50’s for HxB2 and JRFL).  We reasoned that an assay that could 
detect analytes down to 10 nM should provide adequate sensitivity and allow us to 
capture 9 half-lives of elimination data.  But with limited access to LC/MS/MS 
instrumentation (at the time), and with numerous different moieties attached to PIE12 
with several more being planned for PIE12-Trimer, we wanted an assay that could easily 
accommodate all PIE12 variants.  We therefore decided to develop a fluorescence 





A FRET assay promised numerous benefits.  Fluorescent dyes have extraordinary 
extinction coefficients and can be detected with high sensitivity and throughput on 




commonly available 96-well fluorescent plate readers.  Furthermore, a FRET assay 
would be based entirely upon binding events, which made it amenable to our plethora of 
PIE12 conjugates independent of their molecular weights.  Lastly, we envisioned that our 
FRET assay could be amenable to a “homogenous” design, requiring only the addition of 
a few components into one mixture with little or no sample preparation. 
Other commercial tools made FRET sound even more appealing.  Licor’s 
IRDye800 fluoresces in the near-IR spectrum, a region where biological samples absorb 
and emit little.  Further, Licor developed a FRET pair that utilizes an unusual “dark 
quencher” (QC1) along with its standard IRDye800.  Unlike normal FRET where a new 
signal is detected when two fluors approach each other, dark quenchers absorb the energy 
of a nearby fluor, quenching its fluorescence.  Fluorescence is only restored (dequenched) 
when the two moieties are separated. 
Such a quenching pair can be utilized for a competition-based assay where 
addition of unlabeled analyte displaces labeled ligand, resulting in increased fluorescence 
with increasing unlabeled analyte.  Specifically, excess QC1 dark quencher conjugated 
PIE12 (300-500 nM) is added to a limited amount of IRDye800-labeled pocket-
containing target (10-20 nM of 5-Helix or IZN17) resulting in the binding a large fraction 
of pockets according to the equation F = C/ (C+ KD) where F is fraction occupied, C is 
concentration and KD is the affinity of PIE12-QC1 for HIV pockets (~20 nM; 300 nM 
PIE12-Q1 occupies ~94% of sites).  FRET occurs according to the equation                     
E = 1 / (1 + (R/R0)6), where E is the FRET efficiency, R is the distance between the 
fluors, and R0 is the Forster distance defined for a given FRET pair (65 Å for QC1 with 
IRDye800).  Using IZN17 labeled with IRDye800 on its N terminus, the highest 




observed quenching (FRET efficiency) approached 80%, corresponding to a distance of 
52 Å between the two fluors. 
When a plasma sample containing unlabeled analyte is added (PIE12, PIE12-
trimer, or any PK-modified conjugate thereof), it competes with QC1-PIE12 for binding 
to the pockets.  When QC1-PIE12 is displaced, an incremental increase in fluorescence is 
observed.  Notably, the dark quencher and IRDye800 fluors cannot be switched between 
the pocket-containing target and PIE12 because the PIE12-dye is always in excess, which 
means only a fraction of it will be bound to the pocket at all times such that free PIE12-
IRDye800 would constantly produce an extraordinarily high background signal. 
The maximum achievable FRET signal is determined by the concentration of 
IRDye800-labeled pocket-containing target.  More target means higher maximum signal, 
however, with more target, a higher concentration of PIE12-QC1 has to be added to 
effectively quench that target.  Eventually a balance must be struck because too much 
QC1-PIE12 begins contributing significantly to the background fluorescent signal, and 
too much QC1-PIE12 also prevents effective competition from analyte in plasma. 
The “IC50” of this assay is also somewhat arbitrary.  It reflects the amount of 
analyte required to displace 50% of previously bound pockets, which is a function of how 
much QC1-PIE12 is originally added.  Complications arise when considering PIE12 
monomer analytes vs. PIE12-Trimer analytes, which have extraordinarily different 













Throughout my experiments I encountered multiple unanticipated challenges.  By 
careful planning, many of them were overcome.  Eventually I succeeded in developing a 
functional FRET assay in buffer.  However, plasma samples affected the assay with 
animal-to-animal variation, preventing its utility for reliable quantitation.  At the risk of 
waxing too comprehensive, I will chronicle only the most meaningful lessons learned. 
The two most insurmountable challenges that ultimately halted the pursuit of a 
FRET-based assay involved inexplicable increases in fluorescence.  First, fluorescence 
was affected by the addition of every component to the assay, even those that should not 
have had any impact whatsoever.  For example, IRDye800 conjugated to PIE12 would 
increase in fluorescence following the addition of unlabeled PIE12; there is no logical 
reason why this should happen, and it certainly shook our confidence in accurately 
understanding the FRET response.  Furthermore, I found that these inexplicable 
responses also depended on the order of addition of components, implying that the assay 
never truly came to equilibrium (even after days). 
The second insurmountable problem was that the fluor was drastically affected by 
something in plasma that varied from animal to animal, making reproducible quantitation 
impossible.  The same amount of fluor in plasma samples from different animals 
produced wildly different signals, preventing the development of a meaningful standard 
curve.  Moreover, the offending component could not be removed from plasma following 
acetonitrile crash, speed-vac, and resuspension of plasma samples (Table A-1). 
A third challenge was producing enough identical dye-labeled materials that could 
reproduce  the  results  of  a  previous  batch  of  material.   Dye-labeled  conjugates  were 




Table A-1.  Animal-to-Animal Variable Effect on IRDye800 
10 nM IRDye800-PIE12 placed in: Fluorescent Units 
50 mM HEPES, pH 7.4  
+ 10% Superblock 12.3 
50% plasma from Rat A 111.4 
50% plasma from Rat B 121.8 
50% plasma from Rat C 141.3 
50% plasma from Rat D 102.2 
50% pooled rat plasma 92.4 
10% pooled rat plasma 95.0 
ACN-crashed rat plasma, spun, speed-
vacuumed, and resuspended in 50 mM 





always limited because of the expensive and short supply of dye and never seemed to 
behave the same from batch to batch, further complicated by the challenges of cutting 
pure fractions from the HPLC (especially after labeling on resin, when several truncated 
products would co-elute).  Subtle differences in pH, organic content, denaturant, 
temperature and timing in the stock or assay would produce significant changes in 
fluorescent signal.  This finicky behavior was not unique to Licor’s IRDye800; Cy7.5 and 
DyLight-800 both shared similar unpredictable sensitivities. 
 Several plates were assessed for compatibility with the FRET assay.  Many plates 
had autoflorescence in the IR range, but usually less than 1% of the signal produced by 
the assay.  What mattered most was well-to-well reproducibility.  I found that Greiner 
Bio-One !-Clear high-bind Fluotrac-200 384-well black plates with clear bottom were 
best (Greiner 781097), with coefficients of variance (standard deviation divided by 
average signal) of less than 2%.  Plasma was also found to produce an autofluorescent 
background signal that was significant at 700 nm but negligible at 800 nm.  We 
eventually found that the volume in each well also mattered.  Twenty-five !L of dye-




containing plasma actually produced a larger signal than fifty !L (at the same 
concentration); this was an illogical but reproducible finding.  The discovery also 
complicated the assay, because evaporation readily changed the volume in wells within 1 
hour.  To address this, all plasma incubations were done in independent tubes before 
transferring contents to the plate.  An automatic pipetter also helped to reduce variability. 
 A Licor Odyssey instrument was used to read the plates.  The limit of detection 
was 150 pg of IRDye800 labeled antibody in 50 !L of plasma (~3 fmoles of fluor, or 60 
pM fluor).  The instrument itself produced a slight left-to-right signal bias (high to low), 
so assays were generally constructed in vertical columns.  Thirty-two nM unconjugated 
IRDye800 saturated the instrument detector (at 600 units).  The fluorescence was 
generally reduced after protein conjugation, so 50 nM of labeled conjugate was the 
maximum before saturating the detector.  
 Because of difficulties producing and properly folding 5-Helix (a target with one 
free pocket), we directed our efforts to labeling IZN17 with IRDye800.  IZN17 trimerizes 
in solution to produce a three-pocket target.  To avoid three fluors on every trimer of 
IZN17, we decided to add unlabeled IZN17 in order to cause shuffling of the monomers, 
aided by incubation for 1 hour at 50 °C.  Surprisingly, we found the ratio of unlabeled 
IZN17 to IRDye800-IZN17 was increasingly beneficial (up to 10:1) for quenching by 
QC1-PIE12 and dequenching with PIE12; rationally, at some point adding unlabeled 
IZN17 would produce a sink of unlabeled IZN17 trimers that would bind PIE12 analyte 
without any corresponding signal, but we never reached a point where adding unlabeled 
IZN17 hurt sensitivity to D-peptide.  This was illogical, but was nevertheless a reality.  




To explain it we had to invoke some sort of solubilizing activity of D-peptide on 
IRDye800-labeled IZN17. 
 While troubleshooting the assay, we did confirm that dark-quencher labeled 
PIE12 had good affinity for the pocket.  In pseudoviral infectivity assays, QC1-KGPIE12 
and PIE12GK-QC1 had IC50’s (HxB2 strain) of 40 nM and 66 nM respectively (vs. 37 
nM for PIE12).  Attempts were also made to develop better targets (in terms of solubility 
and responsiveness to quenching and dequenching).  I developed “five and a half” helix 
and truncated IZN17 targets to bring the fluors closer together for improved FRET.  
However, neither of these constructs behaved much better than regular IZN17.  I also 
developed a pocket-mutant of IZN17 and added this in a 10:1 ratio to IRDye800 labeled 
IZN17 to create one-pocket targets.  This strategy also did not readily improve the assay. 
 Eventually we succeeded in developing a functioning FRET assay in 50 mM 
HEPES, pH 7.4 buffer.  Unlabeled IZN17 and IRDye800 labeled IZN17 were combined 
in a 10:1 ratio with QC1-PIE12 in 6 M Guanidine at 10x concentrations.  Upon dilution 
into buffer, the signal was appropriately quenched.  Diluting into analyte-containing 
buffer recovered the signal, but oddly, the signal could be recovered to higher values than 
the uninhibited control (Fig. A-1).  This assay also quenched and dequenched 
successfully in plasma, but did not match the responses observed in buffer, and varied in 
response from animal to animal, crippling the utility of the assay. 
After discovering the animal-to-animal variability we gave up on the homogenous 
FRET assay design and developed an ELISA assay that could accommodate a washing 
step.    We   reasoned  that  a  wash  step  might  remove  whatever   fluorescence-altering  
 







Figure A-1.  Functioning FRET Assay.  Dashed lines are associated with 10 nM IZN17 
(3.3 nM trimers), where each monomer component is labeled with IRDye800.  Solid lines 
are associated with 10 nM IRDye800 labeled IZN17 spiked with 100 nM unlabeled 
IZN17 in order to preferentially create trimers with only one IRDye800. A) IZN17 targets 
are quenched with increasing concentrations of QC1-PIE12. B) Quenched IZN17 can be 
dequenched by adding increasing concentrations of unlabeled PIE12. 




component was present in plasma.  We analyzed plates with streptavidin and Neutravidin 
pre-blocked with Superblock or bovine serum albumin (BSA) (Pierce).  We found the 
Superblock/Neutravidin combination was able to bind the most IZN17.  We developed 
the assay with PIE12-trimer in mind so that binding to IZN17 would be irreversible, and 
synthesized PIE12-trimer labeled with IRDye800.  Although IRDye800-PIE12-trimer did 
not bind to the Neutravidin plates, we did observe nonspecific binding once IZN17 was 
immobilized on the plate (compared to IRDye800-PIE12-trimer prebound with IZN17 
and then pulled onto Neutravidin). 
Unfortunately, no variant of the assay removed the effects of plasma.  Once the 
IRDye800 fluor became exposed to plasma its fluorescence was altered and could not be 
recovered by washing.  Further, too many (or too long) washes began removing 
Neutravidin from the bottom of the plate.  I redesigned the ELISA so that the fluor would 
be added last after plasma was removed.  Biotinylated IZN17 was added to plasma to 
bind PIE12-trimer analyte, which was then added to the Neutravidin wells and incubated 
for " 2 hours to pull down biotylated-IZN17.  The plasma was washed away, and 
IRDye800-PIE12-trimer was added to bind any remaining available IZN17 target.  This 
design worked in buffer, but still it failed to avoid plasma effects (Fig. A-2).   
One surprising complication was that the binding of biotinylated IZN17 to 
Neutravidin or streptavidin was not rapid, and was further reduced in the presence of 
plasma  (Fig. A-3).   Once again,  the  assay  never  appeared  to come to equilibrium.  To 
overcome the challenge of delayed equilibrium I employed IZN17-labeled magnetic 
beads.    Unfortunately,  IRDye800-PIE12-trimer  was  found  to  bind  nonspecifically  to  
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Figure A-2.  ELISA Design and Function. A) Biotinylated IZN17 was added to 
samples (buffer or plasma) to bind analyte.  These samples were then transferred to 
Neutravidin plates to pull down IZN17.  The wells were then washed to remove unbound 
sample components.  IRDye800-PIE12-trimer was then added to bind any IZN17 lacking 

























Figure A-3.  Kinetics of Binding Biotinylated IZN17 to Neutravidin and 
Streptavidin in Plasma and Buffer Samples.  IRDye800-PIE12-trimer was incubated 
with biotinylated IZN17 in buffer and rat plasma (RP).  The samples were then 
transferred at different times to Neutravidin plates blocked with Superblock (NA/SB), 
and streptavidin plates blocked with Superblock or BSA (SA/SB and SA/BSA, 
respectively) to control the timing of pull-down.  Wells were washed to remove unbound 
















them, independent of blocking agent used.  This was the last fluorescence-based assay 
attempt I made before turning to the more robust LC/MS/MS technique. 
 
 
Suggestions for Future Troubleshooting 
 
 With anticipated changes to our PIE12-trimer designs (e.g., polydisperse PEG 
scaffolds), a functional ELISA may provide more reliable quantitation than LC/MS/MS, 
although an ELISA would be unable to distinguish between active metabolites.  If efforts 
to develop an ELISA are to be undertaken, I most fervently recommend using a non-
fluor-based readout, like an enzyme; every fluor I used in FRET and ELISA was too 
unpredictable for reliable quantitation of plasma samples. 
 I also recommend a cleanup of plasma samples before analysis by ELISA.  
Untreated plasma interferes with protein-protein interactions like the biotin pull-down by 
Neutravidin.  Several washes, like those required to remove untreated plasma, also 
negatively affect the assay.  Instead, I recommend using an acetonitrile crash of plasma 
samples, followed by speed-vac to dryness and resuspension in aqueous buffer (e.g., 50 
mM HEPES, pH 7.4).  My efforts to cleanup plasma samples for functional quantitation 
in pseudoviral assays have shown that PIE12-trimer conjugates can be successfully 
recovered by this method.  Note that this method does not remove plasma components 
that affect fluorescence.  I would minimize washes of Neutravidin plates, unless 
covalently-linked Neutravidin plates can be developed or acquired. 
As interest in a mass-independent assay is rekindling in the Kay lab, I give my 
very best wishes to the future students whose opportunity it is to progress beyond my 
own efforts.  May these lessons be a boon to you.  Amen. 
